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Infogr.am of the study result 
The words represent factors (variables) included in the case-control study. The 
word sizes reflect the magnitudes of the adjusted odds ratio between cases and 
controls. Only some of the variables were statistically significant. 
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Abstract 
 
Seasonal influenza is a serious public health problem that can cause severe illness, 
hospitalisation and death. Influenza vaccination is one of the most effective 
methods for preventing influenza and its complications. In Hong Kong, people 
aged 50 to 64 were added as a recommended priority target group for influenza 
vaccination by the Department of Health starting from 2011/12. The coverage rate 
of the influenza vaccine for this age group was 8.5 percent in 2012/13.   
 
In order to explore the reasons for the low influenza vaccine coverage rate, a 
systematic literature review and a case-control study were conducted. The 
literature review aimed to explore what demographic, social and psychological 
factors were associated with the uptake of influenza vaccination among adults 
from 18 to 64 years. The result of the review was used to inform the design of a 
case-control study, which aimed to determine factors associated with the uptake of 
influenza vaccination amongst adults aged 50 to 64 years in Hong Kong. The 
literature review and the case-control study are presented in publication format.   
 
The case-control study was conducted using street intercept interviews from 17 
July to 15 August 2013. Cases were adults aged 50 to 64 years who received 
influenza vaccination in 2011/12 or 2012/13, while controls were the same as 
cases, except they did not receive the vaccine during the same period. Multinomial 
logistic regression analysis was performed on the data to explore associations 
between vaccination status and the variables. The study had a total of 604 
respondents: 193 cases (vaccinated) and 411 controls (non-vaccinated), with a 
case-to-control ratio of 1:2.1. The factors which possessed the strongest 
associations with influenza vaccination were: ‘eligible for free government 
vaccine’; ‘willing to receive flu vaccination for free’; ‘perceived having severe or 
moderately symptoms when contracting flu’; and ‘accept advice from health 
professional’.  
 
Word counts 300      
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1. Introduction 
1.1 Seasonal influenza vaccination for people aged 50 to 64  
Seasonal influenza vaccination (referred to as vaccine or vaccination below) 
policy and programmes remain an important aspect of national health provision. 
In a World Health Organization (WHO) survey, 50% of the surveyed countries 
reported having established policies on seasonal influenza vaccination, and an 
additional 19% reported having recommendations in place for risk groups.1 Most 
countries recommended that people with a high-risk of influenza-related 
complications or hospitalization, and people at the two extremities of age, to get 
vaccinated.1 
 
Many health authorities in the world have not provided national influenza 
vaccination services for people aged 50 to 64 years, with the exception of Belgium 
and Ireland.2, 3 Besides, a few countries, such as the US, Austria and Estonia, 
recommend that all people aged 6 months or above should receive influenza 
vaccination.4,5 In Hong Kong, experts specialized in influenza vaccination have 
held a different view and opined that people aged 50 to 64 years should be one of 
the recommended group. Those who receive financial assistance in this age group 
were included in the Government Vaccination Programme (GVP) for free 
influenza vaccine since November 2011; a year after the 2009 H1N1 influenza 
pandemic period ended in August 2010.6 
 
The Southeast Asia region, where Hong Kong is situated, is regarded as an 
epicentre for the emergence of new strains of human and avian inﬂuenza 
viruses.7,8 Hong Kong is the place where H5N1 avian influenza first made its 
appearance in 1997, and was amongst the earliest places affected by severe acute 
respiratory syndrome (SARS) in 2003. Additionally, it was also where the 1968 
influenza pandemic (Hong Kong flu) originated. The Department of Health (DH) 
in Hong Kong has implemented stringent health measures against influenza and 
respiratory diseases.    
 
The coverage rate for people aged 50 to 64 was very low following the launch of 
the new vaccination policy – just 8.5% in 2012/139 and 3.1% of those eligible for 
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free influenza vaccine under GVP.10 There are many unsolved questions to be 
explored regarding the reason for this low coverage rate. This thesis begins by 
exploring the related demographic, social and psychological factors of vaccination 
behaviour.   
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1.2 Roadmap of influenza vaccination policy change 
Influenza vaccination is constantly advancing and new discoveries have emerged 
as a result of continuous viral mutation, the use of new vaccines (e.g., 
quadrivalent influenza vaccine) and changes in the vaccine market. The revision 
of vaccination policy and services is an on-going task for health authorities 
wishing to maximize their preparedness for influenza epidemics and pandemics. 
The WHO advocates for countries to include recommended priority groups for 
annual influenza vaccination, and most countries follow their recommendations.11 
In the 25 countries and areas of the Western Pacific region, health-care workers 
and the elderly were most frequently recommended for vaccination; 96% 
countries and areas recommended vaccinating these groups, followed by pregnant 
women (76%), people with chronic illnesses (72%) and children (60%).1  
 
Take the example of the US to illustrate the evolution of the influenza vaccine 
policy on recommended groups. Over the last three decades, the Advisory 
Committee on Immunization Practices (ACIP) has made a number of stepwise 
incremental changes to the annual influenza vaccine recommendations. Finally, in 
2010 its recommendation included all of the US population aged 6 months and 
older.12,13 From the 1960s to 1986, the categories of persons recommended for 
influenza vaccination in the US were primarily those who were at high risk from 
complications, such as the elderly, persons with chronic medical diseases, 
pregnant women, and children.12 These groups are the same as those 
recommended by the WHO today.11  
 
Since 1987, ACIP expanded vaccination to include people in contact with high-
risk individuals; i.e., home carers and caregivers of high-risk groups were 
recommended.14 From 2000 to 2009, the ACIP has incrementally added more and 
more subgroups to its recommendations: in 2000, adults from 50 to 64; 15  in 
2004 ,children aged 6 to 23 months;16 in 2006, children aged 24 to 59 months; in 
2008, children aged 5 to 18 years; 17  and in 2010, national universal 
recommendations for all persons 6 months and older.13  
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If policy in the US represents the movement towards a universal recommendation 
for vaccination, then many other developed countries are situated at various stages 
along this path. In 2009, the US was the country with the largest influenza vaccine 
dose distributed anywhere in the world.18 Europe and the Americas account for 
75% to 80% of the global influenza supply each year.18 In a study of 29 European 
Union (EU)/European Economic Area (EEA) countries, the ‘WHO-recommended 
high-risk groups’ were all or partly accepted by all countries; household contacts 
with high-risk groups were recommended by half of the countries.19 A minority of 
European countries (Austria, Belgium, Estonia, and Ireland) was ahead and 
included those aged 50-64 in their recommended groups, although this 
recommended group does not necessarily receive reimbursement for 
vaccination.20  
 
Ideally, public health policy should be founded on an evidence-based decision 
making process. Scholars have agreed that this complicated process requires an 
integration of evidence from multiple domains across disciplines.21 Concerning 
the influenza vaccine policy change, at least three areas have to be considered, 
namely: 1) the best available research evidence on vaccine efficacy and 
effectiveness, disease burden, economic evaluation, and vaccine safety; 2) 
practitioner expertise and other available resources, including prioritisation of 
health needs, availability of skilled staff, and vaccine 
transport/logistic/storage/disposal; and 3) the perception, values, affordability, and 
preferences of people and stakeholders.22,23 In the real world, policy change is not 
always backed up by solid scientific evidence. Even in the US, an authoritative 
review report has criticised ACIP’s recommendations as ‘often…[being] based on 
professional judgment and not on scientifically sound data’.12 This might have 
been more the case in the past when data was not easily accessible, as well as in 
resource-limited developing areas. 
 
In Hong Kong, immunisation against various infectious diseases has been 
implemented since the 1960s.24 In 1992, an Advisory Committee on Immunisation 
(ACI) was set up under the DH to review strategy on immunisation.25 Since 1998, 
the Government has been providing free seasonal influenza vaccination to target 
groups at public hospitals/clinics. In 2004 after SARS, the Scientific Committee 
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on Vaccine Preventable Diseases (SCVPD) was set up to succeed ACI. The 
SCVPD has included all the ‘WHO-recommended high-risk groups’. Later, it 
expanded its recommended group to include children aged 6 months to 5 years in 
2008/09, and those aged 50 to 64 years in 2011/12.6,26 It is an exciting prospect to 
follow up on the effectiveness of these vaccination implementations in Hong 
Kong and explore how they are contributing to controlling influenza outbreaks.   
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1.3 Influenza vaccination policy changes in Hong Kong 
1.3.1.   Rationale and evidence-based drivers behind policy change  
The major driver behind the vaccine policy change in 2011/12 was due to a real 
increase in influenza-attributed ICU admissions and deaths among the 50 to 64 
years,6 plus an anticipated increase in the years to come when the influenza 
A(H1N1)pdm09 strain was predicted to circulate in the population. This group 
was more susceptible than the other recommended groups to severe influenza 
complications in the 2011/12 winter.6 The offer of vaccine was the best method for 
protecting against influenza-related hospitalisation.  
 
Although there can be other direct and indirect benefits resulting from the 
expansion of the vaccine-recommended group, these were not stressed in the 
health policy documents. Such benefits could include a decrease in work-day loss 
and an in-direct protection of household vulnerable groups by herd immunity 
(elders and children). There was no noted advocacy by healthcare providers - 
inside or out-side the government - to push the change of this policy. 
 
A number of enabling factors facilitated this policy decision and its 
implementation. A well-established annual seasonal vaccine delivery system in the 
public and private clinics, and hospitals, was already in place; and with more than 
150 vaccination locations. 27 There was flexibility for policy makers to decide 
whom to include for free or subsidised vaccination so as to control the costs 
incurred. Plenty of vaccines were supplied by at least 5 vaccine companies at 
steady market prices.28 A preliminary enquiry of healthcare providers and medical 
associations indicated that they seemed to have welcomed the change. Although 
there was a concern that once the recommended group was expanded, it would not 
be easy subsequently to remove this group from the list. Besides, previous local 
study did not support the cost-effectiveness of the influenza vaccine for the 
working-age population and the elderly.29   
 
1.3.2.   Expected public health impact and outcomes  
The expected impact following the implementation of the influenza vaccination 
programme to include the 50 to 64 years age group would be a decrease in severe 
influenza complications. This outcome would be monitored by regular hospital 
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surveillance on the number of ICU admissions and deaths. There was also an 
expected increase in vaccine coverage for this age group. DH did not set a target 
on the coverage, partly because there was no vaccine coverage data collected for 
this age group at that time. A surrogate marker as pre-policy coverage was that 
13.1% of adults in Hong Kong received an influenza vaccine within the past 12 
months.30 There would be an expected indirect cost reduction in terms of work 
production and decreased infection of household members due to herd 
immunity.29  
 
1.3.3.   Process of policy change 
In early January 2011, the surveillance system in the Department of Health (DH) 
documented an increase in the number of hospital admissions due to influenza 
among people aged 15 to 64 years.31 As a result, a new surveillance mechanism 
was set up on 24 January 2011 to monitor the situation. Since then, public and 
private hospitals have had to report all influenza-associated deaths and admissions 
to intensive care units (ICU) to the DH during peak influenza seasons.31 
 
In April 2011, a Working Group on Influenza Vaccination under the DH studied 
the local epidemiology and possible causes of the increase in hospitalisations. The 
group concluded there was a real increase in ICU admission and fatal influenza 
cases in healthy individuals aged 50 to 64 years in the winter of 2010/11. The 
incidence of ICU admission or fatal influenza cases was 1.8 per 100,000 people in 
those aged 50 to 64 years.32 This incidence was higher than the corresponding 
numbers in any other age group, including young children aged below 6 years (0.7 
per 100,000) and elders over 65 (0.6 per 100,000).6 In addition, most (41%) of the 
influenza-related deaths had affected people aged 50 to 64 years. In contrast, 
during previous influenza seasons – excepting summer 2009 – about 85% of all 
fatal cases of influenza occurred in the elderly over 65 years old.32   
 
In May 2011 the Working Group presented the findings to an expert panel – the 
Scientific Committee on Vaccine Preventable Diseases (SCVPD) – to review 
influenza vaccination policy for the following year.6 In June 2011, the SCVPD 
suggested expanding the recommended priority groups to include people aged 50 
to 64 years in 2011/12.32 The decision was based on the local context, the 
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likelihood that the influenza A(H1N1)pdm09 strain would continue to circulate in 
the coming years, and that the vaccine had good protection against clinical 
influenza in healthy adults.6  
 
DH had studied and advised the Government on the health needs, the cost and 
feasibility of providing free or subsidized influenza vaccinations to this additional 
target group, for inclusion in the 2011/12 Government Vaccination 
Programme * (GVP). Based on the DH and SCVPD’s recommendations, the 
Government approved extending the scope of the free vaccination in the 2011/12 
GVP, launched on 1 November 2011, to cover recipients of the Comprehensive 
Social Security Assistance (CSSA) † aged 50 to 64. 33, 34 No free or subsidized 
influenza vaccination service was provided by Government to non-recipients of 
CSSA. 
 
Table 1  Timeline on events of the policy change 
Dates (2011) Events 
Early January  Observed an increase in the number of hospital admissions 
due to influenza among people aged 15 to 64 years 
24 January  Set up a new surveillance mechanism in all public hospitals 
April  Working Group on Influenza Vaccination reviewed the 
situation 
May  SCVPD reviewed influenza and the vaccination policy 
July  SCVPD advised DH on expanding the recommended priority 
groups to include people aged 50 to 64 years in 2011/12 
July to September  DH studied and advised the Government on the extension of 
GVP to cover recipients of the CSSA aged 50 to 64 
1 November  Launch of 2011/12 GVP 
 
1.3.4.   Low influenza vaccination coverage (the problem) 
The coverage rate for people aged 50 to 64 was very low following the launch of 
the new vaccination policy on the 1 November 2011. In 2012/13, only 8.5% of all 
people aged 50 to 64 received influenza vaccination9; while in 2011/12, 3.1% of 
eligible people in this age group were administered free influenza vaccine under 
the Government Vaccination Programme.10 By comparison, vaccination coverage 
                                               
 
* Under the GVP, free seasonal influenza vaccination is provided to eligible persons at public clinics. 
† CSSA Scheme is a social safety net for those who cannot support themselves financially.  It is designed to 
bring their income up to a prescribed level to meet their basic needs. 
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in 2012/13 for children under 5 years, elders over 65 years, and people with 
chronic diseases were 28.4%, 39.1% and 28.2%, respectively.9 The figures show 
that vaccination coverage was low, in those who were eligible for free vaccination 
and those who paid out-of-pocket. 
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1.4 Thesis overview 
1.4.1.   Research aim 
The overall research aim of this thesis is to explore the reasons for the low 
influenza vaccine coverage rate (8.5% in 2012/13) in people aged 50 to 64 in 
Hong Kong.     
 
1.4.2.   Research objectives 
1. To assess the health needs for influenza vaccination in people aged 50 to 64 in 
Hong Kong using epidemiological, comparative and corporate approaches. 
2. To examine factors associated with the uptake of seasonal influenza 
vaccination in adults aged 18 to 64 years old by systematic literature review.  
3. To determine which factors (variables) were associated with influenza vaccine 
uptake in residents of Hong Kong aged 50 to 64 years in 2011/12 and 2012/13 
using a case-control study.   
 
1.4.3.   Knowledge gap 
Why another study on influenza vaccine uptake? 
Since healthy middle-aged adults have not previously had been the focus of efforts 
to promote influenza vaccination in many countries, a review of the literature 
yielded only a few publications on their vaccination behaviours. 35 , 36  Besides, 
these studies used national data collected a decade ago. There has been one Hong 
Kong survey published as ‘Letter to the Editor’ in 2013 by Prof Shui Shan LEE, 
who is a member of my Advisory Committee for this research37, which stated that 
the vulnerability of people 50 to 64 year for influenza ‘is less well appreciated’ 
compared to elders. 
 
This research also quantifies the association between the factors associated with 
the uptake of influenza vaccine more precisely with regard to the 50 to 64 age 
group. It recruited a sufficient number of cases (vaccinated respondents) so that 
even a small OR of 2 could be detected at a significance level of 0.05 and power 
level of 80%. The sample size of this age band is larger than vaccination surveys 
with thousands of subjects targeted to explore issues pertinent to the whole Hong 
Kong population.9,38 The result is that this study provides related new data and 
understanding of vaccination behaviour in this age group, and will serve as a 
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reference for health workers planning influenza vaccination services and devising 
health promotion strategies.    
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1.5 Thesis structure 
This Doctor of Public Health (DrPH) thesis is a hybrid of traditional and 
publication formats. The document provides a complete and systematic account of 
the research, presented in a logical and connected manner. Two research papers 
prepared for publication have been included in chapters 3 and 5, respectively. 
 
Chapter 1 introduces the thesis. Chapters 2 to 5 then address the three research 
objectives listed above in Section 1.3.2. The methods and results of each research 
questions are presented within these chapters.   
 
Chapter 2 provides background information on the local context, i.e., the needs of 
influenza vaccination for people aged 50 to 64 in Hong Kong. It presents the 
epidemiology, diseases burden, control measures, cost-effectiveness, vaccination 
policy, and stakeholders’ perspectives on influenza vaccination for this age group.   
 
Chapter 3 is a research paper based on a systematic literature review of the factors 
associated with the uptake of seasonal influenza vaccination in adults aged 18 to 
64 year-old.   
 
Chapter 4 contains information on the design and pilot of the case-control study to 
determine factors associated with the uptake of seasonal influenza vaccine in 
people aged 50 to 64 years in Hong Kong. 
 
Chapter 5 is a research paper on the case-control study. The unpublished subgroup 
analysis of the research results is also included.   
 
Chapter 6 presents an overview of the thesis as a whole, and contains a discussion 
of the results of all the chapters. It also points out the implications of the findings 
on health service and policy, suggests potential areas for future research, and 
details the dissemination plan of the research findings. 
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Chapter 7 is an integrating statement summarising the learning processes over the 
course of the DrPH degree. It is followed by the annexes as supplementary 
information, and references.  
 
Figure 1  DrPH thesis structure  
 
 
 
  
1 •Introduction of the thesis 
2 •Background on local context 
3 •Systematic literature review (paper 1) 
4 & 5 •Case-control study (paper 2) 
6 •Discussion and recommendation 
7 •DrPH integrating statement 
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1.6 Role of the researcher 
Being a public health physician in the DH Vaccination Office, I was an officer 
accountable to the government influenza vaccination programmes from 2009 to 
2012. From 2010 to 2012, I was a member of the team which was responsible for 
assessment, formulation, promotion, execution, and evaluation of the expansion of 
influenza vaccination service for people aged 50 to 64.    
  
I proposed this research because I was dissatisfied with the extremely low 
vaccination coverage in the above age group after the Government Vaccination 
Programme was launched. I generated the research framework and methods; 
drafted research protocols and questionnaires; identified, analysed and interpreted 
the data; and finally wrote and revised the report. The data collection was assisted 
by interviewers from a marketing company. I personally analysed the data and 
consulted a statistician on statistical formula, statistical analysis and interpretation. 
The thesis has been copy-edited by Mr. Cathel Hutchison to ensure a high 
standard of language and structure.  
 
 
1.7 Timeline 
I commenced the research in May 2012. Planning and preparation for the case-
control study took a year to undertake, before the pilot was conducted in June 
2013. I collected the data in July and August of 2013. My research time line is 
shown in the Gantt Chart in Table 2. 
  
 
Table 2  Gantt Chart showing the research timeline  
 
5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
Supervision and monitoring
1 Meeting with supervisor Cont' -
2 Seek advisory committee members' advice Cont' -
3 Send progress report to advisory committee Cont' -
4 Meeting with advisory committee Cont' -
Review meeting
1 Prepare review report May 12 May 13
2 Prepare DrPH review meeting Aug 12 Nov 13
3 Prepare resubmit review report Nov 12 Jun 13
Ethics approval
1 Prepare / renew ethical approval (local) Aug 12 May 13
2 Prepare / renew ethical approval (LSHTM) Sep 12 Jul 13
Systematic literature review
1 Conduct database search, review and writing Mar 13 Aug 13
2 Revise, update ane rewrite search Nov 13 Mar 14
Case-control study
1 Pilot survey Jun 13 Jun 13
2 Data collection Jul 13 Aug 13
3 Data input and collation Jul 13 Sep 13
4 Data validation and quality control Aug 13 Sep 13
5 Data entry and clearning in database Aug 13 Oct 13
6 Analyse data Oct 13 Jan 14
Writing-up
1 Prepare first draft of the thesis report Sep 13 Apr 14
2 Finish first draft on two published articles - 15/3/14
3 Revise thesis report Apr 14 May 14
4 Submit thesis report 15/5/14 n/a
Examination
1 Prepare for exam May 14 Jul 14
2 Viva 15/7/14 -
2014
Duration (Month 2012 - 2014)
Task Start Finish 20132012
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2. Background on health needs  
 
This chapter uses epidemiological, comparative and corporate approaches to 
provide background information on the local context, i.e., the need for influenza 
vaccination amongst people aged 50 to 64 in Hong Kong. The needs assessment 
draws upon the models of Stevens and Gilam39 and Wright and Cave.40 Table 3 
summarises the framework of this needs assessment, as well as the approaches, 
tasks, information used, and the sources drawn upon.   
 
In brief, an epidemiological approach explores what is effective and for whom.39 
Using this approach, local surveillance data was collected to identify and quantify 
the epidemiological nature of influenza. The cost-effectiveness of vaccination and 
the current service were then reviewed.     
 
A comparative approach is then employed to compare the levels of service 
provided to different populations.40 Following this, an examination of influenza 
vaccination recommendations, service provisions and cost-effectiveness analyses 
of vaccination programmes for the 50 to 64 population in other countries has been 
conducted. To do this, information was gathered from health authorities’ 
publications and cost-effectiveness studies. 
 
A corporate approach is used to explore stakeholders’ demands, wishes and 
alternative perspectives on the influenza vaccination service. Stakeholders in this 
study included experts, policy-makers and users. Their views were collected 
through meetings, surveys, published literatures, and communication of different 
forms. 
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Table 3  Approach, task, information and sources for the needs assessment  
Approach Task Information on Source of information  
 
 
 
 
Epidemiological 
(chapter 2.1) 
To identify the health problem  Local influenza epidemiology (2.1.1) ˙ Surveillance data from DH and WHO 
To estimate the size and nature of 
the problem 
Disease burden of influenza, vaccine coverage 
and health status (2.1.2) 
˙ Local surveillance data from hospitals  
˙ Vaccination statistics from DH   
To study the mode of transmission Influenza transmission (2.1.3) ˙ Published literature from medical databases  
To explore influenza vaccine as an 
intervention to reduce 
Vaccine effectiveness, efficacy as an methods to 
reduce influenza transmission (2.1.4) 
˙ Published literature from medical databases 
To review existing vaccination 
services  
Current local service provision (2.1.5) ˙ Programme data and budgets from DH and 
online information 
 
 
 
Comparative 
(chapter 2.2) 
 
To compare overseas influenza 
vaccination recommendations and 
services  
 
Health Authorities’ recommendation on influenza 
vaccination (2.2.1) 
˙ National health authorities documents 
˙ WHO website  
Experience of national vaccination service (2.2.2) ˙ Reports from health authorities 
Disease burden of ILI (2.2.3) ˙ Published literature from medical databases 
Health economic evaluation on vaccination (2.2.4) ˙ Published literature from medical databases 
 
 
Corporate 
(chapter 2.3) 
 
To find out what experts, 
professionals and user want 
Experts’, professionals’ and stakeholders’ opinion 
and view (2.3.1) 
˙ Scientific Committee expert opinion    
˙ Meetings with health-care providers 
Users’ attitude, knowledge, perception and 
behaviour (2.3.2) 
˙ Studies and surveys on patient opinion  
˙ Published literature from medical databases 
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2.1 Epidemiological Approach 
2.1.1.   Local influenza epidemiology  
Hong Kong is a high-density city with population of 7.18 million people living in 
1,104 km2, 41  People aged 50 to 64 constitute 22% of the population or 1.56 
million, with more than 95% of them being Chinese.41,60 The city is located on the 
coast of Southern China and has a subtropical climate. The Southeast Asia region 
is regarded as an epicentre for the emergence of new strains of human and avian 
inﬂuenza viruses.7,8 
 
In Hong Kong, seasonal influenza is usually more prevalent from January to 
March and July to August, as reflected by the epidemiology surveillance data from 
the sentinel surveillance system, hospitals and laboratory.6,42 For the past three 
years, the average influenza-like illness (ILI) consultation rate among general 
outpatient clinics ranged from 1.9 to 9.3 per 1000 consultations, and among 
sentinel private doctors ranged from 20 to 60 per 1000 consultations.43 (Figure 2 
& 3)  
 
There is a ten-fold ILI consultation rates difference between general outpatient 
clinics and private doctors was mainly due to disease case mix. Study showed 
among patients had upper respiratory tract infection, 19% consulted the general 
outpatient clinics and 81.3% consulted private doctors. 44 Recent study showed 
doubled the attending patients identified general outpatient clinics as their main 
provider for chronic disease management than private doctor.45 The difference in 
patient demography should have also contributed but this is harder to quantify. 
 
Figure 2 & 3  Influenza-like illness surveillance among sentinel general 
outpatient clinics (left) and sentinel private doctors (right), 2012-201443  
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From 2009 to 2011, influenza A(H1N1)pdm09 was the predominant influenza 
strain in Hong Kong. 46  In 2012, inﬂuenza A(H3N2) (48.4%) and influenza 
A(H1N1)pdm09 (47.4%) were the major circulating viruses.47 In the winter of 
2013/14, influenza A(H1N1)pdm09 predominated (72%) while in 2013 summer it 
was inﬂuenza A(H3N2) (85%) (Figure 4).43 Similarly, these two influenza viruses 
have been the predominant viruses in 2013 and early 2014 in Southeast Asia and 
China.48,49  So far, the majority of influenza A(H1N1)pdm09 tested in other parts 
of the world and in Hong Kong remains sensitive to oseltamivir and there has 
been no observed trend in increasing oseltamivir-resistance.49,50,51  
 
Figure 4  Influenza virus detections in 2013-1443 
 
 
2.1.2.   Estimate size and nature of the problem  
Worldwide disease burden of influenza 
Every year, influenza epidemics result in substantial morbidity, mortality and 
economic loss: 250,000 to 500,000 deaths worldwide, 3 to 5 million cases of 
severe illness, and 2% to 10% annual attack rate with 0.6 to 2.5 workdays lost per 
illness. 52 , 53 , 54  The estimated rates of influenza-associated deaths varied 
substantially by age group in different seasonal influenza epidemics, but were 
usually highest amongst elders. 
 
Influenza in working adults results in substantial health-care demand, direct 
medical costs, and indirect costs from work absenteeism and reduced productivity 
induced by the illness. No estimated figure was found in Hong Kong. The US 
Centers for Disease Control and Prevention (CDC) estimated that 2 to 10% annual 
attack rates result in 0.6 to 2.5 workdays lost per illness.52,53,54 
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Local disease burden of influenza 
In Hong Kong, the modelled estimated of deaths from seasonal influenza was 7.3 
deaths per 100,000 population per year for those aged 40 to 65 years, and 102.0 
deaths for those aged above 65.55 These figures for Hong Kong were similar to 
those for the US, which were estimated as 7.5 and 98.3 per 100,000 population per 
year for those aged 50 to 64 and ≥65 respectively.56   
 
According to the local hospital record of fatal cases who had been diagnosed as 
having influenza in public hospitals from 2005 to 2011, the number of influenza-
related deaths mainly affected persons aged 65 or above and children in the past 
influenza seasons.32 Only after the 2009 pandemic, the age group 50 to 59 was 
more affected. The deaths of these cases were mostly due to influenza 
A(H1N1)pdm09. 58   From 2000 to 2010, the median annual hospitalization rate of 
influenza A was consistently higher than influenza B for all age groups.57 
 
In 2013, Hong Kong had the usual bimodal influenza pattern with a winter peak 
(January to May 2013) and a summer peak (July to October 2013).58 In the winter 
peak, there were 78 ICU admissions, including 29 deaths, with laboratory-
conﬁrmed inﬂuenza infections.58 The majority (79%) of these were infected by 
influenza A(H1N1)pdm09. Elders aged ≥65 years and those between 50 to 64 
years constituted 44% and 30% of all severe cases respectively (Figure 5).47 A 
high proportion (78%) of these severe cases had underlying illnesses. The total 
number of ICU or death cases recorded was higher in the winter than in summer. 
On average, around 4 ICU or death cases per week were recorded in both the 
winter and summer peak.58 
 
Figure 5  Age distribution of the severe cases in 2012 and 2013 Jan to May47 
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Local vaccine coverage 
Influenza vaccine coverage of all recommended priority groups ranged from 8.5% 
to 39.1% in 2010/11 to 2012/13.59 In 2012/13, coverage amongst children under 5 
years, elders over 65 years, and people with chronic diseases were 28.4%, 39.1% 
and 28.2% respectively.9 In the general population aged 18 or above, 14% 
received an influenza vaccination in the past 12 months.38 In 2012/13, 8.5% of all 
people aged 50 to 64 received influenza vaccination.9   
 
Table 4  Seasonal influenza vaccination coverage in Hong Kong 2012/139,38  
Population groups Seasonal influenza  
vaccination coverage (%) 
Children aged 6 months to 5 years 28.4 
Persons aged 18 or above 14 
Persons aged 50 to 64 years  8.5 
Persons aged 65 years or above 39.1 
Persons with chronic medical problems 28.2 
* Respondents from different age groups with self-reported chronic medical problems 
were counted separately in the category “Persons with chronic medical problems”. 
 
Local health status 
Persons with pre-existing chronic diseases, such as cardiovascular disease and 
metabolic disorder, had much higher rates of ICU or fatal outcomes across all ages 
for seasonal patterns. People aged 50 to 64 constitute 22% of the population or 
1.56 million in Hong Kong, with more than 95% of them being Chinese.41,60 
Hypertension is a common disease (48.4%) amongst the 55 to 64 year old 
population.60 The leading cause of death for people aged 45 to 64 was malignant 
neoplasm (53.6%), disease of the heart (11.7%) and injury, poisoning and certain 
other consequences of external causes (6.6%).61  
 
Undiagnosed or asymptomatic cardiovascular, pulmonary diseases in the local 50 
to 64 aged population could be high. A local study reported only 28% of men and 
30% of women in the general population with diabetes mellitus knew that they 
had this condition.62  Another study on adults aged above 20 with hypertension, 
showed that only about half of them (46%) were ever diagnosed as hypertensive 
by a doctor.63  
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2.1.3.   Influenza transmission  
Reviews suggested droplet, aerosol and contact transmissions are possible routes 
of influenza virus transmission.64,65,66 The transmissibility of seasonal influenza 
was estimated by modelling data from the US, France and Australia over the past 
30 years, with data suggesting a basic reproduction number (R0)‡ from 0.9 to 
2.1.67,68 Different climate variables, such as temperature and humidity, affect the 
transmissibility and mode of transmission of influenza. 69, 70 The spread is also 
determined by people’s social contact and mixing patterns, such as exposure time 
and degree of physical contacts.71   
 
Experts generally agree that vaccination is the first line of defence for reducing 
influenza morbidity and mortality.72 There are other public health measures that 
could mitigate the spread and impact of influenza. These include: social distancing 
measures (isolation, quarantine, school closure); personal behavioural change 
(wearing masks, decrease social gathering); disinfection (hand washing, checks 
for fever); antiviral medication; international travel measures (travel advice, entry 
screening) and risk communication.73  
 
2.1.4.   Immunisation to reduce influenza transmission in healthy adults 
aged 18 to 64 years old 
Seasonal influenza vaccine protection depends on how closely matched the 
vaccine viruses component and the circulating viruses are, how well a person 
generates antibodies, and the timing of the vaccination. WHO stated that “in 
industrialized countries, influenza vaccines offer approximately 70–90% 
protection against clinical disease in healthy adults, provided there is a good 
match between the vaccine antigens and circulating virus(es).”52,74 This statement 
is commonly cited without detailed explanation of what it actually means. 
Therefore I conducted a literature search to examine how protective the influenza 
vaccine is for healthy adults aged 18 to 64 years old. The results are summarized 
below.  
 
 
                                               
 
‡ R0 is the average number of secondary cases infected by each primary case 
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Types of influenza vaccine 
Commonly available seasonal influenza vaccines can be broadly classified into 
inactivated influenza vaccines (IIV) and live attenuated influenza vaccines 
(LAIV). Inactivated influenza vaccines come in the form of trivalent vaccine 
(IIV3) and quadrivalent vaccine (IIV4), and they consist of three or four seasonal 
influenza viruses respectively. There are two different influenza type A strains and 
one influenza type B strain for IIV3 and an additional type B strain for IIV4. IIV3 
have been used for over 60 years and IIV4 was newly registered in 2014. LAIV 
was registered from 2009 to 2013 for use among healthy non-pregnant people 
aged 2-49 years, but it is currently not registered in Hong Kong.26,75  
 
Only inactivated TIV, but not live attenuated influenza vaccine, was recommended 
for use by SCVPD for those aged 50-64.26  In addition to the intramuscular route, 
an intradermal TIV for adults aged 18 years or above has been licensed in Hong 
Kong since December 2009. Research demonstrated that the intradermal injection 
resulted in similar antibody responses in people aged 18-60.76 
 
Indicators of vaccine protection 
The serum antibody response to the haemagglutinin (HA) is most commonly used 
to indicate influenza vaccine efficacy. This also serves as a benchmark for 
licensure of IIVs. Scientists are still exploring whether hemagglutination-
inhibition (HAI) antibody titre is a good indicator of vaccine protection, and in 
search of other serology biomarkers. 77 , 78  Before a new vaccine is authorised, 
vaccine efficacy is evaluated in randomized controlled clinical trials conducted in 
healthy individuals of different age groups. 79  Following the introduction of 
vaccination programs, vaccine effectiveness (VE) in the community is best 
determined through observational studies.79 
 
Vaccine efficacy 
A recent meta-analysis analysed eight randomised controlled trials of adults aged 
18 to 65.80 The result demonstrated the pooled efficacy of IIV3 against culture 
confirmed influenza to be 59% (95% CI 51%-67%). Another Cochrane review on 
vaccine for health adult estimated a higher vaccine efficacy of 73% (95% CI 54%-
84%), when content matched WHO recommendations and circulating strain but 
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decreased to 44% (95% CI 23% to 59%) when it did not.81 The efficacy of LAIV 
was shown by several studies to be comparable with IIV.82,83   
 
Age and immune response 
A quantitative review found that antibody response in the elderly (>65 years) is 
considerably lower than in younger adults and was estimated to be 17-53%.84 The 
limited efficacy of inactivated influenza vaccine in elderly individuals is 
associated with decreased production of vaccine-specific antibodies, rather than a 
reduced quality (avidity) in antibody. 85 Since aging is a gradual physiological 
process, it is probable that vaccine efficacy will slowly drop when age advances 
for middle-age adults towards their 60s. There have been attempts by vaccine 
manufactures to improve the vaccine protection, such as increasing the dose of 
antigen, intradermal administration, adding of adjuvants, etc. Some of these new 
products have been authorised and marketed.79 
 
Vaccine effectiveness (VE) 
Many countries, including the US, Europe, the UK, Canada, and Australia, 
conduct annual large-scale VE studies to monitor the performance of vaccine in 
the community. Their findings contribute to vaccine strain selection as well as for 
disease surveillance. A good example is the Influenza Monitoring Vaccine 
Effectiveness (I-MOVE) in Europe. 
 
Review and studies on VE for IIV have shown variable results in different 
vaccination seasons. The VE depends very much on the degree of antigenic 
matching between vaccine and the circulating virus stain, and could range from 
negative to 70%.81,82 VE estimates also differ because of clinical consultation 
outcome measurements, the use of study methodology and residual confounding 
factors.86,87 
 
For example in 2012/13, nearly all the influenza A and B viruses detected globally 
were antigenically similar to the WHO’s recommendation for the influenza 
trivalent vaccine.49 The US CDC and European Centre for Disease Control and 
Prevention (ECDC) estimated that the interim VE against all influenza types in 
their target groups in 2012/13 was 62% and 50.4% respectively, both indicating a 
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moderate effectiveness. 88 , 89  Whereas in 2011/12 when there is poor antigenic 
matching, the VE estimated by the I-MOVE study in Europe was 25%.90  
 
Reduction in workday loss and physician visit 
A Cochrane review demonstrated that influenza vaccination has a modest effect in 
reducing influenza symptoms in healthy people aged 16 to 64 years old and on 
decreased the working days lost. 91  In healthy adults younger than 65 years, 
influenza vaccination reduced ILI, working days lost and physician visits in years 
when the vaccine and circulating viruses were similar, as proven by randomized 
control trials conducted in the US in 1990s. 92, 120 For working adults aged 50 to 
64 years, research found that vaccination was associated with a significant 
reduction in the rate of ILI (adjusted odds ratio, 0.48; 95% CI 0.27–0.86) and 
fewer days of illness, absenteeism, and impaired on-the-job performance.93 
 
Pandemic influenza vaccine 
High-risk group receipt of influenza A(H1N1)pdm09 monovalent vaccine was 
associated with and a very high reduction in infection, hospital admission and 
severe complications.94 An observational study in Scotland showed monovalent 
influenza A(H1N1)pdm09 vaccine has a VE of 77% in preventing laboratory-
confirmed influenza; and 19.5% prevention of influenza-related emergency 
hospital admissions.95 In the last ‘Hong Kong Flu’ pandemic in 1968 to 1969, the 
monovalent vaccine VE for H3N2 was effective 65% against ILI, provided 93% 
protection against influenza, and 65% against hospitalisations.91  
 
Currently, seasonal and pandemic influenza vaccines are manufactured in exactly 
the same manner.12 If the manufacturing technology has not much improved since 
the 2009 H1N1 pandemic, there will probably be insufficient quantities of vaccine 
available quick enough, at least in the early phase of the next pandemic.  
 
Safety and adverse events 
The vaccine is safe and severe adverse events are rare. The most common adverse 
effects following IIV administration include transient local reactions (15-20%), 
such as pain and swelling. Some common systemic side effects are fever, 
headache, malaise, and myalgia. Severe adverse events such as Guillain-Barré 
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syndrome (1 to 2 per 1 million vaccines), meningitis or encephalopathy (1 in 3 
million doses distributed), and anaphylaxis (9 in 10 million doses distributed) are 
rare.26,96,97 According to the DH Pharmacovigilance Unit, there were two serious 
adverse events (one Guillain-Barre Syndrome and one transverse myelitis) 
following seasonal influenza vaccination in 2010/11. Each severe adverse event 
was reviewed by DH and so far DH continues to support that this vaccine is safe. 
 
The most common adverse reactions following LAIV administration (≥ 10%) are 
runny nose or nasal congestion in all ages, fever > 37.8C in children 2-6 years of 
age, and sore throat in adults.26,98 
 
Summary on vaccine protection  
After the review and analysis, I concluded that annual vaccination remains an 
effective way to prevent seasonal influenza, mitigate the severity of illness and 
reduce the impact of the disease for adult below 65. The influenza vaccine offers 
good efficacy despite variations of VE in some seasons.  
 
2.1.5.   Current local service provision  
Starting from 1 November 2011, people aged 50 to 64 years in Hong Kong were 
added as one of the nine priority recommended groups for receiving influenza 
vaccination. 99  Free vaccination was available to people aged 50 to 64 years 
receiving CSSA and those with chronic medical problems under the Government 
Vaccination Programme.100§ Five percent of people aged 50 to 64 fell into this 
group.101,102 The remaining 95% have had to pay out-of-pocket and attend private 
clinics if they want to receive influenza vaccination.   
 
Those eligible for free government vaccine may attend one of 150 public clinics 
for vaccination service.27 Those who wanted to pay out-of-pocket can attend 
over 1,600 private clinics providing influenza vaccination service. 103  Public 
clinics and private practices are widely distributed throughout the region.  
 
                                               
 
§ Those with chronic medical problems are already included in the Government vaccination programme. 
These are people who have chronic cardiovascular (except hypertension without complication), pulmonary, 
metabolic or renal problems. 
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The price of the vaccination should be affordable to the majority of people aged 
50 to 64. The charges for one dose of influenza vaccine, including the cost of the 
vaccines and consultation fees, ranged from HKD$140 to HKD$280 (USD$18 to 
USD$36), with a median of $180 (USD$23).104 Given the majority (~70%) of 
the people aged 50 to 64 earned $4000 to $19999 (USD$513 to USD$2564) a 
month, the price of the vaccine is 0.7-3.5% of their monthly income.41 Most of 
the male (89%) and female (55%) in their 50s were employed. For those aged 60 
to 64 years, half of the males were still working.41 However individuals in low-
income families without CSSA - e.g. housewives, unemployed and new-
immigrants - are neglected and less likely to pay out-of pocket for the vaccine.     
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2.2 Comparative approach  
2.2.1.   Health Authorities’ recommendation for people aged 50 to 64 years 
Many developed countries recommend the influenza vaccination for children, 
pregnant women, elders, health-care workers, and those with chronic diseases. 
However, the upper age limit for influenza vaccination recommendation differs 
between countries. The US, Austria and Estonia recommended that all people 
aged 6 months or above receive influenza vaccination; and Belgium and Ireland 
included those aged 50 to 64 years old.4,19, 105 , 106  WHO and some countries 
(Australia, Canada, Taiwan, UK) recommend those of 65 years or 
older. 107 , 108 , 109 , 110 , 111   China 112  and several European countries (Germany, 
Hungary, Iceland and Greece)106 recommended age 60 or above. Most countries 
did not include adults aged below 60 without other risk indications as their 
recommended group for seasonal influenza vaccination.110   
 
2.2.2.   Overseas national vaccination service provision  
In the US, the Advisory Committee on Immunization Practices had recommended 
that healthy adults aged 50 to 64 be vaccinated since 2000.15 The US CDC opined 
that an age-based influenza criterion for vaccination, may be more successful in 
reaching individuals with medical conditions that put them at higher risk of 
influenza complications, as compared with criteria based on recognition of the 
specific high-risk disease conditions.15 Other benefits included decreased work 
absenteeism and the need for medical visits and medication, including 
antibiotics. 113  The coverage rate of this age band in the US was 45.1% in 
2012/13.114 
 
In Belgium, 54% of the target group received an annual vaccination,2 in contrast 
around 29% in Ireland.19 In Austria, influenza vaccination is recommended for 
everyone since 2002, including those over the age of 50 years. Only eight years 
later in 2010, the US recommended universal influenza vaccination. However, the 
influenza vaccination rate amongst the general public is low (<10%) in Austria 
and the number of vaccine distributed has even been in decline since 2006.20 
Estonia is another country which recommends influenza vaccination to 50 to 64 
year olds, with a low coverage of 1% among children and the elderly.19,105 In both 
Austria and Estonia, people have to pay for the full cost of vaccination, and the 
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lack of free or subsidised vaccination is probably one of the key reasons for the 
low coverage rates.  
 
2.2.3.   Disease burden of ILI of 50 to 64 years  
ILIs was common in the community, and accounted for a large portion of illness, 
work loss, and impaired work performance during the influenza season.115 For 
people aged 50 to 64, ILI was responsible for 45% of all days of illness during the 
influenza season and 39% of all illness-related work days lost.115 In the US study, 
amongst those people not under high-risk, the mean cost per case (USD$22,304) 
and the medical cost per death (USD$118,575) was highest for the 50-64 years 
among all the other age groups. Of the total economic burden of influenza which 
included all kinds of medical costs, death and loss of earning, 64% was borne by 
those ≥65 years; 50–64 years bore 21%; 18–49 years bore 10%; and children bore 
5%.116  
 
In the 2009 pandemic, the WHO recorded the highest case fatality rate amongst 
the 50-60 year-old population in many countries. 117  The influenza 
A(H1N1)pdm09 strain disproportionately affected children and young adults, with 
the highest rate of severe disease leading to hospitalisation in those under 5 years. 
Reviews suggested there could possibly be partial immunity to the influenza 
A(H1N1)pdm09 virus in the older population. 118  This might explain why the 
incidence of severe influenza complication in the elderly was relatively smaller 
than in those between 50-60 years.  
 
2.2.4.   Health economic evaluation on influenza vaccination 
Economic analyses of influenza vaccination amongst adults aged 50 to 64 varied 
markedly between places. Among the economic appraisal methods, cost-
effectiveness analysis (CEA) and cost-utility analysis (CUA) are commonly used 
as economic evaluation tools to assess influenza vaccination. 119  Many studies 
have indicated that vaccination targeted at specific groups reduces health-care 
costs, direct medical costs and indirect costs from work absenteeism, and 
increases productivity.53,92,120 The challenge of interpreting the impact and cost-
effectiveness of influenza vaccination from these studies lies in the details of the 
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model assumptions, such as case definition, disease burden estimates and vaccine 
efficacy estimation.121 
 
Cost effectiveness studies in Australia108, the UK122 and the US123 suggest that 
national influenza programmes for 50 to 64 years olds were highly effective; and 
likely to be cost-effective in Spain 124 , Brazil, France, Germany and Italy. 125 
Among these countries, the cost-effectiveness ratio from the perspective of the 
healthcare system, ranged from US$1,151/quality adjusted life year (QALY) 
saved in Brazil to US$38,316/QALY in Italy.108,119-125 This is highly cost-effective 
if benchmarked against the UK cost-effectiveness threshold, set by the National 
Institute for Health and Care Excellence, of $40,000 to $60,000 per QALY 
gained.126 There was even a net-cost saving from a societal perspective, indicating 
that the calculated cost incurred to vaccination programmes was less than the cost 
resulting from work day loss, medical care and others costs combined.108, 119-125 
 
A local Hong Kong study indicated that territory-wide influenza vaccination for 
the working age population did not cut publicly-funded medical costs, with an 
estimated cost-benefit ratio of 3.81:1**.29 The working age population referred to 
all adult, and as such, there was a substantial proportion of healthy young adults 
included in the model. There were also assumptions that a lower influenza-
attributable hospital admission rate and a low absenteeism of workers than other 
places. These model assumptions lead to a low cost-effectiveness in the research 
result. Another study in Hong Kong found that the influenza vaccination of 
elderly people (aged 65 years or above) living in the community was cost-
effective from a societal perspective.127 Locally, it is possible that an influenza 
vaccination policy targeted towards the higher end of the age range from 50 to 64 
years would be more cost-effective.  
 
  
                                               
 
**  By proportion HK$3.8 spent on vaccination can save HK$1 because influenza-like illness has been 
prevented. 
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2.3 Corporate approach  
2.3.1.   Experts’, professionals’ and stakeholders’ opinion and view  
Many health authorities in the world have not provided national influenza 
vaccination services for the group under study, despite studies demonstrating the 
cost-effectiveness of this approach. Local experts specialized in influenza 
vaccination in Hong Kong held a different view. A meeting was convened by DH 
on June 2011 and the panel of experts in the SCVPD suggested including adults 
aged 50 to 64 years as a high-risk target group for vaccination.32 The decision was 
based on the local context, the likelihood that the influenza A(H1N1)pdm09 strain 
would continue to circulate in the coming years, and a good protection provided 
by the vaccine against clinical influenza in healthy adults.4  
 
Internal meetings and communications with representatives of public health-care 
providers of DH clinics and public hospitals were held. The meetings collected 
views on the feasibility of expanding service provision to include giving free 
vaccination to eligible people aged 50 to 64. Most services agreed that they had 
the capacity to undertake the additional workload. 
 
2.3.2.   Users’ attitude, knowledge, perception and behaviour  
Determinants of health behaviours, in particular on uptake of influenza 
vaccination, have been extensively examined from different perspectives. In 
performing a systematic review of the literature in Chapter 3, numerous studies 
were found on attitude, knowledge, perception, and behaviour towards influenza 
vaccination. The literature primarily focuses on elders, children, health-care 
workers and other high-risk populations. Healthy middle-aged people had not 
previously been the focus of efforts to promote influenza vaccination in many 
countries. As such, only a few publications on healthy middle-aged adults were 
found.  
 
Two local surveys on public’s perception of influenza vaccine, which included 
middle-aged adults, were identified. One household survey was conducted on 
people aged 50 to 64 years37 and the other general population survey was on 
adults aged 18 years and above.38 The former survey found that ‘previous 
vaccination history’ and ‘age between 60 to 64’ were the main associations with 
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vaccination. The general population survey was conducted by the Hong Kong 
Medical Association in 2013 on adults aged 18 years and above. It found that the 
two most common reasons for refusing vaccination were ‘in good health condition, 
and were not afraid of getting influenza’ (39%) and ‘no such habit/never thought 
of/not necessary’ (18%).  
 
There were also several local surveys conducted by DH128 and local universities 
on public’s attitude on the monovalent H1N1 vaccine. 129 , 130 In these surveys, 
perceptions of the low risk of the pandemic influenza and concerns about adverse 
effects after vaccination were the primary reasons for avoiding vaccination. 
Respondents seldom complained about cost and accessibility.   
 
In the US, the 2004 National Immunization Survey showed that older age (OR 1.4 
to 2.1), higher education level (OR 1.4), recent doctor visit (OR 2.0), and beliefs 
about vaccine effectiveness (OR 2.7) were variables which were frequently 
positively associated with increased vaccination in people aged 50 to 64 years.35 
In 2003, a national Australian study on the determinants of vaccination in people 
aged 40 to 64 years and over, identified that the choice of influenza vaccination 
was influenced more by beliefs on vaccine effectiveness (OR 4.8), having medical 
risk factors (OR 4.8), and in occupational risk group (OR 2.4), than socio-
demographic factors such as gender and income.36  
 
 
  
 43 
 
2.4 Discussion and Summary on needs assessment 
2.4.1.   Discussion 
Epidemiology approach 
The epidemiological approach demonstrated that influenza accounted for a 
substantial mortality and morbidity in people aged 50 to 64. The conclusion was 
mainly based on local ICU admission and fatal cases, the disease pattern of the 
influenza virus and the vaccination status of people aged 50 to 64. The evidence 
was convincing, but there were limitations to the hospital surveillance data. The 
admission criteria for local ICU admission in each hospital differed and it was 
uncertain whether physicians’ had a preference for admitting patients from certain 
age groups. It would be useful to compare previous trends but information is not 
available in the public domain. 
 
In many parts of the world, influenza A(H1N1)pdm09 disproportionately affected 
children and young adults, with the highest case fatality was recorded in the 50 to 
60 year-old population. 131  Review suggested there could possibly be partial 
immunity to the influenza A(H1N1)pdm09 virus in the older population.132 This 
hypothesis was supported by subsequent studies which showed 33% of humans 
over 60 years had cross-reacting antibodies to influenza A(H1N1)pdm09 virus by 
hemagglutination-inhibition and neutralization tests.132,133   
 
In 2010, WHO estimated that influenza A(H1N1)pdm09 would continue to 
circulate for some years to come 134 , and it has continued to be the major 
circulating strain in Hong Kong since its emergence in 2009. The attack rate of the 
influenza A(H1N1)pdm09 strain is expected to decrease in subsequent years 
because more people have developed immunity following infection or 
vaccination. In addition, other strains could possibly become predominant and 
present a different epidemiological pattern. Local surveillance does not indicate 
the current dominant influenza virus H3N2 has increased serious influenza 
complications in people aged 50 to 64.135   
 
Local cost-effectiveness studies on the 50 to 64 age groups have not indicated that 
influenza vaccination has been cost saving from a society-wide perspective. Some 
reviews even doubt the effect of vaccination in reducing hospital admission and 
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complication rates in healthy people aged 16 to 64.80,170 The seasonal vaccine in 
2014/15 will contain influenza A(H1N1)pdm09 component and protect the 50 to 
64 age group from this virus, which has caused high ICU admission and deaths in 
this age group.136 
 
Comparative approach 
Except in the US, Austria and Estonia, most countries did not include healthy 
adults aged 50 to 64 as a recommended target group. Similar to the US, Hong 
Kong had low influenza vaccine coverage and a high proportion of diagnosed 
chronic diseases (diabetes and cardiovascular disease) amongst adults in their 
mid-50s. The US strategy is to use an age-based vaccination criterion in defining 
risk group and covered those aged 50 to 64, regardless of their chronic disease 
status. This could reduce severe influenza complications and death by vaccinating 
all with know or unknown chronic disease status.  
 
Based on the searched information, I could not determine why health authorities 
have chosen not to provide government influenza vaccination services for healthy 
individuals between 50 to 64 despite favourable findings in cost-effectiveness 
studies. Possible reasons for this could be insufficient evidence, inappropriate 
study assumptions, overlapping vaccination services by employers or private 
companies, or strained health-care manpower in the public sector. The experience 
in Hong Kong differed from other countries in term of health-care systems, 
vaccination coverage, disease patterns and acceptability of influenza vaccination. 
Overseas practices and recommendation from overseas studies were not directly 
applicable in a local setting.     
 
Corporate approach 
The local professions in the SCVPD agreed that there was a need to recommend 
that the 50 to 64 year-old should be offered vaccination. For the general public, 
surveys have informed us that many Hong Kong adults perceive vaccination to be 
unnecessary and worry about the side effects. The findings highlighted the 
discrepancies between the normative need of the professionals and the felt need of 
the public. Health promotion strategy should be formulated to decrease this gap 
and increase the acceptability of the influenza vaccination service. 
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2.4.2.   Summary  
In Hong Kong, influenza causes significant illness and economic loss among 
people aged 50 to 64. The vaccination rate in this age group was low (8.5%). Most 
countries did not include healthy adults aged 50 to 64 as a recommended target 
group for seasonal influenza vaccination. Local experts expressed that there was a 
need to vaccinate this group, but most adults in the population did not perceive 
this need.    
 46 
 
3. Systematic literature review (Research paper 1) 
 
This chapter examines what factors associated with the uptake of seasonal 
influenza vaccination in adults aged from 18 to 64 years old. It presents a research 
paper based on a systematic review of the literature, as well as related unpublished 
data.   
 
3.1 Research paper 1  
Title:  Factors associated with the uptake of seasonal influenza vaccination in 
adult: A systematic review 
 
Author(s): May PS YEUNG, Richard COKER  
 
Type of publication: Original contribution  
 
Stage of publication: Pending submission 
 
Academic peer-reviewed: Pending 
 
Authors’ Affiliations:  Faculty of Public Health and Policy, London School of 
Hygiene & Tropical Medicine 
 
Candidate’s role:  I conceived of the study, wrote the systematic review protocol. I 
reviewed all the searched titles and abstracts, and read all of the selected full text 
articles as an independent reviewer.   
 
Keywords: seasonal influenza vaccine uptake, systematic review, healthy adults, 
associated factors 
 
Word count abstract: 239 
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Abstract 
Background 
Seasonal influenza (‘influenza’) epidemics results in significant economic loss 
due to worker absenteeism and decreases in productivity in the general adult 
population. Influenza vaccination (‘vaccination’) has proven to be effective but 
vaccine coverage for non-high risk adults is low in many countries. Studies on 
different populations have shown a variety of factors that influence attitudes in the 
general population on vaccine uptake. 
 
Objective 
This study aims to use a systematic and evidence-based approach to explore the 
demographic, socio-psychological factors associated with the uptake of influenza 
vaccination amongst adults from 18 to 64 years. 
 
Methods 
A systematic literature review was performed on literature searched in databases 
EMBASE, MEDLINE, Cochrane Library and Electronic Theses Online Service 
(EThOS), up until November 2013. A critical appraisal framework was designed 
to assess the methodological quality of the studies. 
 
Results 
Twenty-three articles met the inclusion criteria and were selected for outcome 
analysis and 21 are quantitative observational studies. Advance in age and having 
chronic diseases were strongly indicative of vaccine uptake. Perceptions such as 
vaccine efficacy and vaccine safety and adverse events, were more influential than 
the level of knowledge on influenza and its vaccination. Advice from 
doctors/health professionals/family/close friends, and free vaccination, were also 
key factors in association with uptake of vaccination.   
 
Conclusion 
This study highlighted that perceptions, advice from doctors/health 
professionals/family/close friends and free vaccination were changeable factors 
that are positively associated with influenza vaccination in adults aged 18 to 64 
years. 
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Introduction 
Seasonal influenza (‘influenza’) is a constant public health threat that causes 
severe illness, hospitalisation and death amongst high-risk groups. Influenza 
transmission largely occurs in the community, and large-scale and frequent 
epidemics can result in significant economic losses due to worker absenteeism and 
decreased productivity.1, 2 Controlling the incidence of seasonal influenza remains 
a challenge.    
 
For most healthy adults, influenza is a mild and self-limiting disease. Influenza 
vaccination is effective in reducing influenza-like illnesses, working days lost and 
physician visits.3, 4  A recent review showed no evidence that vaccination can 
reduce hospital admission or complication rates.5   
 
The vaccination coverage rates in non-high risk adults of 18 years and above have 
been low in many developed countries. Non-high risk groups usually include 
individuals of less than 65 years of age without a chronic disease, as well as those 
not working in the health-care sector. In Australia, European countries and the US, 
the influenza coverage rates in non-high risk adult ranged from 5.8% to 35.7%.6-8   
 
In a global policy survey, 40% of the 157 countries reported having an established 
policy regarding seasonal influenza vaccination.9 The WHO and the health 
authorities of most countries do not recommend healthy adults to receive annual 
vaccination against seasonal influenza.10 Some exceptions include the US, Austria 
and Estonia, who recommended that all people aged 6 months or older should 
receive influenza vaccination.11-13   
 
The recent pandemic in 2009 may have shifted perspectives on vaccinating 
healthy adults. Reviews on international epidemiology reported that influenza 
A(H1N1)pdm09 virus disproportionately affected and increased hospitalisation 
and death in adults aged below 65.14-16 It was estimated that 80% of deaths in the 
pandemic 2009 were amongst people younger than 65 years of age.  This differed 
markedly from typical seasonal influenza epidemics, during which 80-90% of 
deaths are estimated to occur in people of 65 years and older.17 Similarly, in the 
influenza pandemic in 1969/70, people of working age were most severely 
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affected.18 The influenza A(H1N1)pdm09 virus continued to be the predominant 
circulating strain in North America, Europe and China after the 2009 pandemic.19   
 
Other benefits of vaccinating healthy adults included decreased work absenteeism 
and need for medical visits and medication, including antibiotics.20 Besides, many 
middle-aged adults have undiagnosed medical conditions such as diabetes 
mellitus.21, 22 Vaccination provides moderate protection to both high-risk and non-
high-risk groups from influenza as well as its complications.5, 23     
 
More recent reviews have found that the use of influenza vaccine was associated 
with a lower risk of major adverse cardiovascular events.24 This may be due to 
physiological changes in the lungs by the influenza virus in lower blood oxygen 
levels, or directly injure heart muscle cells, leading to heart failure.25  
 
In many countries, only high-risk groups are subsidised or offered a free 
vaccination service. Health authorities have generally concentrated their 
vaccination promotion campaigns on high-risk groups. A better understanding of 
the reasons behind people’s choice of vaccination will guide the planning of health 
and promotion programmes for improving general population vaccine coverage.    
 
Objective and PICOS  
The objective of this paper is to systematically review factors associated with the 
uptake of the seasonal influenza vaccination (refer as influenza vaccine or vaccine 
below) in healthy adults aged 18 to 64 years. Details associated with the research 
question formulated using population PICOS are:26 
• Participants: studies of adults from general population aged 18 to 64 years 
• Intervention/exposure: any factors affecting the outcome, e.g., demographic, 
psychosocial, health-care system associated with outcome 
• Comparator: those who did not receive annual seasonal influenza 
vaccination  
• Outcome: uptake of receiving influenza vaccination 
• Study design: all types of studies with quantitative data on the strength of 
association between intervention and outcome.  
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Method 
A systematic review was performed in November 2013 on published literature in 
medical databases EMBASE (1947 to 2013 November), MEDLINE (PubMed) 
(January 1966 to October 2013) and Cochrane Library (1996 to present) including 
Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database 
of Systematic Reviews (CDSR) and Database of Abstracts of Reviews of Effects 
(DARE) via Cochrane Library.  
 
Additional search  
The search was further amplified by scanning the reference lists and 
bibliographies of relevant papers. Search for dissertation and theses from 
Electronic Theses Online Service (EThOS) using the defined keywords was also 
performed. 
 
Inclusion criteria 
Subjects were individuals aged 18 to 64 years in the general population, 
irrespective of influenza immune status. The publications were in English. 
 
Exclusion criteria 
Studies were excluded if: 
• more than 50% of study participants were not adults from the general 
population aged 18 to 64 years, e.g., health-care workers, pregnant women 
or patients with chronic disease(s); or only subjects from high-risk group 
were sampled. 
• the study aim/objective was only related to the 2009 H1N1 pandemic 
vaccination 
 
Keywords 
Keywords used include a combination of free text terms and Medical Subject 
Heading (MeSH). Search terms for included seasonal influenza vaccin*, influenza 
vaccin*, human, accept*, attitude, intent* and perception.   
Study selection and data extraction 
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Articles were first screened by title, then abstract and/or full text. For selected 
articles, the following data was extracted for each selected article: author and date 
of publication; place; study design; time of data collection; theoretical model used 
(if any); and factors associations with intentions/behaviour. 
 
Assessment and reporting of included studies 
Since most of the selected studies were observational studies and surveys, a 
critical appraisal framework was designed to assess the methodological quality of 
non-randomised trials. For these studies, the transparency or clarity of the 
reporting is considered key.27 Reference has been made to the US CDC 
Transparent Reporting Evaluations with Nonrandomized Designs27 and National 
Health Service’s (NHS) Critical Appraisal Skills Programme (CASP)28 in 
reviewing the quality of the articles. The reporting of this review follows the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Statement.29 This is to ensure scientific rigour and comprehensiveness in 
reporting. 
 
Results 
The search was performed on November 2013 November and a total of 2,235 
articles published in English were identified. Twenty-three articles fulfilled the 
inclusion criteria were retained for critical appraisal and analysis. Most of these 
articles are quantitative observational studies. There were eighteen cross-sectional 
surveys; 1 case-control study; 1 randomised-control trial; 2 longitudinal studies; 
and 1 meta-analysis. The studies were carried out in the following countries: 
Australia, China, Japan, 11 European countries, France, Netherland, Spain, and 
the US.  The data of the articles were collected from 1997 to 2012. Twenty-one of 
these articles were of high or moderate methodological quality. The summary of 
the characteristics and key results of these articles are shown in Table 1. 
 
The uptake of vaccination is known to be associated with multiple factors. In the 
selected studies, the results were mostly subjective opinions given by study 
participants, rather than an objective accounts using health-care quality indicators. 
The strengths of associated factors with influenza vaccination uptake are 
presented by adjusted odds ratios (ORs) in Table 2.   
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The associated factors were categorised into 8 groups (demography, knowledge, 
need, health behaviour, belief and perceptions, health-care system, advice and 
social support and external environment). The important findings from each 
article have been included. The quality of the evidence (i.e., OR) of individual 
factors are shown in Table 2, and this is based on critical appraisal of the cited 
articles.   
 
Theories and models of behaviours 
Most selected articles did not state what behavioural theory or model they used. 
The Health Behavioural model was the commonest model and was cited in three 
articles. The Protection Motivation Theory, Theory of Reasoned Action, 
PRECEDE model and Utilities Theory were each used separately in one article. 
 
Demography 
Increasing age was an important factor associated with uptake of vaccination in 
studies in European and Asian populations (OR 1.06-23.7).6, 31, 39, 41 Education 
level and being health professionals were inconsistently associated with getting 
vaccinated in different studies.6, 37, 39, 40, 48 Sex, ethnic origin, income, employment 
and household size were not consistent predictors of influenza vaccination in 
different European countries.6, 36 
 
Knowledge on influenza and influenza vaccine 
There was a weak association between increased knowledge and vaccination, and 
the strength of association was relatively weak when compared to most of the 
other groups. People with better knowledge of influenza and its vaccination (OR 
1.6-3.3)39,45 and on the effective measures to prevent influenza (OR 1.59-3.06)45, 
were more likely to get vaccinated. Those who had better knowledge of 
vaccination required annually (OR 1.59)39, vaccine being recommended to some 
high-risk groups (OR 1.30)45, and on other general information of influenza 
transmission and treatment (OR 1.25)35, were slightly more likely to choose to be 
vaccinated than those without adequate knowledge.    
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Needs 
Presence of chronic disease(s) was the most frequently stated reason for people 
getting vaccinated (OR1.38-13.7).6, 31, 32, 35-37, 40, 43, 48 Recent visits to a medical 
doctor may or may not be associated with vaccination.31, 44, 45 People consulted 
doctors for acute and chronic illnesses and therefore visiting a medical doctor did 
not imply having long-term illnesses. The association of living with children or 
elders at home was inconclusive.48, 50 It is uncertain if self-reported health status 
had an association.38, 44   
 
Health behaviour   
Previous influenza vaccination was a good predictor for subsequent vaccination 
(OR 4.06-5.18).33, 40, 43, 50 Health behaviour such as smoking was not associated.42, 
50 No data was found on other health behaviours such as drinking or frequent 
exercise.   
 
Belief and perceptions   
Belief and perception were difficult to distinguish from each other so they were 
grouped under the same heading. Perception of vaccine efficacy (OR 2.7-10.55) 
had the strongest association in this group.37, 44, 45 Perceived vaccine safety and 
adverse events after vaccination were a concern (OR 10.5) and fear of adverse 
reaction deterred people from getting vaccinated (OR 0.21).45 Perceived chances 
of contracting influenza (OR 1.62-5.40) and perceived health impact of having 
influenza (OR 2.21) were also positively associated with intention to get 
vaccinated.39 It is inconclusive whether fear of injections had an association.38, 45   
 
Health-Care System   
Free vaccination (OR 4.5-7.8) was strongly associated with vaccination.46, 48 
People who had easy access (OR 1.8) and who were satisfied with health-care 
service were more likely to receive the influenza vaccine (OR 1.23).31,42 The 
usefulness of interventions to remind clients, such as telephone calls and post card 
reminders, was uncertain.46 
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Advice and social support  
Doctors’ advice (OR 4.03-7.82) and health professionals’ advice (OR 1.23-13.0) 
was significantly correlated with influenza vaccination.6, 31, 45, 47 Recommendation 
from health-care workers was an intervention encouraged by many of the selected 
articles based on its strong association. Relatives’ or close friends’ advice (OR 
17.74), or they having received influenza vaccination in the last year (OR 6.44), 
were associated with acceptance of influenza vaccine in a Japanese study.45, 47 
 
External environment   
Past experiences of infectious diseases and widespread severe epidemic could 
influence people’s perception of vaccination.52 The post-pandemic effect on 
seasonal influenza vaccination varied in different places. In Beijing China, a study 
did not find impact of the 2009 pandemic on vaccination in the 2010/11 season.51 
In France, there was a moderate negative effect of the 2009 pandemic on 
vaccination in the following two seasons.30 
 
Discussion 
A person’s decision to uptake influenza vaccination is influenced by a number of 
contributing factors. Most of the selected articles were surveys and they reflected 
the conscious subjective opinion of individuals. Choice of uptake could be also 
influenced by change of health service, media, culture, values and social norms.   
 
Interpretation of the result 
This study is a systematic and evidence-based approach to the survey design. A 
range of odds ratios for factors associated with influenza uptake are presented and 
grouped artificially into 8 domains. The studies reviewed used broad and imprecise 
terms, e.g. ‘knowledge of influenza and influenza vaccination’ or ‘access to health-
care settings’ could be subject to individual interpretation. Hence the odds ratios 
are not meant to be compared by their absolute values, neither within nor across 
domain. However, the consistency and coherence of high ORs of a factor was 
strongly indicative of a high strength of association across populations.   
 
Advance in age and having chronic disease(s) were the two most consistent and 
strongly associated factors with influenza vaccine uptake. Increase in age usually 
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increases the chance of contracting chronic diseases so these two factors were 
related.   
 
Perceptions such as vaccine efficacy, and safety and adverse events, were more 
closely related to vaccination than knowledge. Meta-analysis supported risk 
perceptions are central to many health behaviours.53 Although there is a general 
consensus that knowledge is positively correlated with positive health behaviours, 
the selected studies demonstrated a mild association of the two here.   
 
If greater knowledge increased the tendency to be vaccinated, one would expect 
doctors, nurses and other health professionals to have a high vaccination rate, 
irrespective of whether it was compulsory or not. However, being a health 
professional was not associated with vaccination in some European countries 
(Germany, Italy and Poland).6 The coverage rates were generally low amongst 
health professionals in the same study on 11 European countries, with coverage 
ranging from the lowest at 6.4% (Poland) to 26.3% (Czech Republic).6 Of course, 
a belief in the professional duty of care or a perception of a greater occupation 
hazard would also provide reasons for health professionals to be vaccinated. 
 
Advice from health professionals/family/close friends, and free vaccinations, were 
crucial factors which determined the choice of many to be vaccinated. Hence, 
health professionals could help to implement influenza vaccination programmes 
and contribute to increasing the vaccination coverage rates in their patients. 
 
Past experiences of influenza pandemic vaccination and the widespread severe 
epidemic, could influence perception on vaccination. Although evidence 
demonstrated that pandemic was only insignificantly or moderately negatively 
associated with (i.e., reduce) later seasonal vaccination. 
 
Excluding articles from pH1N1 vaccine 
The reason for excluding articles related to the pH1N1 pandemic vaccination was 
the determinants for influenza vaccination were different from that of pandemic 
vaccination.48 Systematic reviews found that younger age, believing in vaccine 
safety and/or effectiveness, and higher socioeconomic status, were important 
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determinants of the pH1N1 vaccine.54, 55 The perceived mild nature of the disease 
was one of the major reasons the public refused the pH1N1 vaccine.56 The impact 
of extensive media publicity on Guillain-Barre syndrome and adverse pregnancy 
outcomes could have caused a reduction in the pH1N1 vaccination campaign 
worldwide. In addition, the pH1N1 vaccine was a one-off dose and administered 
as an emergency measure in the pre-pandemic time. Therefore, the types and 
magnitudes of factors associated with the uptake of vaccination could possibly 
differ. 
 
Heterogeneity and unsuitability for pooling results using meta-analysis 
While the selected studies all examine the factors associated with the uptake of the 
seasonal influenza vaccination, there are substantial heterogeneities amongst 
them. There is diversity in the demography of the study respondents because data 
was collected from more than 15 countries. Methodological variation exists 
because studies had different aims, sampling subject recruitment criteria, scope of 
question asked, and outcomes measurement.  
 
A meta-analysis of the adjusted ORs in the selected articles was not performed. 
Firstly, since most of the associated factors (variables) were examined in one to 
three studies, pooling of data would not represent the overall result. Secondly, 
meta-analysis is unsuitable for a group of studies with sufficient heterogeneity. 
Thirdly, observational studies were conducted in non-controlled environment 
subject to much bias and residual confounding. Meta-analysis should be 
considered when a group of studies is sufficiently homogeneous in terms of 
participants, interventions and outcomes to provide a meaningful summary.137   
 
Common confounders and effect modifiers 
Health seeking behaviour is a complex model and factors could possibly interact 
with one another. For example, advice from a doctor and health professionals 
could be linked to other associated factors. Older people and those with chronic 
disease(s), visit their doctors more frequently. The frequency of doctor visits could 
also be influenced by gender, ethnic origin, income, employment, household size, 
etc. Personal contact with a doctor and health-care workers allowed information to 
be gathered and enhance one’s knowledge on influenza and its vaccine. Patients 
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attended clinic have higher chance of exposure to other vaccination measures, 
such as being recruited to free vaccination programs, introduced to media 
campaigns, enrolled to the recalls and reminder systems than those who did not. 
The association between these factors could be confounding or have a modifying 
effect on each other.   
 
Common limitations of the selected studies 
Since most included articles are cross-sectional surveys, recall bias and/or report 
bias exist. For self-administered questionnaires, misclassification could have 
occurred due to cultural or religious difference, e.g., the report of having chronic 
disease(s). Nonetheless, the approach of analysing self-reported data on chronic 
conditions were reasonably accurate.57 The sample was also restricted by the 
sampling method, e.g., individuals without a home telephone were excluded for 
telephone interviews.  
  
Relationship between perception, intention and behaviour 
People who have positive perceptions towards vaccination or even expressed their 
interest in receiving the vaccine, does not necessarily lead them to receive the 
actual vaccination.58 A meta-analysis with 47 experimental tests on behavioural 
intentions and behaviour, concluded that a medium to large change in intention 
leads to a small to medium change in behaviour.59 Even in those intended to get 
vaccinated, only half had actually been vaccinated.60 So there is an anticipatory 
perception-intention-practice gap and one needs to be cautious and be vigilant for 
additional components that could contribute to people’s practices on vaccination. 
Thus it was difficult to identify a causal relationship in the cross-sectional 
surveys. One possible method may be to follow up participants in their actual 
behaviour afterwards. 
 
Conclusion 
This study highlighted that perceptions, advice from doctors/health 
professionals/family/close friends and free vaccination were changeable factors 
that are positively associated with influenza vaccination in adults aged 18 to 64 
years. 
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Fig 1.  Flow diagram of study selection process      
 
 Electronic database search 
Cochrane 214 
Medline 1602 
1799 excluded for 
• Not fulfilling inclusion criteria 
• Duplicated 
• Irrelevant 
• Only describe pandemic 
• Non-English articles 
2235 titles were screened by 
keywords and/or eye browse 
Additional search 
Google 400 
EThOS 19 
 
32 full text articles were critically appraised 
436 abstracts were read 
408 excluded  
• Non-eligible study participants  
• Non-English articles 
• Review, letters to editors, 
comments 
 
Additional search 
From reference list 4 
9 excluded 
• Not fulfilling inclusion criteria 
• Duplicated study 
• Poor quality 
 
23 included for outcome analysis (Table 1) 
(18 cross-sectional surveys, 1 case-control study, 
1 randomised-control trial, 2 longitudinal studies 
and 1 meta-analysis). 
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Table 1.  Characteristics and key results of the included studies  
First author, 
publication year, 
place of study 
Study design  Participants Data collection 
method and date 
Key findings: 
Factors associate with behaviour or intention of receiving 
influenza vaccine in healthy adults†† 
 
Major limitations 
Blank et al.,6 2009  
(Austria, Czech 
Republic, France, 
Finland, Germany, 
Ireland, Italy, Poland, 
Portugal, Spain and 
UK)  
Cross-sectional 
survey 
Approximately 
1200 to 2000 
representative 
adults per 
country 
Annually repeated 
population-based 
surveys (telephone, 
postal or face-to-
face) on influenza 
vaccination; 
2006/07 to 2007/08 
The associated factors were being elderly (OR 2.4 -23.7), 
suffering from a chronic medical condition (OR 1.8 -13.7) or 
belonging to both of these risk groups drastically enhanced 
the odds ratios (OR 3.1-120.1) in all countries. Working as 
health professional was less strongly correlated with influenza 
vaccination and in some countries non-significant. 
Misclassification such as 
interviewees describing 
themselves as chronically ill 
may stem from local 
differences in the 
comprehension of the term 
chronic illness, e.g., due to 
cultural or religious influences. 
Caille-Brillet et al.,30 
2013 
France 
Longitudinal 
study 
 
1,451 individuals 
from 575 
households 
Data from Cohort 
for Pandemic 
Influenza 
(CoPanFlu); Dec 
2009 
A moderately negative effect of the 2009/10 pandemic on 
vaccination behaviours.  Amongst the population with no risk 
factors, the post-pandemic influenza vaccine coverage 
decreased, with people aged 15 to 24 years and 45 to 64 years 
being most likely to abandon vaccination. 
The CoPanFlu France cohort 
was originally designed to 
assess the relative risk of 
infection by the pH1N1, not the 
uptake of influenza vaccination. 
Carrasco-Garrido et 
al.,31 2009 
Madrid, Spain 
Cross-sectional 
survey 
7,341 adults 
aged 16 and 
above 
Personal, home-
based interviews 
using structured 
questionnaire; Nov 
2004 to Jun 2005 
Those who believed they were satisfied with the health 
services were more likely to receive the vaccine (OR = 1.23).  
Age (comparing aged 50-64 with 16-49, OR 1.97), chronic 
conditions (OR 3.9) and visit to a GP for medical consultation 
(OR1.55) were also associated. 
The response rate on the 
questionnaires was 40%. Self-
reporting data were not 
validated and there was no 
explanation on checking on 
validity.   
Cassidy et al.,32 2009 
US 
Cross-sectional 
study 
 
1,311 patients 
attending AED 
Interview AED 
patients and 
retrieve records; 
Dec 2005 Mar 
2006 
Factors associated with vaccination agreement were 
comorbidity (OR 1.48) and being 50 to 64 years old with prior 
immunization (OR 2.44). Factors unrelated to vaccination 
were age, sex, race and pregnancy.  
Random interviewer effect was 
statistically significant.  Many 
who agreed to be immunized 
(74%) were already vaccinated. 
Chapman and 
Coups,33 1999 
US 
 
 
Cross-sectional 
survey 
79 university 
employees and 
435 corporate 
employees  
Interview and self-
administered 
questionnaire; fall 
1997 
Factors associated included perceived effectiveness (r = 0.49), 
likelihood of side effects (r = -0.31), previous flu shot (r = 
0.66) and older age (r = 0.10) and percentage of co-workers 
who also received the shot (r = 0.24). 
For the university employees, 
vaccine acceptors and decliners 
were recruited in different 
ways. 
                                               
 
†† All ORs (Odds ratios) showed are adjusted OR and statistically significant with p≤0.05, unless otherwise stated 
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First author, 
publication year, 
place of study 
Study design  Participants Data collection 
method and date 
Key findings: 
Factors associate with behaviour or intention of receiving 
influenza vaccine in healthy adults†† 
 
Major limitations 
Chapman and 
Coups,34 1999 
US 
 
Cross-sectional 
survey 
 
412 corporate 
employees 
offered a free flu 
vaccine 
Interview and self-
administered 
questionnaire; 1-10 
Dec 1997 
There was a small relationship (OR 2.38) between vaccination 
acceptance to monetary time preferences (extent to which one 
value future outcomes relative to immediate ones). Other 
variables, such as perceived effectiveness of the vaccine were 
more predictive. 
The relationship between time 
preferences and vaccination 
acceptance was weak and 
inconsistent, although it was 
statistically significant. 
Cohen et al.,35 2012 
New York, US 
Cross-sectional, 
part of a 
randomised 
controlled trials 
(RCT) 
2,788 
participants from 
509 households 
(contained ≥3 
people in the 
household) 
20 minute 
structured 
interview, 2006/07 
and 2007/08 flu 
seasons 
Positively associated factors were female gender, older age, 
higher education, greater primary respondent knowledge of 
flu, having been born in the USA, and having a chronic 
respiratory condition (OR 2.03). The most common reasons 
for not being vaccinated were the beliefs that vaccination was 
unnecessary or ineffective. 
Data were collected as part of a 
larger community study of 
households.  Data for all 
participants were reported by a 
single household respondent. 
Endrich et al.,36 2009 
Austria, Czech 
Republic, France, 
Finland, Germany, 
Ireland, Italy, Poland, 
Portugal, Spain and 
UK 
Longitudinal 
survey 
92,101 
participants from 
11 different 
European 
countries 
Annually repeated 
population-based 
surveys (telephone, 
postal or face-to-
face) on influenza 
vaccination; 
2001/02 to 2006/07 
Chronic illness was consistently correlated with vaccination 
across 11 European countries (ORs from 1.38 to 3.06).  
Belonging to the risk group (aged ≥65 years, or suffering from 
chronic illness or work in the medical field) was the strongest 
predictor of having received the vaccination (OR 1.94 - 
11.83).  Other socioeconomic factors (gender, household 
income, size of household, educational level and population 
size of living residence) were differently expressed amongst 
countries.   
Information about 
characteristics of non-
responders was lacking.  All 
data collections rely on self-
reported information which 
may be a source of potential 
error. 
Horby PW et al.,37 
2004 
Australia 
Cross-sectional 
survey 
 
1,496 people 
aged 40 to 64 
years 
Computer-assisted 
telephone 
interview; 19 
October to 15 
November 2001 
Independent factors associated with vaccination were: 
belief that influenza vaccine is effective in preventing 
influenza (OR 4.8); the presence of chronic disease (OR 1.6); 
and occupational risk group (OR 2.4). 
The response rate was 30%. 
Bias in excluding household 
without a fixed telephone and 
of residents and recall bias.  
Hong Kong Medical 
Association,38 2013 
Hong Kong, China 
Cross-sectional 
survey 
 
1,013 Cantonese-
speaking Hong 
Kong Citizens of 
age 18 or above 
Web-based 
Computer Assisted 
Telephone 
Interview; 6 to 16 
November, 2012 
Only 68.4% of people knew influenza vaccination is the most 
effective means of preventing influenza infection. A large 
number of respondents believed that taking in more Vitamin C 
(52%) can help protect them against influenza. Over 80% of 
people did not know ‘herd immunity’. 
The data was presented as 
percentage and without 
statistical comparison and 
adjustment. 
Lau et al.,39 2012 
Hong Kong, China 
Cross-sectional 
survey 
 
1,102 Hong 
Kong Chinese 
adults aged 18-
64 years 
Random telephone 
survey; Apr to May 
2006  
Associated factors included adults of age ≥30 years (OR1.91), 
those who attended university (OR 2.25), health professionals 
(OR 2.46), knowledge that IV was required annually (OR 
1.59), perceiving that influenza could cause severe or very 
Individuals without a home 
telephone were excluded 
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First author, 
publication year, 
place of study 
Study design  Participants Data collection 
method and date 
Key findings: 
Factors associate with behaviour or intention of receiving 
influenza vaccine in healthy adults†† 
 
Major limitations 
severe harms (OR, 2.21) and having been recommended by 
some health professionals to take up IV (OR 5.96). 
Liao et al.,40 2013 
Hong Kong, China 
Cross-sectional 
survey 
 
505 Chinese 
students and 
employees from 
a university 
Online survey 
Wave 1: Jan and 
Mar 2009; Wave 2: 
Jan and Mar 2010  
Feeling at risk was an affective-cognitive dimension 
of risk perception predicted subsequent vaccine uptake.  
Chronic conditions (OR 4.55), past vaccine uptake (OR 5.18) 
and married (OR 2.71) were associated with subsequent 
vaccine uptake. 
Study population was restricted 
to university students and 
employees.  Low response rate 
(30%) in Wave 2. 
Lin et al.,41 2010 
US 
Randomised 
cluster trial  
2,389 workers 
aged 18-49  
Questionnaire; 
2007-2008 
vaccination season 
Factors associated with previous influenza vaccination were 
older age (OR 1.06), female, higher education (OR 1.54) and 
greater support for injectable vaccine (OR 2.34). 
The main part of the study was 
comparing choice of vaccine 
type (intranasal or injectable).   
Looijmans-van den 
Akker et al.,42 2007 
Netherland 
Cross-sectional 
survey 
 
1,725 Dutch 
patients age over 
50 years random 
selected in a 
university 
medical centre 
database 
Self-administered 
questionnaire; 2005 
No substantial differences in determinants associated with not 
complying with influenza vaccination between smokers and 
non-smokers.  Most important associated factors of not 
complying in smokers and non-smokers were patient's beliefs 
not to be susceptible to disease (OR 4.0 vs 2.8, CI: 2.0, 3.9), 
finding it difficult to go to the GP for vaccination (OR 2.5 vs 
OR 1.8) and being against vaccination (OR 2.4 vs 1.8). 
The response rate on the 
questionnaires was 43% on a 
university medical centre 
database.  There may be 
differences in intent to comply 
among heavy and light 
smokers. 
Mok et al.,43  2006 
Hong Kong, China 
Cross-sectional  
survey 
452 outpatient 
clinic patients 
age ≥18 years, 
able to read and 
speak Chinese 
Self-administered 
questionnaire; Sep 
to Oct 2004 
Factors associated with intention to be vaccinated were 
chronic disease (OR 1.69), having received the flu shot in the 
previous year (OR 4.06), perceived susceptibility (OR 0.53, 
and reinforcing factors from family (OR 0.72, non-vaccinated 
compared to vaccinated) and doctor (OR 0.71).  
Limited to recruiting Chinese in 
an out-patient setting. 
Santibanez et al.,44 
2010 
US 
Cross-sectional 
survey 
 
4,835 
participants at 
50-64 years old  
Telephone survey; 
Feb to May 2004 
Associated factors included age, education level, recent doctor 
visit (OR 2.0), and beliefs about vaccine effectiveness (OR 
2.7), chances of getting sick with the flu (OR 5.4). Beliefs 
about influenza vaccination varied by race/ethnicity, 
education, and gender. 
Participants’ medical conditions 
were unknown; low random-
digital-dial response rate (51%) 
Takahashi et al.,45 
2002 
Japan 
Case-control 
study 
 
98 out-patients 
age 18 years or 
above 
Telephone 
interview; 
Nov 1998 to Feb 
1999 
Associated factors were recommendation by a family member 
and/or a close friend (OR 17.74); belief in influenza vaccine 
efficacy (OR 10.55); having a family member and/or friends 
who had been vaccinated before (OR 6.44); physician's 
recommendation (OR 4.03); knowledge about the influenza 
vaccine (OR 3.06); and fear of adverse reactions (OR 0.21, 
negative acceptance). 
Cases and controls were 
selected from a single hospital 
which reduce generalisation of 
the study.  Most of the 
participants in this study were 
female and elderly.   
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First author, 
publication year, 
place of study 
Study design  Participants Data collection 
method and date 
Key findings: 
Factors associate with behaviour or intention of receiving 
influenza vaccine in healthy adults†† 
 
Major limitations 
Thomas et al.,46 2011 
Multiple (review)  
 
 
 
Meta-analysis 
on randomised 
controlled trials 
(RCT) 
Forty-four RCTs 
were included 
Meta-analysis with 
pooled OR and 
systematic analysis 
No recommendations for practice can be drawn from this 
review.  Interventions such as personalized postcard, home 
visits, reminder to physicians, free vaccine, and financial 
incentives to physicians were reviewed for those aged 60 
years and older in the community. 
The quality of most RCTs was 
graded as at high risk of bias 
and no recommended 
intervention was suggested. 
Uscher-Pines et al.,47 
2010 
US 
 
 
 
Cross-sectional 
survey 
 
4,040 adults 
aged 18 and 
above 
Draw data from a 
nationally 
representative 
survey conducted 
on March 5-24, 
2010 
Adults aged 19-49, as newly recommended for influenza 
vaccination, were less likely to believe flu vaccines were safe 
(44% vs. 63%); to have ever been vaccinated (36% vs. 64%); 
to be vaccinated following a health-care provider 
recommendation (44% vs. 52%); and to visit a doctor's office 
during vaccination season (41% vs. 69%). 
Secondary data was used.  
Uncertain exactly how the data 
collection process was done 
and how well it was done. 
Vaux et al.,48 2011 
France 
Cross-sectional 
survey 
 
10,091 people 
from 8,905 
households 
Telephone survey, 
May 2009 to April 
2010 
The main associated factor with seasonal influenza 
vaccination were at risk group (OR 4.0), university graduate 
(>2 years) (OR 2.5) and offered free vaccine (OR 4.5).  Other 
factors associated with pandemic vaccination, such as, 
household with one or two children <5 years and occupation 
were not a determinant for seasonal influenza vaccine uptake. 
This study excluded households 
without telephone and those 
with only mobile-telephones.  
The small numbers in some 
groups caused wide confidence 
intervals. 
Vlahov et al.,49 2012 
New York City, US 
Cross-sectional 
survey 
991 participants 
from medically 
underserved area 
Street-intercept 
method; 10 min 
survey; end of the 
2009/10 flu season 
Factors associated with lack of interest included being black 
(OR 3.9), uncomfortable with government (OR 2.12), 
concerned about getting flu (OR 1.62) and no 
recommendations from health-care providers (OR 1.43) 
Uncertain if the OR was 
adjusted for confounding 
factors. Bias due to Street-
intercept method. 
Wada and Smith,50 
2012 
Japan 
Cross-sectional 
survey 
 
3,192 Japanese 
aged 20 to 69 
years 
Web-based survey 
for those registered 
in a web-based 
survey company 
Factors associated with vaccination included vaccination in 
previous year (OR 3.81), the number of children per 
household (1 compared with 0; OR 1.37), and household 
income ($50,000 to <$100,000 compared with $0 to 
<$50,000; OR: 1.30). Smoking was inversely associated (OR: 
0.79).  
The study population was 
recruited through a web-based 
survey company, thus 
introducing recruitment bias.   
Wu et al.,51  2013 
Beijing, China 
Cross-sectional 
survey 
 
13,002 Chinese 
adults ≥18 years 
Interviewers visited 
the households and 
conducted face-to-
face interview; Jan 
2011 
The influenza vaccination coverage did not change 
significantly after the influenza pandemic.  Positive associated 
factors with influenza vaccination included older age and 
higher level of education vaccination in 2009/2010 and 
2010/2011.  The most commonly reported reason for non-
vaccination was ‘I don’t think I am very likely to catch the 
flu’ (49.3%). 
Odds ratio was not given in the 
majority of analysis. Given the 
large sample size, uncertain if 
this is part of another study. 
  
 
Table 2.  Summary of factors (variables) associated with uptake of influenza vaccination 
* Findings of 3 selected studies34, 38, 47 were not presented in this table but included in the text.   
                                               
 
‡‡ All references in black are of high methodology quality and blue of moderate methodology quality. 
 Group Factors‡‡ Odds Ratio  
(range of mean OR)     
1 
 
Demography - age6, 31, 39, 41 
- education level6, 37, 39, 40, 48 
- being health professional6, 36, 37, 39 
- married40 
- gender, ethnic origin, income, employment, household 
size6, 36, 48 
- 1.06-23.7 
- insignificant / 1.54-
2.25  
- insignificant / 2.4-4.9 
- 2.71 
- insignificant or varies 
 
2 Knowledge - knowledge of influenza and influenza vaccination39, 45  
- knowledge of effective measures to prevent influenza37, 45 
- knowledge that vaccination was required annually39  
- knowledge of influenza vaccine being recommended45 
- general knowledge on transmission and treatment of 
influenza and upper-respiratory infections35 
- 1.6-3.3 
- 1.59-3.06 
- 1.59 
- 1.30 
- 1.25 
3 Needs - presence of chronic disease(s) 6, 31, 32, 35, 36, 37, 40, 43, 48 
- visit to physician recently31, 44, 45  
- living with children and/or elders48, 50 
- self-reported health status44 
- 1.38-13.7 
- insignificant / 1.55-2.0 
- insignificant / 1.37  
- insignificant 
4 Health 
behaviour 
- previous influenza vaccination status33, 40, 43, 50 
- smoking 42, 50 
- 4.06-5.18  
- insignificant / 0.79 
5 Belief & 
perceptions 
- perceived vaccine efficacy37, 44, 45 
- perceived vaccine safety and adverse events45   
- perceived chances of contracting influenza44, 49 
- perceived health impact of having influenza39 
- fear of adverse reactions45 
- scare about injection45 
- 2.7-10.55 
- 10.5  
- 1.62-5.40 
- 2.21 
- 0.21  
- insignificant 
6 Health-Care 
Systems  
 
- free vaccination46, 48 
- access to health-care settings42  
- satisfied with the health services31   
- client reminder system (e.g., telephone, post cards)46  
- 4.5-7.8 
- 1.8 
- 1.23 
- inconsistent result  
7 Advice & 
social 
support 
- advice from doctors6, 31, 45  
- advice from health professionals31, 45 
- advice from family and/or close friends45 
- cues to action (relative and friends receive vaccine)45  
- 4.03-7.82 
- 1.23-13.0 
- 17.74 
- 6.44 
8 External 
environment 
- pandemics30, 51  - insignificant / moderate 
negative (i.e., reduce 
vaccination )  
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3.2 Supplementary research details   
3.2.1.   Search details  
The search was performed on 21, 25 and 27 November 2013 on published 
literature in medical databases EMBASE, MEDLINE (PubMed), Cochrane 
Library, Google Scholar and Electronic Theses Online Service. A total of 2,235 
articles were retrieved and were screened by keywords. The titles of 436 articles 
were relevant and their abstracts were read. Below were the key words used and 
the number of articles found in each of the database.  
 
Search results of keyword search in EMBASE and MEDLINE (on 21 Nov 
2013) 
 
Search results of keyword search in Cochrane Library (on 21 Nov 2013) 
                                               
 
§§ Technology Assessments 
*** Economic Evaluations 
Step # Keywords EMBASE MEDLINE 
   1 seasonal influenza vaccine.mp. 
or *Influenza Vaccines/ 
15624 13307 
2 human.mp. 15852575 2390834 
3 accept*.mp. 392682 313130 
4 attitude/ 54528 39357 
5 intent*.mp. 89555 69082 
6 perception/ or perception.mp. 227054 249365 
7 1 and 2 and 3 524 576 
8 1 and 2 and 4 29 5 
9 1 and 2 and 5 116 110 
10 1 and 2 and 6 132 110 
 Total 801 801 
Step # Keywords 
1 Title, abstract, 
keywords 
influenza vaccination  
2 search all text accept*  
3 search all text attitude    
4 search all text intent*    
5 search all text perception    
 Result Reviews Trials Methods Tech Ass§§ Econ Eva*** 
 1 and 2 16 70 0 2 17 
 1 and 3 5 28 2 1 0 
 1 and 4 21 26 1 1 14 
 1 and 5 5 4 1 0 0 
 Total 214     
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Search results of keyword search using Google Scholar (on 25 Nov 2013) 
Google scholar <http://scholar.google.com> is an engine provides a search of 
scholarly literature across disciplines and sources, including theses, books, 
abstracts and articles on the internet. Google Scholar by default listed the fastest 
searched results. The first 100 results of each of the steps below were browsed. 
Out of the 400 results, 29 abstracts were read and 3 were included for critical 
appraisal. 
 
Search results of keyword search using Electronic Theses Online Service 
(EThOS) (on 27 Nov 2013) 
Electronic Theses Online Service (EThOS) is the UK’s national thesis database 
across more than 300,000 theses in over 120 institutions for free search of UK’s 
doctoral research theses. The title and/or abstracts of the 19 theses were read and 
none was included for critical appraisal. 
 
 
  
Step # Keywords Result 
1 Seasonal influenza vaccination and accept* First 100 
2 Seasonal influenza vaccination and attitude First 100 
3 Seasonal influenza vaccination and intent* First 100 
4 Seasonal influenza vaccination and perception First 100 
 Total 400 
Step # Keywords  Result 
1 Seasonal influenza vaccination   3 
2 Vaccine and accept*  9 
3 Vaccine and intent*  3 
4 Vaccine and perception  4 
 Total  19 
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3.2.2.   Critical appraisal of the selected articles 
Twenty-three articles were selected and critically appraised for eligibility. These 
articles were mostly observational studies and surveys. There were 18 cross-
sectional surveys, 1 case-control study, 1 randomised-control trial, 2 longitudinal 
studies, and 1 meta-analysis.  
 
A critical appraisal framework with ten questions was designed to assess the 
methodological quality of non-randomised trials. Each question represents a 
methodology quality criterion and one point is scored if that criterion is fulfilled. 
Therefore a ten is the maximum score which can be given and represents a very 
high quality study. These questions were formulated with reference to the US 
CDC Transparent Reporting Evaluations with Nonrandomized Designs 138  and 
National Health Service’s Critical Appraisal Skills Programme (CASP) 139  in 
reviewing the quality of the articles. 
 
Table 5  Review questions as quality assessment tool for critical appraisal  
 
  
Aspects Question 
Design 1. Was the study design appropriate to answer the research 
question? 
Representativeness 2. Were the study participants representing the target 
population, i.e., good sampling method to reduce 
selection bias? 
Sample size 3. Was the sample size large enough? 
Response rate or 
loss to follow-up 
4. Was the percentage of response rate or loss to follow-up 
acceptable when compared to other studies?  For 
studies with secondary data analysis, is there a large 
proportion of missing data? 
Validity 5.  Was / were data collection tools (questionnaire or 
others) shown to be valid and reliable? 
Outcome 6.  Was / were the outcome(s) measurement appropriate? 
Reporting 7.  Were the absolute and confidence intervals of main 
primary and secondary result listed to indicate 
precision?   
Confounders 8.  Were the confounders adjusted statistically or 
identified? 
Interpretation 9.  Was the general interpretation of the results reasonable 
in the context of study findings and current theory? 
Generalisability 10.  Could the findings of the study be generalised to the 
target population (external validity)? 
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The overall methodological qualities of the articles vary from 4 to 10. The 
majority of them are moderate to high quality: ten scored 8-10 (high quality); 
eleven scored 5-7 (moderate quality); and two below 5 (low quality). Nearly all 
the articles (>90%) presented the studies with a good design, and clearly described 
the appropriateness and methods of the outcome measures. All the studies have 
large sample sizes. Some of them had biased samples, low response rates or other 
reasons which prevented the result to be suitable for generalising to their target 
populations. Half of the studies did not mention or give enough information on the 
questionnaire designs, thus losing score on the criterion validity. The two studies 
scored below 5 were not included in Table 2 ‘Summary of factors (variables) 
associated with uptake of influenza vaccination’, but their findings are referred to 
in the text. The assessment result of each article on each critical appraisal criterion 
is detailed in Table 6.   
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Table 6  Summary of methodological assessment of the 23 selected studies 
  
Study††† Design Representative 
Sample 
size 
Response 
rate* Validity Outcome 
Report-
ing 
Confound
-ers 
Interpret-
ation 
General
-ise 
Overall 
score‡‡‡ 
Blank et al (2009)6  Y Y Y Y ? Y Y Y Y Y 9 
Caille-Brillet et al 
(2013)30 
Y Y Y Y Y Y Y Y Y Y 10 
Carrasco-Garrido et 
al (2009)31 
Y Y Y N N Y Y N Y Y 7 
Cassidy et al 
(2009)32 
N N Y Y Y  Y Y N Y N 6 
Chapman and Coups 
(1999)33 
Y N Y Y Y Y N N N N 5 
Chapman and Coups 
(1999)34 
Y Y Y N N Y N N N N 4 
Cohen et al (2012)35 Y Y Y ? Y Y N N Y Y 7 
Endrich et al 
(2009)36 
Y Y Y ? Y Y Y Y Y Y 9 
Horby et al (2005)37 Y N Y N ? Y Y Y ? N 5 
Hong Kong Medical 
Association (2013)38 
Y Y Y Y Y Y N N Y Y 8 
Lau et al (2012)39 Y Y Y Y N Y ? Y Y N 7 
                                               
 
††† ( ) denotes the year of publication 
‡‡‡ the highest score is 10 
*   a response rate lower than 50% is considered unsatisfactory 
Y=Yes, N=No, ?=Unknown or insufficient information  
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Study††† Design Representative 
Sample 
size 
Response 
rate* Validity Outcome 
Report-
ing 
Confound
-ers 
Interpret-
ation 
General
-ise 
Overall 
score‡‡‡ 
Liao et al (2013)40 Y Y Y N Y Y Y Y Y N 8 
Lin et al (2010)41 Y N Y Y Y N Y N Y N 6 
Looijmans-van den 
Akker et al (2007)42 
Y Y Y N N Y Y N Y Y 7 
Mok et al (2006)43 Y Y Y Y Y Y Y Y Y Y 10 
Santibanez et al 
(2010)44 
Y Y Y Y ? Y N Y Y Y 8 
Takahashi et al 
(2002)45 
Y Y Y Y N Y Y Y Y N 8 
Thomas et al 
(2011)46 
Y N Y Y Y Y Y Y Y N 8 
Uscher-Pines et al, 
(2010)47 
Y Y Y ? N Y N N N N 4 
Vaux et al (2011)48 Y Y Y Y Y Y Y Y Y Y 10 
Vlahov et al (2012)49 Y N Y ? ? N Y ? Y Y 5 
Wada and Smith 
(2013)50 
Y N Y Y N Y Y Y Y N 7 
Wu et al (2013)51 Y Y Y Y ? Y N N N Y 6 
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4. Design, sample and pilot of Case-control study  
 
In this chapter I describe the design and pilot of my case-control study. It includes 
the research objective, hypothesis, sample size calculation, sampling method, 
questionnaire development, and describes the pilot phase implementation and 
results. 
 
4.1 Research objective, question and hypothesis 
 
Objective  
The objective of this study is to determine which factors (variables) are associated 
with influenza vaccine uptake in residents of Hong Kong aged 50 to 64 years in 
2011/12 and 2012/13.  
 
Research question  
What were the differences between those residents of Hong Kong aged 50 to 64 
years who received influenza vaccine during the period from 2011/12 to 2012/13 
and those who did not? 
 
Hypothesis  
There were differences in associated factors (variables) between those Hong Kong 
residents aged 50 to 64 years who received influenza vaccine in 2011/12 and 
2012/13, and those who did not. 
 
Null hypothesis 
There were no differences in associated factors (variables) between those Hong 
Kong residents aged 50 to 64 years who received influenza vaccine in 2011/12 
and 2012/13, and those who did not. 
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4.2 Sample size calculation 
The calculation of sample size was undertaken according to the formula proposed 
by Fleiss for unmatched case-control study with dichotomous exposure 
variable.140,141,142 The software Epi Info was used for sample size calculation. The 
sample size was calculated with a significance level of 0.05 and a power level of 
80%. With odds ratio (OR) 2.07, case to control ratio 1:2, and the percentage of 
exposure in control 10%, it was estimated that 551 participants (184 cases and 
367 controls) were required. The estimated response rate was 50% and at least 
1,102 people had to be approached for data collection. 
 
Fleiss formula 
n1 = {Zα/2√[(r+1)𝑝𝑝 𝑝]+Z1-β√(rp1q1+ p0q0)}2 / [r(p1-p0)]2 
n1: number of exposed, n2: number of unexposed; n2=rn1 
r: allocation ratio of referent to study group size 
p𝑝 q𝑝 𝑝𝑝= (p1+rp2)/(r+1)  
𝑝𝑝=1- 𝑝𝑝  
Zα/2: standard normal deviate corresponding to the probability of an alpha 
error=5% 
Z1-β: standard normal deviate corresponding to a power of 1-β=80% 
R: ratio of unexposed to exposed 
p1: proportion of exposed with disease and q1=1- p1 
p0: proportion of exposed without disease and q2=1- p2 
Assumptions: 
i. OR under the null hypothesis,OR0=1  
ii. Anticipatory OR, ORa=2.07 
iii. Alternative hypothesis (for two-sided test), OR ≠1  
iv. Exposure in control=10% 
 
Effect size  
The effect size referred to the OR of previous studies in my systematic literature 
review.§§§ The list of variables positively associated with influenza vaccination 
with OR ranged from 2.07 to 18.7. One factor – fear of adverse reactions – was 
negatively associated with influenza vaccination, with an OR of 0.21. Therefore 
an OR of 2.07 has been used to calculate the sample size required.  
                                               
 
§§§ The systematic literature review presented in Chapter 3 in this thesis was updated on November 
2013. The ORs used for this sample size calculation was based on the previous version of the 
review done on March 2013. 
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Exposure  
A low percentage of exposure in control (10%) was chosen to allow for a larger 
sample size, and account for unknown probabilities in most factors in the control. 
Here, the term ‘exposure’ refers to factors or variables associated with the uptake 
of vaccination. Most ‘exposure’ factors (variables) in this study were beliefs or 
perceptions rather than external exposures. There are 38 variables and their 
probability in the control group varies.   
 
Power  
Although there is no formal standard for power, by convention a power of 80% is 
used in many studies. Therefore 80% was chosen to determine the sample size. 
Besides, different values of power (e.g., 80%, 85% and 90%) were applied to 
explore and scope the required sample size. For a power of 90%, 749 people 
would be required. For a power of 80%, 551 people (184 cases and 367 controls) 
were required.   
 
Response rate 
In some well-designed health surveys on vaccination conducted in Hong Kong, 
the response rates ranged from to 72.4% to 80%.128,143 A study concluded that the 
average response rate of different kinds of surveys was around 55%.144 To allow 
for the uncertainty in the actual response rate, a lower percentage of 50% was 
selected for sample size calculation. During the pilot, the ratio of total participants 
to non-participants was around 1 to 2, i.e., one successful interview when two 
people were asked. Therefore at least 1,102 people had to be approached during 
data collection. 
 
Case to control ratio  
The case to control ratio is 1:2. This was chosen because of the small number of 
cases available for the study. In the general population aged 18 or above, 14% 
received influenza vaccination in the past 12 months.38 There were 1.56 million 50 
to 64 year olds in Hong Kong in 2011, constituting 22% of the population.99 
During the pilot, most time was spent in identifying eligible cases. This chosen 
ratio was selected after consideration of the time, cost and manpower available. 
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4.3 Sampling  
Participants were randomly recruited using street-intercept technique. This 
technique allowed a large number of eligible subjects to be screened and 
approached.   
 
4.3.1.   Target and sampled population 
The target population was adults aged 50 to 64 years living in Hong Kong. The 
sampled population was adults aged 50 to 64 years living in Hong Kong, recruited 
in the 6 selected districts during the random time slots. The cases were adults aged 
50 to 64 years who received influenza vaccination in 2011/12 or 2012/13, while 
controls were the same as cases, except they did not receive the vaccine during the 
same period. 
 
4.3.2.   Selection of sampling districts and venues 
The population census in Hong Kong is collected based on 18 district council 
districts. For logistics and manpower convenience, 6 districts were selected for the 
street intercept interview. In order to choose representative districts, districts were 
screened based on household incomes145, median age146 and highest education 
level attained147, as indicated by the 2011 Population Census. The districts with 
lowest, mean and highest household incomes, median age and highest education 
level attained have been included. These districts are Kwun Tong, Sha Tin, Tai Po, 
Wan Chai, Wong Tai Sin and Yuen Long. Southern and Islands districts were 
excluded because of travel difficulty.   
 
Table 7  District with the lowest, median and highest household incomes, 
median age and education level   
  Lowest Mean Highest 
Median monthly 
household incomes 
Kwun Tong,  
Wong Tai Sin  
Tai Po, 
Southern, 
Islands 
Wan Chai 
Median age Yuen Long Sha Tin Wong Tai Sin 
Median highest 
education level 
Wong Tai Sin Sha Tin Wan Chai 
 
After selecting the 6 districts, site visits took place in June 2013 to decide on 
suitable venues for interviews. Two high-traffic venues near underground train 
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stations and shopping malls were selected from each district. The selections were 
based on the potential number of eligible subjects who could be recruited at each 
venue. For each time slot, one to three interviewers was deployed to each district 
and they worked at the same venue or at different venues, depending on the 
availability of eligible subjects they encountered on the street.   
 
4.3.3.   Interview schedule 
The fieldwork covered weekday office-hours, weekday evenings and weekends to 
avoid over-representation of participants who are unemployed. A random time slot 
(morning, afternoon or evening) and dates from 15 July to 15 August 2013 were 
generated using software Microsoft Excel and agreed to by the interviewers.  
 
Table 8  Interview timetable   
Location Date Time Hours No. of interviewers 
No. of 
interviews 
Kwun Tong 27/07/2013 Sat 9:00 -- 13:00 4.0 3 46 
  06/08/2013 Tue 9:00 -- 12:00 3.0 2 11 
  07/08/2013 Wed 13:00 -- 17:30 4.5 2 59 
  12/08/2013 Mon 9:00 -- 12:00 3.0 3 9 
Shatin 04/08/2013 Sun 13:00 -- 18:00 5.0 3 76 
  05/08/2013 Mon 17:00 -- 21:00 4.0 1 9 
  06/08/2013 Tue 12:00 -- 21:00 9.0 1 22 
Tai Po 03/08/2013 Sat 15:00 -- 19:00 4.0 3 73 
  08/08/2013 Thur 9:00 -- 17:00 8.0 3 19 
  11/08/2013 Sun 13:00 -- 17:00 4.0 3 14 
  12/08/2013 Mon 16:00 -- 20:00 4.0 1 8 
Wan Chai 21/07/2013 Sun 10:00 -- 18:00 8.0 3 33 
  30/07/2013 Tue 16:00 -- 20:00 4.0 3 49 
  08/08/2013 Thur 14:00 -- 18:00 4.0 1 12 
  13/08/2013 Tue 9:00 -- 13:00 4.0 1 8 
  15/08/2013 Thur 14:00 -- 19:00 5.0 1 10 
Wong Tai Sin 25/07/2013 Thur 9:00 -- 12:00 3.0 2 20 
  02/08/2013 Fri 14:00 -- 17:30 3.5 3 57 
  09/08/2013 Fri 14:00 -- 21:30 7.5 1 20 
Yuen Long 17/07/2013 Wed 14:00 -- 17:00 3.0 2 10 
  10/08/2013 Sat 9:00 -- 12:30 3.5 3 20 
  11/08/2013 Sun 14:00 -- 20:00 6.0 1 21 
 
The same number of cases and controls were to be recruited in each district. The 
estimated minimum sample size was 551 and 92 successful interviews, with 31 
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cases and 62 controls from each district. If the number of participants was fewer 
than the targeted number in a district, the interviewers would recruit more 
participants in the next scheduled visit in the same district. If at the end an 
insufficient number of respondents were recruited in one district, the remaining 
interviews required would be added to the next scheduled visit to the next district. 
 
In each time slot, one to three interviewers would be deployed to each district. The 
interviewers were stationed in areas of high pedestrian traffic, such as near 
underground train stations and shopping malls, during the random time slot 
assigned. A total of 210 man-hours were spent on collecting the interviews, and a 
total of 616 interviews were completed. 
 
4.3.4.   Interviewer training 
Interviews were conducted by four trained research interviewers who were fluent 
in Chinese and English and who had at least one year telephone interview or street 
polling hands-on interview experience. I held one briefing session for the 
interviewers on 28 May 2013. In the briefing, I explained the research details and 
trained the interviewers on the interviewing techniques. I talked about research 
design, case and control definitions, procedures and completion of questionnaire. 
We also discussed how to make initial contacts, how to identify eligible 
respondents, how to obtain consent, and how to avoid influencing or biasing 
responses.   
 
4.3.5.   Interview procedures 
During the assigned date and time, the interviewer approached every adult who 
appeared to be 50 to 64 years old. Interviewers identified themselves and asked 
the eligible subject whether they wanted to participate in a 10-minute interview. 
To determine their eligibility, subjects were asked their age and their residence 
status. Then the interviewers informed the participants about the nature and 
purpose of the study, and invited their voluntary participation. Spoken or written 
consent from respondents was obtained for all the interviews. The interviewer 
asked and documented all the questions listed in the questionnaire using pen and 
paper, and checked its completeness before approaching the next participant.   
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4.4 Questionnaire  
Questionnaire development  
The questionnaire was designed with the purpose of seeking information on 
factors (variables) associated with the uptake of influenza vaccination. The 
questionnaire construction involved the following steps:148,149,150   
1. Search for relevant validated and published survey instrument 
2. Review questionnaires in related studies and surveys  
3. Specify domains and items based on the systematic literature review result  
4. Draft questionnaire 
5. Translate questionnaire from English to Chinese 
6. Seek advice from a panel of experts    
7. Pilot the questionnaire 
8. Revise and agree on the final questionnaire  
  
The questionnaire is in Annex 1.   
 
Content 
A search was done for validated survey instruments. There were well-designed 
questionnaires for people’s acceptance of influenza vaccine but most of these were 
not publicly available or had a different focus which was not best suited for this 
study.35,38, 151  Reference were taken from several questionnaires on influenza 
vaccination designed by health authorities (e.g., DH128, ECDC152).  
 
The content of the questionnaire was determined by the systematic literature 
review on factors (variables) associated with the uptake of influenza vaccination. 
There were 38 factors (variables) identified which were then grouped into 8 
domains. The 8 domains were: predisposing demography (9 variables); knowledge 
(5 variables); need (3 variables); health behaviour (4 variables); belief and 
perceptions (7 variables); health-care system (6 variables); advice and social 
support (3 variables) and external environment (1 variable). The domains and 
variables are listed in Annex 2. 
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The questionnaire consisted of 38 questions: 11 on demography and 29 covered 
all the factors (variables). The questions were predominantly multiple choice. The 
five-point Likert-type scale was adopted for grading in 4 questions. The 
demographic questions were positioned at the start of the questionnaire to screen 
for suitable participants and serve as a warm-up. 
 
Language and translation 
The questionnaire was printed in Chinese and English with language set at 
primary education level. More than 95% of people aged 50 to 64 years in Hong 
Kong are Chinese and 75% have attained primary education level or above.99 The 
questionnaire was originally written in English because the questions in the 
references for the questionnaire were in English. It was then translated by two 
separate bilingual translators from English into Chinese.   
 
Review by experts 
The draft questionnaire was sent to a panel for comment and feedback. The panel 
comprised of 5 experts: 1 public health physician at the DH Vaccination Office, 1 
infectious disease specialist, 2 general practitioners and 1 statistician. The panel 
was asked to comment on the content and face validity, the relevance of the 
variables and whether the English and Chinese wordings conferred the same 
message. Feedback from the experts was obtained through telephone 
conversations. Most of the advice given by the experts was accepted. Before the 
pilot, the panel validated the whole questionnaire and confirmed their agreement 
with all the questions.   
 
Pilot of the questionnaire 
There were 29 respondents during pilot. Each respondent was approached by two 
interviewers at the same time. During the interview, one interviewer 
communicated with the respondents and filled in the questionnaire, while the other 
interviewer observed and marked down the respondent’s reactions and queries. 
After completing the questionnaire, the respondents were asked about the clarity, 
ease of comprehension, relevance to the topics and length of the questionnaire.    
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A debriefing meeting with the interviewers was held on 2 July 2013. Feedback 
from interviewers and respondents had provided key information for modifying 
and finalising the questionnaire. Most interviewers asserted that the questionnaire 
was too long, as it took up to 15 minutes to complete one questionnaire, and that 
there were also redundant and ambiguous questions. The questions were then 
regrouped and their orders relocated, while unclear and ambiguous questions were 
rephrased or their wordings were clarified. 
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4.5 Pilot  
A pilot study of 29 participants (15 cases and 14 controls) was conducted on the 
20 and 22 June 2013 at Lam Tin and Sha Tin districts respectively. In both 
districts, venues near train stations were chosen because of the large number of 
pedestrians. I conducted the interviews with the assistance of two additional 
interviewers. The aim of the pilot study was to test the logistics, pilot the 
questionnaire, estimate the effect size and sample size, and observe interviewers’ 
practice and skills. 
 
The time required and the response rate was documented to estimate the actual 
manpower and time needed for data collection. On average, 12 minutes was 
required to finish one questionnaire. The interview time of the questionnaire 
interview time for each respondent ranged from 4 to 15 minutes. Most time was 
spent identifying cases, while controls were readily available. Approximately 
every one in two to three person asked agreed to be interviewed. The data 
collected was the entered into an Excel spreadsheet by the interviewers.   
 
A debriefing meeting with the interviewers was held on 2 July 2013 following 
completion of the pilot, to collect feedback and discuss improvement measures. 
The pilot demonstrated a street intercept sampling method was feasible and 
practical for recruiting cases within reasonable constraints of time and effort. This 
was despite there being no incentive for respondents to take the questionnaire. The 
pilot established the procedures and steps of the interview process, and also 
provided useful information for the questionnaire development and improvement 
of data entry logistics. The pilot study had limited statistical power, the results it 
provided were inconclusive; it was not comparable to the associations of the 
variables in the previous systematic review. The sample size calculation remained 
unchanged; as there were no changes in the effect size, response rate and other 
parameters in the calculation. Data collected from the pilot study was not included 
in the case-control analysis.   
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4.6 Data entry and quality control  
4.6.1.   Data entry 
The categorical variables in the questionnaires were coded and entered into 
spreadsheet using Microsoft Excel. The coding and Excel spreadsheet were 
designed by the research student. The data was then entered by five data entry 
assistance, with four of them also being interviewers. The data entry and 
rechecking process lasted for three months, from July to September 2013. 
 
4.6.2.   Quality control 
The two most frequently referred to data quality attributes are accuracy and 
completeness.153 To ensure accuracy, logical consistency was ensured by limiting 
data entry and setting the data validation dialog box in the Excel spreadsheet. A 
coding guide, listing all the code that was produced, was distributed to data entry 
assistants for reference during data entry. The study design and input variables of 
the study were explained to the data entry assistants prior to undertaking the task. 
Misinterpretation of the information in the original documents was minimised 
because all the multiple choice answers were coded. If there was uncertainty, such 
as ambiguous hand-writing or uncertainty in the entry, the data entry assistant 
would discuss the issue with their supervisor. 
 
Ten percent of the questionnaires entered were randomly checked by an 
independent observer (the supervisor). First, a random checklist was generated by 
Excel, then a data entry assistant would follow the Excel random list and re-enter 
the questionnaire data. The supervisor would then double-check this double-entry 
and compare the result with the hard-copy and the first set of data entered. If a 
high percentage (>20%) of inconsistency was found in any questionnaire, the data 
entry assistant who entered the questionnaire would be identified. No high 
percentage of inconsistency was found during the rechecking. 
 
To ensure completeness, any questionnaire with important information or more 
than 20% of the questions missing was excluded. There were 12 questionnaires 
excluded because of missing important data, such as year of birth. No 
questionnaire was excluded because of incompleteness or inconsistency.  
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5. Case-control study (Research paper 2) 
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Abstract 
Background 
In Hong Kong, people aged 50 to 64 were added as recommended priority group 
(recommended group) for influenza vaccination by the Department of Health 
(DH) starting from 2011/12 onwards. The coverage rate of influenza vaccine for 
this age group was suboptimal at 8.5% in 2012/13.  
 
Objective 
To determine which factors were associated with uptake of influenza vaccination 
amongst adults in Hong Kong aged 50 to 64 years.  
 
Methods 
A case-control study was conducted in communities by street intercept interview 
from 17 July to 15 August 2013. Cases were adult age 50 to 64 years who 
received influenza vaccine in 2011/12 or 2012/13, while controls were the same as 
cases, except they did not receive influenza vaccine in 2011/12 or 2012/13. 
Multinomial logistic regression analysis was performed on the data to explore the 
associations between vaccination status and the variables.   
 
Results 
A total of 604 respondents were interviewed and included in the analysis. There 
were 193 cases (vaccinated) and 411 controls (non-vaccinated), with a case-to-
control ratio of 1:2.1. When compared, the following were strongly associated 
with vaccination compared to other factors: ‘eligible for free government vaccine’ 
(OR6.38, 95% CI, 3.43-11.87, p<0.001); ‘willing to receive flu vaccination for 
free’ (OR4.84, 95% CI, 2.13-11.03, p<0.001); ‘perceived having severe or 
moderate symptoms when contracting flu’ (OR2.90, 95% CI, 1.21-6.97, p=0.02), 
and ‘convenient to reach a vaccination location’ (OR2.87, 95% CI, 1.06-7.74, 
p=0.04). The majority (89%) of all the respondents were not aware that they 
belonged to a recommended group for influenza vaccination and most (>80%) 
were willing to be vaccinated if it was free.   
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Conclusion 
Factors related to the existing health-care service, advice from health 
professionals, and perception on influenza vaccination had a comparatively strong 
association with influenza vaccination uptake amongst 50 to 64 year-olds, 
compared to other factors.   
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Introduction 
Seasonal influenza vaccination (referred to as ‘influenza vaccination’, 
‘vaccination’ or ‘vaccine’ below) remains an effective measure to protect 
individuals and communities from severe morbidity and mortality induced by 
influenza. To mitigate the disease burden of influenza, many developed countries 
recommend vaccination for high-risk groups such as children, elders, health-care 
workers, pregnant women, and people with chronic diseases. The upper age limit 
for elders differs and most countries do not include adults aged below 60 without 
other risk indications as a recommended group for vaccination.1,2 Some 
exceptions include the US, Austria and Estonia, who recommend that people aged 
6-months or above receive influenza vaccination.3-5   
 
Meta-analysis and literature review demonstrated that the influenza vaccine has a 
moderate effect in reducing clinical symptoms of influenza in healthy people from 
16 to 64 years.6, 7 The vaccine efficacy could be up to 70% in healthy adults when 
content matched WHO recommendations and circulating strain. 6, 8 Vaccine also 
reduced working days lost and physician visits.7, 9, 10 Local cost-effectiveness 
studies on influenza vaccination estimated the cost-benefit ratio to be 3.8:1**** 
amongst the working class.11 Although the vaccine did not provide an overall 
economic benefit in the community, it has yielded significant health benefit by 
reducing severe complications from influenza.5,12,13 Many middle-aged adults 
have undiagnosed medical conditions such as diabetes mellitus and they are at 
higher risk of severe influenza related complications.14,15   
 
Hong Kong, situated in Southeast China, has become vigilant against influenza 
and respiratory infectious diseases, particularly following avian influenza, SARS 
and pandemic influenza H1N1 in 2009. Beginning in 2011/12, people aged 50 to 
64 were added as recommended group for influenza vaccination by the 
Department of Health (DH).16 The influenza vaccination coverage rate of this age 
group in 2012/13 was 8.5%17, while previous data was unavailable. As a 
reference, 13% of those aged 18 to 64 years in the general population had the 
                                               
 
**** By proportion HK$3.8 spent on vaccination can save HK$1 because influenza-like illness has 
been prevented. 
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influenza vaccination in the previous 12 months in 2007.18 The corresponding 
influenza vaccine coverage rates of this age band in the United States (US) was 
45.1% in 2012/13, and 22% in the UK in 2003/4.19, 20 
 
A change in the influenza vaccination recommendation and policy was initiated by 
DH. In January 2011, an increase in the number of hospital admissions due to 
influenza among persons aged 15 to 64 years was observed. Subsequent local 
epidemiological studies showed there was a real increase in Intensive Care Unit 
(ICU) or fatal influenza cases in healthy individuals aged 50 to 64 years, with an 
incidence of 1.8 per 100,000 population. This incidence was higher than the 
corresponding incidences in any other age group, including young children aged 
below 6 years (0.7 per 100,000) and elders over 65 (0.6 per 100,000). Also, the 
largest percentage (41%) of influenza-related deaths during this period were from 
persons aged 50 to 64 years.16   
 
The increase in ILI activity and hospital admission was possibly accounted for by 
the influenza A(H1N1)pdm09 being the dominant circulating virus (~90% of all 
influenza isolates) during the winter of 2010/11.21 A review on international 
epidemiology reported that the influenza A(H1N1)pdm09 disproportionately 
affected and increased hospitalisation and death in adults aged below 65.22-24 
Some observers postulated that the discrepancy was because some elderly might 
have cross-immunity to influenza A(H1N1)pdm09 due to past influenza infection. 
 
Following review and discussion, DH recommended that doctors vaccinate 
healthy people aged 50 to 64 based on the local context. There was a likelihood 
that influenza A(H1N1)pdm09 virus would continue to circulate and vaccination 
is considered to offer good protection against clinical influenza.25 No free or 
subsidized influenza vaccination service was provided by the Government to this 
group, except those who already belonged to the high-risk group and those with 
financial difficulties, i.e., Comprehensive Social Security Assistance (CSSA) 
receivers. Healthy 50 to 64 year-olds, without other risk indicators, had to pay out-
of-pocket if they want to be vaccinated.26  
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After this new vaccination service was launched in 2011/12, vaccination coverage 
was low (8.5%) in this new target group. This study aimed to determine which 
factors were associated with the uptake of influenza vaccination amongst people 
aged 50 to 64 years in Hong Kong.   
 
Method 
A case-control study was conducted in a community setting in Hong Kong from 
17 July to 15 August 2013. Street intercept interview were undertaken in 6 
districts (out of a total of 18). In order to recruit a representative sample of the 
population, districts with the lowest, median and highest household incomes, 
median age and education levels were chosen according to the 2011 Population 
Census.27 The selected districts were: Kwun Tong, Sha Tin, Tai Po, Wan Chai, 
Wong Tai Sin and Yuen Long. The interviewers were assigned a random time slot, 
covering weekday, weekends, office and non-office hours. 
 
Cases and controls 
Cases were (i) those who received influenza vaccine in 2011/12 or 2012/13, i.e., 
from 1 September 2011 to 31 August 2013††††; (ii) aged 50 to 64 years in 2012 to 
2013 (i.e., born between year 1949 to 1962); and (iii) citizens who were resident 
in Hong Kong. 
 
Controls were the same as cases in (ii) and (iii), except they did not receive 
influenza vaccine in 2011/12 or 2012/13. Some controls had received influenza 
vaccine before 1 September 2011. They were classified as control because they 
were not recommended group under the previous vaccination policy. 
 
Inclusion and exclusion criteria 
Cases and controls were included if they: 
• Fulfilled the definitions; and 
• Agreed by oral or written consent; and  
• Understood spoken or written Chinese or English.    
                                               
 
†††† Most influenza vaccines expire before August in each year. Influenza vaccines of next season 
usually are available to doctors in early September. The Government Vaccination Programme 
started in early November in the previous 5 years since 2008/09. 
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Cases and controls were excluded if they refused to participate, were travellers, or 
were not eligible for influenza vaccination due to medical contraindication. 
 
Sample size 
The sample size was calculated with a significance level of 0.05 (two-sided) and a 
power level of 0.80. From a search of the literature, the effect size (odds ratios, 
OR) of factors associated with influenza vaccination varied from 0.2 to 18.7. The 
calculation of sample size was done by the Fleiss formula for unmatched case-
control study with dichotomous exposure variable.28 A minimum sample size of 
551 (cases and controls) was required. To allow for the uncertainty, 50% was used 
for sample size calculation. It was estimated that at least 1,102 people had to be 
approached. 
 
Data collection 
The questionnaire was conducted in the summer 2013 before the next influenza 
vaccination season, which usually begins in September of each year.   
 
Primary data was collected by four trained research interviewers who were fluent 
in Chinese and English and who had at least one year’s experience carrying out 
hands-on interviews. In each time slot, one to three interviewers would be 
deployed to each district. The interviewers were stationed in areas of high 
pedestrian traffic, such as near underground train stations and shopping malls, 
during the random time slot assigned. A total of 210 man-hours were spent on the 
interviews.   
 
Before each interview, the interviewer would inform the respondent about the 
nature and purpose of the study and invited their voluntary participation. 
Interviewees were asked to respond only after informed consent was obtained. 
The interviewers would ask the respondents questions, document all the questions 
in the questionnaire form using pen and paper, and check its completeness before 
approaching the next person.   
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Hypothesis and Null hypothesis 
There were differences in associated factors (variables) between those Hong Kong 
residence aged 50 to 64 years who received influenza vaccine in 2011/12 and 
2012/13, and those who did not. The Null hypothesis assumes no such association. 
 
Pilot 
A pilot study of 29 respondents (15 cases and 14 controls) was done on the 20 and 
22 June 2013. It was conducted by three interviewers in two districts. After filling 
in the questionnaire, respondents’ feedback was collected on the clarity, ease of 
comprehension, relevance to the intended topics and length of the questionnaire. 
The pilot tested the logistics and issues related to the questionnaire; estimated the 
manpower required; the effect size and sample size; and provided an opportunity 
for interviewers to familiarise themselves with the arrangements. 
 
After the pilot was completed, a debriefing meeting was held with the 
interviewers on 2 July 2013. Feedback and suggestions from interviewers were 
adopted to enhance and finalise the interview process and the questionnaire. The 
data collected from the pilot study was not included as part of the results section 
in the report. 
 
Questionnaire design 
The questionnaire was designed with reference to past vaccination questionnaires 
from health authorities29, 30 and relevant studies.31-33 The draft questionnaire was 
then sent for comment to a multi-disciplinary team, comprised of an infectious 
disease specialist, an epidemiologist and general practitioners. The questionnaire 
was in Chinese and English and it had 38 questions including 11 on demographic 
data and 27 covering the factors (variables) to be examined. The demographic 
questions were placed at the start of the questionnaire to screen for suitable 
subject and serve as a warm-up. The questions were predominantly multiple 
choice, while the five-point Likert-type scale was adopted for grading in 4 
questions. Questions were grouped in 8 content domains – demography, 
knowledge, health need, health behaviour, belief and perceptions, health-care 
system, advice and social support, and external environment – for easy 
comparison of variables. 
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Data management 
Logical consistency was ensured by limiting data entry and selecting data 
validation in the data entry software. In addition, at least 10% of the 
questionnaires entered were randomly checked using double entry method by an 
independent observer. Twelve questionnaires were excluded after checking for 
completeness, inconsistency or with important data missing, e.g., year of birth. 
 
Statistical analysis 
Statistical analyses were performed using the software SAS 9.3. Categorical 
demographic data and variables were compared using Pearson chi-square test, 
crude and adjusted odds ratios (ORs) with corresponding 95% confidence 
intervals (CIs) and p-values. For categorical data with any of the cells with an 
absolute number fewer than 5, Fisher´s exact test was used. Any variables with p 
values <0.25 and those with important associations demonstrated in the literature 
were selected for multinomial regression analysis (backward stepwise regression 
algorithms). The regression model is a built-in formula in the SAS software. All 
statistical tests were two-tailed and variables were considered significant at a 
significance level of 0.05.  
 
Result 
The study included 193 cases (vaccinated) and 411 controls (non-vaccinated), 
with a case to control ratio of 1:2.1. The average interview time was 7 minutes 
(standard deviation ±4 minutes) for each questionnaire, and the response rate was 
41.7%. 
 
1. Demography 
Baseline demographic data of cases and controls were compared using Pearson 
Chi-Square Test and odds ratios. The differences between the two groups were 
statistically insignificant on sex, ethics, education level, employment status, 
personal monthly income, current smoking and drinking status. There was no 
statistically significant OR after statistical adjustment, indicating no associations 
was found between vaccination and any of the chosen demographic variables. The 
demography of cases and controls are in Table 1.   
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The majority of the respondents were Chinese, and there were more female than 
male respondents (38.4% vs 61.6%).  Most (86.5%) of those who had an 
occupation were aged 59 or below. Overall, half of the respondents (51.5%) had 
no income. Similarly half of the respondents (53.5%) were unemployed, retired or 
housewives. One in four (26.3%) were housewives; and one fifth (20.03%) were 
retired. The majority of them (71.5%) received at least 9 years education up to the 
secondary level.   
 
There was a slight increasing trend of vaccination in the 55 to 59 group (crude 
OR‡‡‡‡  1.58, 95% CI 1.03-2.41, p=0.04) and 60 to 64 group (crude OR1.83, 95% 
CI 1.20-2.77, p=0.005) when compared to the 50 to 54 group. However, the 
adjusted ORs for both age groups were insignificant.  
 
Comparing cases and controls, people who were health professionals (crude 
OR3.3, 95% CI 1.16-9.41, p=0.03) and social security CSSA recipients (crude 
OR2.7, 95% CI 1.10-6.63, p=0.03), more commonly received the vaccine than 
those who were not. However, there were only 15 health professionals and 20 
CSSA recipients in the respondents, and it may not be valid to conclude there 
were associations of these two variables with vaccination given their low 
representation.   
 
The sample was also compared to the actual district population by age and sex to 
check for representativeness. In the sampled respondents, there was proportionally 
higher numbers of females, particularly in the 50 to 54 and 55 to 59 age groups, in 
most of the sampled districts. This study included more females than males by 
proportion (M:F = 1:1.6), while the overall male to female ratio in the target 
community was 1:1. Other demographic parameters of the sampled population 
such as the age proportion between groups, education level, ethnicity, and the 
percentage of employment, were comparable to the target population (ie., Hong 
Kong general population aged 50 to 64 years). There was no apparent discrepancy 
of the sample and the target population.    
                                               
 
‡‡‡‡ All odds ratios (ORs) mentioned in the text of this article are statistically adjusted ORs, unless otherwise 
stated as crude odds ratio (crude OR). 
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2. Health knowledge related to influenza vaccine 
The majority (89%) of all the respondents were aware that they were 
recommended for influenza vaccination by DH. However, the cases were more 
aware themselves of being recommended for influenza vaccination than the 
controls, (OR2.34, 95% CI 1.23-4.44, p=0.009). There were health knowledge 
differences between the cases and controls in all the questions asked on 
knowledge, including government vaccination services, vaccine reduction in 
influenza-related hospital admission, and vaccine protection to healthy adult. 
However, these associations were statistically insignificant after the OR was 
adjusted. 
 
3. Health needs 
When compared to controls, more cases had chronic diseases; more frequently 
‘visited doctors in the past 3 months’ and ‘lived with children below 6 years or 
elders above 65 years’. However, none of these associations were statistically 
significant after the OR was adjusted. 
 
4. Health behaviours 
There was no association between vaccination and smoking/drinking. Most cases 
(85.4%) expressed they were likely or very likely to receive the vaccine in 
2013/14, compared to only 29.4% amongst the controls. This implies those who 
had previous vaccinations in 2010/11 and 2011/12 would choose to get vaccinated 
again in the coming future. 
  
5. Health belief and perception 
In general, more cases perceived there to be a higher chance of contracting 
influenza in the next 12 months and/or having severe influenza or moderate 
symptoms when compared to the controls. Vaccination was perceived more 
positively by the cases than the controls. More cases than controls ‘perceived flu 
vaccine to be safe’ and ‘believed flu vaccine has additional benefits other than flu 
protection’. More controls than cases perceived the vaccine may lead to severe 
adverse events, and believed themselves to have good health. However, the only 
statistically significant variable was ‘perception of severe or moderate symptoms 
when contracting flu’ with an OR of 2.90 (95% CI 1.21-6.97, p=0.02). 
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6. Health-care system 
There was an association between ‘eligible for free government vaccine’ and 
vaccination (OR6.38, 95% CI 3.43-11.87, p<0.001). When compared with 
controls, more cases were ‘willing to receive flu vaccination for free’ (OR4.84, 
95% CI 2.13-11.03, p<0.001). Nearly sixty percent (59.3%) of all the respondents 
were ‘willing to receive flu vaccination for free’ 36.8% were ‘willing to pay for 
flu vaccine is below HKD$50 (USD$6.4)’ respectively.  The percentage of the 
amount willing to pay for an influenza vaccine was similar between the cases and 
the controls. 
 
Cases had a higher likelihood of being able to access a convenient location for 
vaccination (OR2.87, 95% CI 1.06-7.74, p=0.04). Fewer cases preferred to go to 
public clinic for injection (OR0.35, 95% CI 0.22-0.55, p<0.001). There were no 
associations between differences in response to the government telephone 
reminder service for vaccination, if there was one. 
 
7. Advice   
There was a stronger influence of other’s opinion and action on the cases than for 
the controls in respect to vaccination. When compared, more cases would ‘accept 
advice from health professionals’ (OR2.67, 95% CI 1.19-5.99, p=0.02); and ‘had 
family members receive flu vaccine’ than the controls (OR2.47, 95% CI 1.54-
3.95, p<0.001).   
 
8. External factors 
External factors refer to unpredictable environmental factors, such as the 
occurrence of disease epidemics like SARS or pandemic influenza. High 
percentages of both cases (94.8%) and controls (81.3%) would receive a vaccine 
when there was a disease epidemic. When compared, more cases would receive a 
vaccine during an epidemic and the OR was 2.40 (95% CI 1.07-5.37, p=0.03).   
 
Additional information 
Amongst the controls (i.e., never received vaccination or received vaccine on or 
before 2009/10), 25.6% of them had received vaccine before. Common reasons 
for not receiving a vaccine in the controls were: considered vaccination 
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unnecessary (70.8%); believed they were not in a high-risk group (37.0%); and 
concern about side effects of vaccination (19.0%). Of the controls that had 
previously been vaccinated, 59% had received the vaccine at a public clinic. 
Responses to the multiple answer questions are in Table 3. 
 
Discussion 
Study design and sampling method  
This is a case-control study with vaccination status as the ‘outcome’ and personal 
or external environmental factors as ‘exposures’. The terms factors or variables 
were used instead of exposure because some factors (variables) were inherited 
traits, personal beliefs or perceptions.   
 
The reason for conducting a case-control study was because of the low prevalence 
of eligible cases. Given those aged 50 to 64 years constituted 22% of the 
population and 8.5% of them had received influenza vaccination in 2012/13, less 
than 2% of people living in the region were eligible cases. The difficulty of 
recruiting cases doubled with an estimated response rate of 50%. A case-to-control 
ratio of 1:2 was chosen after some consideration of the time, cost and manpower 
available. 
 
A street intercept interview method enabled the interviewers to screen and 
approach a larger number of people, according to their physical appearance of age. 
Street intercept interview also lowered the rejection rate and enabled a greater 
control in completing the questionnaire. It was estimated that a large number of 
people had to be approached should a telephone or postage survey have been used.   
 
Cases and controls subgroups  
Cases consisted of three different subtypes – those received two vaccines in 
2013/12 and 2012/11 and those received one vaccine in either 2013/12 or 2012/11. 
Some controls had received influenza vaccine(s) before 1 September 2011. They 
were classified as control because:  
• People aged 50 to 64 years were not recommended target group for influenza 
vaccination by the government before vaccination season 2011/12 (i.e., before 
1 September 2011) 
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• It was unclear when the control had received the influenza vaccine, although it 
was certain they had not received the vaccine for at least two years. 
 
Response rate  
The response rate, which is the number of successfully completed interviews 
(numerator) divided by the number of unsuccessful interviews (denominator), was 
41.7%. This low response rate was mainly due to the difficulty in finding cases 
because of the low vaccine coverage rate. The interviews were conducted in 
summer time when the street temperature was >30oC and crowded, and no 
incentive was offered to the respondents. The interviewers approached those who 
looked to be 50 to 64 year-old on the street. The person was counted as an 
unsuccessful interview (denominator) if s/he: 
• Was 50 to 64 year-old but refused to participate; and 
• Was unvaccinated in previous two years (at a stage when too many controls 
were interviewed); or 
• Had language or communication difficulty; or   
• Claimed to have completed the same survey recently.  
 
Result  
There are multi-dimensional factors that might have contributed to people’s choice 
of whether or not to receive vaccination. These factors comprise of social, 
environmental and economic dynamics in a context. The factors were put in a 
multinomial logistic regression model and statistically adjusted for age, 
employment status, receiving social security, and all independent variables. Before 
statistical adjustment, most of these factors had statistically significant crude odds 
ratios. The variables affected each other and many became non-significant after 
adjustment. There would be a confounding effect between variables.  
 
The majority (89%) of all the respondents were not aware that they were in a 
group recommended by the health authority to receive influenza vaccination. 
Amongst the controls, a higher percentage (71%) deemed vaccination to be 
‘unnecessary’. This revealed a failure of DH and health professionals in 
communicating the message that ‘vaccination is recommended’ to this age group. 
Given that there was an association between ‘knowing oneself to be in the 
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recommended group for flu vaccine’ and vaccination, a better communication of 
the risks might have improved the vaccination rate. Health promotion strategy on 
empowerment and enhancement of knowledge on this issue has to be planned and 
supported by health-care policy. 
 
Studies suggested that previous influenza vaccination was a predictor for 
subsequent vaccination (OR 1.62-5.40).34-37 However, past behaviour does not 
provide an insight into the reasons why a person chose to be vaccinated.   
 
Vaccination coverage rate is price sensitive. This was demonstrated in this study 
and in countries which provided vaccine reimbursements to users.38, 39 To receive 
influenza vaccination, most (95%) people aged 50 to 64 years in Hong Kong had 
to pay out-of-pocket. The odd of cases being ‘eligible for free government 
vaccine’ was 6.4 times the controls. Amongst the cases, half (52%) of them 
attended a private clinic or hospitals and paid the vaccination fee out-of-pocket. 
The majority (84%) of all respondents were willing to receive the vaccine if it was 
free or at a price lower than US$6. All these associations indicated a free or 
subsidised vaccination service could possibly increase the vaccination rate. 
 
There was only a mild association between chronic disease(s) and vaccination and 
the association was insignificant after the OR was adjusted (OR1.13, 95% CI 
0.65-1.96, p=0.67).  This result is in contradiction to findings in many studies 
indicating that the presence of chronic diseases was one of the most persistent 
factors associated with vaccination.2, 34, 35, 40-44     
 
‘Accept advice by health professional’ was moderately associated with 
vaccination (OR2.67, 95% CI 1.19-5.99, p=0.02). Several other studies have 
shown that doctors’ and health professions’ advice was associated with influenza 
vaccination.32, 45 Health professionals had a duty to recommended vaccination to 
high-risk groups in order to protect them from influenza and severe complications.  
 
‘Had family member received flu vaccine’ was associated with people’s uptake of 
the vaccination, but ‘accept advice from relatives and friends’ was not. In Japan, 
advice from health professionals, family and/or close friends were strongly 
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associated.32 In the USA and some other western countries, advice from family 
and/or close friends was not a significant factor in acceptance of influenza 
vaccination.46, 47 This could possibly be due to the differences in cultural 
background between individuals in these countries. 
 
This study showed no association between vaccination with smoking and 
drinking. It is uncertain whether people were consistent in their health behaviours. 
Studies have proven that smoking is not associated with vaccination.36, 48 No data 
was found on other health behaviours such as drinking or frequent exercise, 
having a link to vaccination.   
 
Given past experiences of infectious disease epidemics in Hong Kong, people may 
be more inclined to receive vaccination to protect themselves in anticipation of the 
occurrence of a disease epidemic such as SARS or swine influenza.   
 
Previous research has suggested that newly issued recommendations are not 
quickly embraced by the majority of citizens. In the US, government National 
Health Interview Survey data did not show a marked increase in vaccination rates 
amongst adults aged 19 to 49 and 50 to 64, after the US Advisory Committee on 
Immunization Practices expanded its recommendations to these subgroups in 2000 
and 2010 respectively.45, 49 
 
Strengths and limitations 
A case-control study design enabled measurement of many different exposures at 
once and for the combined effects of exposures to be examined. In addition, data 
was collected within a short time-frame. Limitation of a case-control includes the 
information and recall bias of the respondents; difficulty in establishing a 
temporal or sequence of the factors and the outcomes; and the inability to estimate 
the coverage of vaccination in this age band. It may also be impossible to establish 
the timeline of events; for example, it is uncertain whether knowledge was the 
cause or consequence of a person who did not receive an influenza vaccine.  
 
A limitation of using street-intercept selection bias would be the interviewers 
approached those who looked 50 to 64 years and potentially could miss out a 
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number of very young and over-aged looking individual, and the extent of this 
bias is difficult to assess. A test on this during the pilot phase could have provided 
an estimate on the degree of misses. Another bias would be due to sampling of 
respondents from different locations, e.g. in public and private estates, in train 
stations and shopping malls. A comparison of the demographic characteristics of 
the samples collected in different locations, and to those of the relevant 
population, would be useful to identify potential bias. 
 
Further studies 
Sub-group analysis of respondents was performed. These included analysis of 
different age bands (50-54, 55-59 and 60-64) and respondents with or without 
previous vaccination history. These findings were presented elsewhere. 
 
Individual health behaviour is influenced by multifactorial factors comprised of 
social, environmental and economic dynamics in a given context. Studies on local 
vaccination policy and the views of health professionals would provide a 
comprehensive account of the low vaccination coverage in this age group. 
 
Conclusion 
Factors related to the existing health-care service and advice from health 
professionals, relatives and friends, had a comparatively strong association with 
influenza vaccination uptake amongst 50 to 64 year-olds, compared to other 
factors.   
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Table 1.  Demography of the cases and controls 
 
    Case (n=193) 
Control 
(n=411) 
Chi-
square Crude Odd Ratio (OR) 
    No. % No. % p-value OR 95% CI p-value 
Average age (years) ± SD 57.3 ± 4.8  56.3 ± 4.4   - - - 
Sex Male 73 37.8 159 38.7 0.84 0.96 0.68 1.37 0.84 
  Female 120 62.2 252 61.3   1.04 0.73 1.48 0.84 
Age group 50 - 54 59 30.6 176 42.8 0.01 ref ref ref 
  55 - 59 63 32.6 119 29.0   1.58 1.03 2.41 0.04 
  60 - 64 71 36.8 116 28.2   1.83 1.20 2.77 0.005 
Ethnic Origin Chinese 193 100.0 410 99.8 0.49 - - - 
Education 
Level Primary or below 58 30.1 110 26.8 0.69 ref ref ref 
  Secondary 120 62.2 260 63.9   0.88 0.60 1.29 0.50 
  Tertiary or above 15 7.8 37 9.1   0.77 0.39 1.52 0.46 
Occupation Self-employed /  Managing executives 1 0.37 4 1.0 0.14 - - - 
  Professionals 11 5.7 22 5.4   - - - 
  Clerical 22 11.4 61 14.8   - - - 
  Servicing & retailing 33 17.1 68 16.5   - - - 
  Technical /  Nontechnical workers 11 5.7 37 9.0   - - - 
  Unemployed  11 5.7 32 7.8   - - - 
  Retired 52 26.9 69 16.8           
  Housewife 47 24.4 112 27.3   - - - 
Employed Yes 83 43.0 198 48.2 0.27 0.82 0.58 1.15 0.24 
  No 110 57.0 213 51.8   - - - 
Health 
Professionals Yes 9 4.7 6 1.5 0.02 3.30 1.16 9.41 0.03 
  No 184 95.3 405 98.5   - - - 
CSSA recipient Yes 11 5.7 9 2.2 0.03 2.70 1.10 6.63 0.03 
  No 182 94.3 402 97.8   - - - 
Personal 
Monthly 
Income 
(HKD$) 
No income 105 54.7 206 50.4 0.79 ref ref ref 
  9999 or below 29 15.2 59 14.4   0.96 0.58 1.59 0.89 
  10000 - 19999 48 25.0 111 27.2   0.85 0.56 1.28 0.44 
  20000 or above 10 5.2 33 8.0   0.59 0.28 1.25 0.17 
Current smoker Yes 16 8.3 20 4.9 0.10 1.77 0.89 3.49 0.11 
  No 177 91.7 391 95.1   - - - 
Current drinker Yes 34 17.6 80 19.5 0.59 0.88 0.57 1.38 0.59 
  No 159 82.4 331 80.5   - - - 
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Table 2.  Comparing study variables between cases and controls by crude odds ratio and multinomial logistic regression analysis 
  
Cases (193) Control (411) Odd Ratio (Crude) Odd Ratio (Adjusted) 
Count % Count % value 95% CI p-value value 95% CI p-value 
Knowledge                         
Knowing oneself to be in the recommended group for flu vaccine 37 19.6 25 6.1 3.75 2.18 6.44 0.002 2.34 1.23 4.44 0.01 
Knowing flu vaccine provides 70-90% protection in healthy adults 89 46.6 140 34.1 1.66 1.17 2.35 0.005 1.86 1.12 3.10 0.02 
Knowing about the Government Vaccination Programme  128 68.0 219 53.5 1.79 1.25 2.57 0.001 1.09 0.68 1.75 0.72 
Knowing flu vaccine reduces flu complications and related hospitalisation 180 97.8 366 93.4 3.20 1.10 9.30 0.02 0.89 0.25 3.19 0.86 
Needs              
Live with children < 6 years or elderly >65 years 53 27.5 85 20.7 1.45 0.98 2.16 0.033 1.23 0.74 2.04 0.43 
Presence of chronic disease(s) 78 40.4 111 27.1 1.83 1.27 2.62 <0.001 1.13 0.65 1.96 0.67 
Visited doctors in the past 3 months 92 47.7 141 34.3 1.74 1.23 2.47 0.002 1.12 0.67 1.87 0.68 
Behaviour                         
Current smoker 16 8.3 20 4.9 1.77 0.89 3.49 0.11 0.72 0.27 1.92 0.52 
Current drinker 34 17.6 80 19.5 0.88 0.57 1.38 0.59 - - - - 
Belief & perception                         
Perceived having severe or moderate symptoms when contracting flu 17 8.8 15 3.6 2.55 1.25 5.22 <0.001 2.90 1.21 6.97 0.02 
Perceived flu vaccine to be safe 183 98.4 342 89.8 6.96 2.12 22.82 <0.001 3.99 0.78 20.41 0.10 
Believed flu vaccine has additional benefits other than flu protection  181 93.8 356 87.3 2.20 1.15 4.23 0.013 1.36 0.58 3.21 0.48 
Perceived very high and high chance of contracting flu in the next 12 months 55 31.1 77 19.9 1.81 1.21 2.72 0.004 1.03 0.61 1.76 0.90 
Perception of having very good or good health 105 54.4 281 68.4 0.55 0.39 0.78 <0.001 0.72 0.44 1.19 0.20 
Perception of having severe adverse events after vaccine 22 12.2 89 24.9 0.42 0.25 0.70 <0.001 0.64 0.33 1.22 0.18 
Belief in very good or good vaccine efficacy 147 76.2 269 65.5 1.69 1.14 2.49 0.007 0.62 0.36 1.08 0.09 
Health-care system                         
Eligible for free government vaccine 45 23.6 21 5.1 5.71 3.29 9.91 <0.001 6.38 3.43 11.87 <0.001 
Willing to receive flu vaccination for free 184 95.8 309 75.7 7.37 3.50 15.49 <0.001 4.84 2.13 11.03 <0.001 
Convenient to reach a vaccination location  187 96.9 370 90.0 3.45 1.44 8.28 0.002 2.87 1.06 7.74 0.04 
Prefer public clinic for injection 105 54.7 291 71.0 0.48 0.33 0.68 <0.001 0.35 0.22 0.55 <0.001 
Will respond to Government telephone reminder service on flu shot 105 54.4 160 39.6 1.82 1.29 2.57 <0.001 0.84 0.51 1.38 0.49 
Advice                         
Accept advice from health professionals 183 94.8 333 81.2 4.23 2.14 8.38 <0.001 2.67 1.19 5.99 0.02 
Had family member receive flu vaccine  76 41.8 74 18.3 3.20 2.17 4.71 <0.001 2.47 1.54 3.95 <0.001 
Accept advice from relatives and friends 86 44.8 101 24.6 2.48 1.73 3.57 <0.001 1.47 0.84 2.56 0.18 
External factors             
Will receive flu vaccine when there is an epidemic 181 94.8 327 81.3 4.15 2.09 8.23 <0.001 2.40 1.07 5.37 0.03 
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Table 3.  Responses of cases and controls in multiple answer questions 
  Cases (n=191) Control (n=413) Pearson Chi-Square 
Tests 
Count Column 
% 
Count Column 
% 
Chi-
square 
df Sig. 
Flu vaccine 
history 
Received on 2010/11 
and/ or 2011/12 
191 27.8 - - - - - 
  Last dose received > 2 
years 
- - 106 25.6 - - - 
  Never - - 308 74.4 - - - 
Reason for 
receiving 
vaccine 
Advice from health 
professionals 
91 47.2 64 61.0 11.56 8 0.17 
Perceive unsatisfactory 
health 
45 23.3 19 18.1       
Belong to high-risk 
group 
8 4.1 2 1.9       
Perceived vaccine 87 45.1 48 45.7       
Required by work 21 10.9 13 12.4       
Free vaccine 18 9.3 4 3.8       
Protect family 
members 
48 24.9 25 23.8       
Others 5 2.6 5 4.8       
Location 
received 
vaccine 
Public clinic 94 48.7 62 15.0 5.41 4  0.25 
Private clinic 83 43.0 36 34.3       
Hospital 8 4.1 3 2.9       
Others 10 5.2 5 4.8       
Preferred 
location for 
receiving 
vaccine 
Public clinic 105 54.7 291 71.0 28.07 4  <0.001 
Private clinic 85 44.3 127 31.0       
Hospital 7 3.6 21 5.1       
Others 0 0.0 0 0.0       
Other benefits 
for receiving 
vaccine 
Protect Family 
Members 
176 91.2 347 85.0 10.33 3  0.16 
Working Necessity 13 6.7 25 6.1       
Other Reasons 0 0.0 0 0.0       
No 12 6.2 52 12.7       
Medical 
consultation 
Consult Doctors 80 87.0 132 93.6 4.82 2  0.09 
Consult Chinese 
Doctors 
31 33.7 36 25.5       
Reasons for 
NOT receiving 
vaccine 
Unnecessary - - 216 70.8 - - - 
Non-high risk group - - 113 37.0       
Busy - - 78 25.6       
Side effects of vaccine - - 58 19.0       
Flu is a mild illness - - 19 6.2       
Expensive - - 16 5.2       
Do not know where to 
get vaccine 
- - 14 4.6       
Vaccine is ineffective - - 12 3.9       
* All questions, except the first, allow for the selection of more than one choice of answer. 
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5.2 Supplementary research result and discussion 
5.2.1.   Subgroup analysis 
A subgroup analysis had been conducted where the participants were divided into 
three age groups: 50 to 54, 55 to 59 and 60 to 64. In each subgroup, cases were 
compared to controls. There was an increasing trend of vaccination in the 55 to 59 
group (OR1.58, 95% CI 1.03-2.41, p=0.04) and 60 to 64 group (OR1.83, 95% CI 
1.20-2.77, p=0.005) when compared to the 50 to 54 group. Here I explore if there 
is an increasing trend in association with the 38 variables across the three age 
groups. 
 
There is no increasing or decreasing trend observed in any of the variables. 
‘Eligible for free government vaccine’ (OR from 7.72 to 14.83) and ‘willing to 
receive flu vaccination for free’ (OR from 8.04 to 11.46) were factors strongly 
associated with vaccination. ‘Preferred public clinic for injection’ (OR from 0.21 
to 0.24) and ‘perception of having severe adverse events after vaccine’ (OR0.29, 
95% CI 0.09-0.97, p=0.04) were strongly negatively associated with vaccination. 
This means more cases (vaccinated individuals) did not choose to vaccinate at a 
public clinic. More controls (unvaccinated individuals) had a negative perception 
of vaccination to have adverse events. Most variables were found to be 
statistically significant for one age group only. All the statistically significant ORs 
were presented in Table 9.   
 
Interpretation 
There is no gradation in the degree of association of variables with age. One 
possible reason for this is insufficient power to detect the small effect size due to 
small sample size. The sample size for each subgroup is around 200, so the effect 
size could be detected given a moderate degree of prevalence in the exposed 
(e.g., >20%). It appears that there is no real trend of association between 
vaccination and the variables under study. 
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Table 9  Comparing study variables between cases and controls by adjusted odds ratio for different age groups 
  50-54 55-59 60-64 
  Cases (n=59) Control (n=176) Cases (n=63) Control (n=119) Cases (n=71) Control (n=116) 
Factors p value Odds ratio (adjusted) p value Odds ratio (adjusted) p value Odds ratio (adjusted) 
    Value 95% CI   Value 95% CI   Value 95% CI 
Knowing oneself to be in the recommended group 
for flu vaccine - - - - - - - - 0.03 3.40 1.14 10.19 
 
Knowing flu vaccine provides 70-90% protection in 
healthy adults 
- - - - - - - - 0.04 2.39 1.06 5.40 
 
Perceived having severe or moderate symptoms 
when contracting flu 
0.02 5.528 1.36 22.55 - - - - - - - - 
 
Perception of having severe adverse events after 
vaccine 
0.04 0.29 0.09 0.97 - - - - - - - - 
 
Belief in very good or good vaccine efficacy - - - - - - - - 0.01 3.83 1.41 10.41 
 
Eligible for free government vaccine 0.02 14.83 1.43 153.67 - - - - <.0001 7.72 3.07 19.45 
 
Willing to receive flu vaccination for free  0.01 8.04 1.60 40.34 <0.001 11.46 2.99 43.99 - - - - 
 
Preferred public clinic for injection <0.001 0.24 0.12 0.51 0.01 0.21 0.07 0.64 - - - - 
 
Accept advice from health professionals - - - - - - - - 0.02 14.12 1.53 130.64 
 
Accept advice from relatives and friends  - - - - <0.001 3.86 1.81 8.19 - - - - 
 
Had family member receive flu vaccine 
 
0.02 2.431 1.12 5.28 - - - - 0.03 2.71 1.12 6.51 
* Variables with statistically insignificant adjusted OR are not shown 
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5.2.2.   Strengths and limitations of the case-control study 
This case-control study assesses multiple causes relating to one outcome event. It 
is a suitable method for assessing the causes of a new problem with rare outcome. 
This study design proves associations but does not demonstrate causation.154 It 
intended to establish and quantify associations by comparing the odds of the 
exposures in the cases and controls, i.e., the odds ratios. It is retrospective so can 
assess outcomes that happened in the past. The data collection period was finished 
within 2 months, which is relatively short when compared to a cohort study. 
 
The problem of recall bias could be less serious because the cases and controls 
were asked about their vaccination status and related information in recent two 
years. Their answers on demography, knowledge, belief and perceptions, and 
other parameters may not have changed a lot within these two years. Besides, the 
views they had were what they hold true, and it could not be said as biased or 
wrong. So in the study hypothesis, the cases were expected to have different 
views, beliefs and perceptions from the controls. There could give incomplete or 
deliberately inaccurate answers, but it is difficult to validate the answer of a 
respondent. Interviewers and interviewees were not blinded during interviews. 
There would be interviewer bias if the interviewer had strong and different 
presumptions about the cases and the controls. This led to inconsistency in 
questioning, sending non-verbal cues or placing emphasis on interpreting 
answers.155 There was a risk for the interviewees of consciously or subconsciously 
affecting their answers. 
 
Table 10  Strengths and limitations of the case-control study 
Strengths Limitations 
 Suitable for rare outcome  
(8.5% among adults aged 50 to 64) 
 Difficult in finding control to match 
with cases 
 Allow examination of multiple 
exposures or risk factors 
 Established association between 
exposures and outcome, not causation 
 Good for examining past outcomes 
(vaccination within 2 years) 
 Susceptible to recall and information 
bias 
 Obtained result within a short time  
(2 months) 
 Difficult to validate the information 
obtained 
 Interviewers clarified questions; and 
ensure questionnaire was completed  
 Interviewers and interviewees were 
not blinded 
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5.2.3.   Internal validity 
To assess the degree of internal validity, an adopted methodology checklist on 
case-control studies from UK National Institute for Health and Care Excellence 
(NICE) was used.156 Out of the 11 questions, 7 were well covered by the case-
control study. There were inadequacy in identifying the similarities or differences 
between the participants (respondents) and non-participants (non-respondents). 
The response rate is on the low side and without separate figures for the cases and 
controls.   
 
Table 11  Internal validity checklist on the case-control study 
General 
1.1 The study addresses an appropriate and clearly focused 
question 
Well covered, 
in section 4.1 
Selection of Subjects 
1.2 The cases and controls are taken from comparable 
populations 
Well covered, 
in section 4.3 
1.3 The same exclusion criteria are used for both cases and 
controls 
Well covered, 
in section 5.1 
1.4 What percentage of each group (cases and controls) 
participated in the study? 
Overall 
response rate 
41.7% 
1.5 Participants and non-participants are compared to 
establish their similarities or differences 
Poorly 
addressed 
1.6 Cases are clearly defined and differentiated from 
controls 
Well covered, 
in section 5.1 
1.7 It is clearly established that controls are non-cases Well covered, 
in section 5.1 
Assessment 
1.8 Measures were taken to prevent knowledge of primary 
exposure from influencing case ascertainment 
Not applicable 
1.9 Exposure status is measured in a standard, valid and 
reliable way 
Well covered, 
in section 4.4 
Confounding 
1.10 The main potential confounders are identified and taken 
into account in the design and analysis 
Adequately 
addressed 
Statistical analysis 
1.11 Confidence intervals are provided Well covered, 
in section 5.1 
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5.2.4.   External validity – generalisation of research findings  
Provided the internal validity of the case-control study is accepted, I would choose 
to how applicable the findings are to the target population, or to relevant 
populations in other parts of the world. First, I would consider the 
representativeness of the sampled population. Based on the detailed selection of 
the sampling districts, choice of suitable recruitment time, and comparable 
demography of the samples (cases and controls)  with the population, I accept that 
the samples could represent the general population of people aged 50 to 64 in 
Hong Kong. Second, I would examine the randomness of the non-respondents 
because reason for losses due to non-participation could be related to the exposure 
or to the outcome. 157  Given the limitations of the street-intercept interview 
method, it is difficult to solicit views from non-respondents because they just 
walked away. The overall response rate of 41.7% in this study was disappointing, 
but survey research literature reveals that response rates in intercept studies 
seldom exceed 50%. 158 It was assuring that most finished questionnaires were 
completed satisfactorily, with a completion rate of 98%.  
 
Thus I conclude that the findings of the case-control study could be generalised to 
the general population aged 50 to 64 in Hong Kong. However, I have reservations 
in applying the results to other relevant populations. This is based on my general 
knowledge of differences between cultures, beliefs and norms; and also 
differences in the external environment, such as health systems and service 
provision.  
 
5.2.5.   Study improvements 
The case-control study could have been improved if a matched-case control study 
was performed. Each case could be matched with a control from the same age, 
sex, place of residence, or socio-economic status. However, the matched 
parameters (e.g., age or sex) cannot be examined in the study. There would also be 
a substantial increase in time and cost in recruiting and matching eligible control 
participants. Yet, matching could eliminate the influence of known and unknown 
confounding factors that are difficult to measure.159 
  
 115 
 
The questionnaire could have been better designed by enhancing 
conceptualisation with a prior focus group discussion, and by establishing 
reliability with additional statistical tests. Instead, the conceptualisation and 
content of the questionnaire was formed through literature review. The 
questionnaire’s reliability could have been improved if a double interview was 
performed for each interviewee during pilot. Then statistical reliability tests such 
as test–retest reliability coefficients and Pearson’s correlation could be calculated 
during questionnaire development. A double interview would be more plausible if 
the interviews were conducted in a clinic or centre setting than in the street.  
 
During sampling, in addition to keeping a pen and paper record, it would have 
been better if all interviews were audio-taped for cross checking and audit 
purposes. For a study with a larger budget, a note pad could be used so that direct 
input of data into the relevant field could save subsequent input effort. Besides, 
pictures and animations could be used to arouse participants’ interest.   
 
The response rate of the case-control study was 41.7%. To improve response rate, 
some proven effective measures had been considered: giving incentives such as 
gift or cash coupon; and distributing attractive questionnaires on colour paper with 
appealing look.160,161,162 These were not implemented because the response rate 
during the pilot phase was around the expected average response rate of surveys 
of 55%144 , and that the questionnaires were filled by the interviewers.  
 
Other subgroup analyses could have been performed if time allowed. Clearly there 
might be differences in subgroups with or without chronic disease(s); working and 
unemployed; receiving social assistance and those who were not; those ever 
vaccinated and those never vaccinated. Identifying an increasing or decreasing 
trend in OR could help to establish dose-response relationships and suggest 
causations. Possible problems are small sample size in some subgroups, e.g., there 
were only 20 social assistance recipients. Interpretations of significant OR should 
err on the side of caution because sometimes ‘data dredging’ or ‘data fishing’ can, 
by chance, uncover unexpected associations.  
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6. Discussion and Recommendation  
 
This chapter is an overview of the thesis as a whole, and contains a discussion of 
the results of all the chapters. It also points out the implications of the findings on 
health service and policy, suggests potential areas for future research, and details 
the dissemination plan of the research findings.  
 
6.1 Concluding remarks 
6.1.1.   Achieving research objectives  
In the introduction of this thesis, I identified three research objectives and I 
achieved these using three different study methods.  First, I assessed the health 
needs for influenza vaccination in people aged 50 to 64 in Hong Kong, using 
epidemiological, comparative and corporate approaches. This served to provide 
background information on understanding the broader context of my research, and 
deepened my knowledge on what is known about this topic. Second, I examined 
the factors associated with the uptake of seasonal influenza vaccination in adults 
aged 18 to 64 years old through systematic literature review. The reviewed 
information on factors (variables) associated with the uptake of influenza 
vaccination was essential in formulating the content of the case-control study 
questionnaire. Lastly, I conducted a case-control study to determine which factors 
(variables) were associated with influenza vaccine uptake in residents of Hong 
Kong aged 50 to 64 years. The result provides new data and insight which will 
serve as a reference for influenza vaccination services.  
 
6.1.2.   Original contribution  
This work provides new data and understanding of the factors affecting 
vaccination amongst middle-aged adults. The case-control study quantifies factors 
associated with the uptake of influenza vaccine more precisely with regard to the 
50 to 64 age group. It enhances understanding of vaccination behaviour by 
providing the latest information. Since many places have not included this age 
group in their national vaccination programmes, the result should guide health 
workers planning influenza vaccination services and strategies for middle-aged 
healthy adults.   
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6.1.3.   Scope of the thesis   
Individual health behaviour is influenced by multifactorial factors which are 
interactions of ‘socioeconomic and political context’, ‘individual’s structural 
determinants’, and ‘intermediary determinants of health’. 163,164 Given the breadth 
of the thesis’s scope, its focus and case-control study is concerned with the latter 
two. The most important ‘individual’s structural determinants’ proxy indicators 
are income, education, occupation, social class, gender, and race/ethnicity.  The 
main categories of ‘intermediary determinants of health’ are material 
circumstances; psychosocial circumstances; behavioural and/or biological factors; 
and the health system. 
 
What is not included in the thesis and the case-control study belongs to the 
‘socioeconomic and political context’ of influenza vaccination. These are the 
governance, health and social policy, cultural norms and societal values.163 In 
addition, the health implementation, equity and stakeholders’ role (e.g., health 
professionals, vaccine industry) have not been addressed.  
 
6.1.4.   Conceptual framework and health behaviour theories  
A conceptual framework explains, either graphically or in narrative form, the main 
things to be studied – the key factors, constructs or variables – and the presumed 
relationships among them.165 A framework is not explicitly described in this thesis 
because the understanding is sufficient and clear without citing theories, using 
concepts and drawing diagrams. A conceptual framework diagram was 
constructed for this thesis, but I decided not to include it because I felt readers 
could understand the thesis equally well, if not better, without the diagram.  
 
Although no theories were mentioned, framework, theories and models explaining 
and predicting health behaviours were studied during the course of the research 
design. These theories have been extremely influential in conceptualising, 
predicting and changing health behaviour. 166 One of the earliest models is the 
Health Belief Model which explains differential behaviour in utilisation of 
prevention programmes such as immunisation.167 Other health promotion theories 
and models such as Theory of Reasoned Action 168 , Theory of Planned 
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Behaviour169 and The Social Learning Theory were studied. These theories cite 
environmental, personal, and behavioural characteristics as the major factors in 
behavioural determination. Understanding these theories can help to define the 
scope of the research and acknowledge what is and is not included in the thesis to 
explain vaccine uptake behaviour. 
 
6.1.5.   Comparing results of the systematic literature review and the case-
control study   
The result of the case-control study is compared with the systematic literature 
review. By doing this, I compared factors associated with vaccination uptake in 
people aged 18 to 64 living in different parts of the world, with  those aged 50 to 
64 living in Hong Kong. While the presence of chronic disease(s) is one of the 
consistent factors with high OR in many studies, it was not a significant factor in 
the local study group. Free vaccination, ‘accept advice from health professionals’ 
and cues to action (‘had family member receive flu vaccine’), were consistently 
associated with vaccination in both the review and the case-control study. 
‘Convenient to reach a vaccination location’ and ‘will receive flu vaccine when 
there is an epidemic’ were two associated factors which were not commonly 
mentioned in studies done in other parts of the world. 
 
Table 12  Comparing factors with high odds ratios (OR) in the systematic 
literature review and the case-control study 
Systematic literature 
review 
OR Case-control study OR 
Presence of chronic 
disease(s) 
1.38-13.7 Eligible for free government 
vaccine 
6.38 
Advice from health 
professionals 
1.23-13.0 Willing to receive flu 
vaccination for free 
4.84 
Perceived vaccine efficacy 2.7-10.55 Perceived having severe or 
moderate symptoms when 
contracting flu  
2.90 
Advice from doctors 4.03-7.82 Convenient to reach a 
vaccination location 
2.87 
Free vaccination 4.5-7.8 Accept advice from health 
professionals 
2.67 
Cues to action (relative and 
friends receive vaccine) 
6.44 Had family member receive 
flu vaccine 
2.47 
Perceived chances of 
contracting influenza 
1.62-5.40 Will receive flu vaccine when 
there is an epidemic 
2.40 
*‘Age’ with OR 1.06-23.7 was not included because subjects in the case-control study were all 50 to 64 years; 
‘advice from family and/or close friends’ with OR=17.74 is not included because of estimated cultural bias 
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6.1.6.   Controversies of influenza vaccination    
Some recent studies have questioned the benefit of influenza vaccine efficacy. A 
Cochrane review concluded that the vaccine had modest effects in reducing 
working days lost, but had no effect on reducing hospital admissions or 
complication rates in healthy adults.91 Two other reviews stated there was a lack of 
evidence on protection of vaccine in adults aged 65 years or older.80,170 Later there 
was another study on a reanalysis of one of these reviews and concluded in favour 
of vaccination in the elderly population.171 
 
Till now, experts generally agree that vaccination is the first line of defence for 
reducing influenza morbidity and mortality.72  Influenza vaccine would continue to 
be used by health authorities to protect high-risk people from influenza related 
complications. Revision of vaccination policy and service is an on-going task for 
health authorities wishing to maximize influenza epidemic and pandemic 
preparedness. 
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6.2 Informing policy 
6.2.1.   Argument on health inequality and health inequity   
The policy decision to limit the government vaccination service to those receiving 
CSSA§§§§ and having chronic diseases amongst 50 to 64 year-olds has caused 
major concern and stimulated discussion. Most (95%) of this group recommended 
by DH to receive influenza vaccine had to pay out-of-pocket if they choose to be 
vaccinated. Firstly, this decision may fail to meet public expectations, as people 
may have expected that all the groups recommended for vaccination by the DH 
would enjoy free or subsidized vaccination services. Secondly, it raised issues 
around equality and led to people arguing why free service was limited to CSSA 
recipients only. Thirdly, the differences in vaccination service provisions to the 
different recommended target groups have caused confusion in health promotion. 
 
The advantage of this decision was that only a small amount of additional funding 
was incurred, and therefore this additional budget did not require approval from 
the Legislative Council – which saved a lot of time. The moderately increased 
workload and budget could easily be absorbed by the existing service provision in 
the public sector. This service expansion minimized competition with other health 
priorities for resources.   
 
Although the price of receiving an influenza vaccination constitute <3.5% of a 
monthly income, this does not necessarily mean socio-economically deprived 
groups who are ineligible for free vaccination would be willing to pay for the 
vaccine. Subsidised vaccination would attract those who are willing to pay for a 
discounted price, and these people may be among ‘the better off’ – those who 
have easier access to vaccination services, who are better informed about the 
availability and effectiveness of the vaccine, who work less demanding working 
hours, etc. The inverse care law, first described by Julian Tudor Hart in 1971, 
states that the availability of good medical care tends to vary inversely with the 
need for it in the population served.172 
 
                                               
 
§§§§ CSSA Scheme is a social safety net for those who cannot support themselves financially. It is designed to 
bring their income up to a prescribed level to meet their basic needs. 
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To tackle this inequity, there is a need to find ways to diminish the vaccination 
barriers and/or enhance protection by herd immunity. Hong Kong has the highest 
income disparity in Asia (Gini coefficient 0.537 in 2011) and the government has 
started to put forward poverty alleviation policies in recent years. 173 , 174  Free 
influenza vaccination or special healthcare allowance could be included as part of 
the package to support those below the poverty line. Indirect protection (herd 
immunity) can be achieved by selectively vaccinating groups that are important in 
transmission, such as young children living in families below the poverty line. 
However, the low vaccination rate in the population and amongst the high-risk 
group (8.4% for children under 5 and 39.1%for elders over 65), plus a high 
mobility of city people, renders achieving herd immunity a challenging prospect.9 
 
6.2.2.   Evidence-based recommendations on policy change  
 
Recommendation 1: The provision of free or subsidized vaccine for people age 50 
to 64 years could probably improve the coverage rate.   
 
The case-control study evidenced that the most important barrier to influenza 
vaccination as being financial. Any policy initiative to increase vaccine uptake 
will need to address the financial barrier. The first and second most strongly 
associated factors with vaccinations both related to financial incentives – ‘eligible 
for free government vaccine’ (OR6.38) and ‘willing to receive flu vaccination for 
free’ (OR 4.84). This was further supported by the systematic review of a strong 
association of free vaccine and vaccination (OR7.8). In addition, study on the 
influenza vaccine provision in 157 countries found policy measures that directly 
impact on patients (i.e., money reimbursement and communication) were highly 
correlated with higher vaccine dose distribution rate in the population, irrespective 
of a country’s development status.18 
 
An alternative would be to provide a subsidy or repayment for the vaccine. In the 
case-control study, one in four (24.7%) of the cases and controls were willing to 
receive the vaccine if it cost below HKD$50 (USD$6.4), and an additional 12.1% 
was willing to pay if it cost below HKD$100 (USD$12.8). The median cost of one 
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dose of influenza vaccine, including the cost of the vaccines and consultation fees 
was $180 (USD$23).104 A subsidy of $130(USD$16.6) could lead to a substantial 
increase in people’s willingness to receive influenza vaccination, especially 
amongst those that have not been vaccinated (controls) in 2011/12 and 2012/13. 
 
Table 13 Amount willing to pay for influenza vaccine in the case-control study 
Amount willing 
to pay  Case % Control % Total  Total % 
$0 108 56.0% 250 60.83% 358 59.3% 
< $50 49 25.4% 100 24.33% 149 24.7% 
< $100 22 11.4% 37 9.00% 59 9.8% 
<$150 2 1.0% 9 2.19% 11 1.8% 
> $150 3 1.6% 0 0.00% 3 0.5% 
Fee is not a 
concern 9 4.7% 15 3.65% 24 4.0% 
 193  411  604  
 
Recommendation 2: Health promotion should address ‘the perception of having 
severe or moderate symptoms when contracting flu’, ‘knowledge of oneself to be 
in the recommended group for flu vaccine’ and ‘good vaccine protection for 
healthy adults’.   
 
Even if there are restrictions on funding, resources and service provision, DH still 
has an obligation to explore ways to increase vaccination coverage in this newly 
recommended group; as well as find other measures to reduce serious influenza 
mortality and morbidity. If DH with continues the existing policy and receives no 
additional funding, health promotion could target this group and encourage out-of 
pocket payment. There needs to be a health promotion strategy and activities 
targeted at the 50 to 64 age group. Health providers could be engaged, with or 
without incentives, to promote the benefit of vaccination. Other measures, such as 
personal hygiene and healthy life style, should also be promoted to improve 
general health and decrease influenza related morbidity. The high affordability of 
an annual influenza vaccine for the general public could be the basis of success. 
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Recommendation 3: Review on the policy  
 
Public health policy makers in DH should conduct a review of the impact and 
cost-effectiveness of this vaccine policy after it has been implemented for three 
years. Depending on the target coverage set by DH, they can choose whether to 
provide a free vaccination for this group, or just give them subsidy for injection in 
the private sector. The amount of money given as a subsidy affects the coverage – 
the larger the amount, the greater the incentive would be to the vaccine recipient 
and healthcare provider. The review data on vaccine impact and cost would 
support an appeal for additional funding by the Secretary in the Bureau and in the 
Legislative Council. In contrast, if the review result is unfavourable, DH may 
consider maintaining current service provision. DH should further consult the 
SCVPD to decide if adults aged 50 to 64 should remain as a recommended group.  
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6.3 Future research 
During the research process, a significant amount of time was needed to search for 
relevant information on people aged 50 to 64 year or middle-aged adult. This 
suggested more research or data presentation on this age group would improve 
understanding and inform future vaccination planning. Many of the influenza 
vaccination studies on general populations have included this age group. For a 
study with a large sample size, a subgroup analysis would yield valuable 
information. Here, I suggest some fruitful avenues: 
 
• Reassess if there is local health needs for people aged 50 to 64 to be included 
as the recommended target group for influenza vaccination in the coming year. 
There is constant change in the impact of influenza strains on disease mortality 
and morbidity. 
 
• Explore and engage with overseas health counterparts on the reasons for not 
including people aged 50 to 64 in their vaccination programme. Many 
overseas health authorities chose not to recommend this age group for 
influenza vaccination despite favourable cost-effectiveness analysis. 
 
• Examine views and practices of health professionals on recommending 
influenza vaccination to people aged 50 to 64. Health professionals’ advice is 
associated with vaccination uptake their view influences the vaccination 
coverage.  
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6.4 Dissemination plan 
In order to share the research findings with interested public health workers, the 
two research papers will be submitted to peer-reviewed journal(s). In addition to 
this, a summary will be written in the Hong Kong Medical Association magazine 
to inform local practitioners. A poster presentation on the case-control study was 
held in the Annual Scientific Meeting of the Hong Kong College of Community 
Medicine on the 22 September 2014. (Annex 3) Relevant sections of this research 
will be communicated to the DH Vaccination Office for policy and service 
improvement. 
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7. Integrating Statement of DrPH 
7.1 Introduction  
This integrating statement summarizes my learning processing since 2007 during 
the course of my Doctorate in Public Health (DrPH). A DrPH is a degree which 
combines theoretical and practical knowledge on leadership, management and 
research. I enrolled on this degree a few years after I finished a master’s degree in 
public health and worked in the Department of Health as a public health 
physician. I decided to undertake this degree with a view to gain insight into 
international best practices in public health policy, leadership skills and the 
application of evidence-based medicine. 
 
The DrPH consists of three components, structured chronologically: the taught 
courses, the Organisational and Policy Analysis (OPA) and the research project. 
Taught courses took place between late 2007 and early 2008, the OPA attachment 
from June to November 2010 and the research project since 2012. I began this 
degree as full-time student in September 2007, temporarily stopped for half year 
in 2009, and resumed part-time at the end of the same year.   
 
Figure 6 Timeline of the DrPH study 
 
 
7.2 Taught courses  
The taught components consisted of compulsory and selected modules. The core 
compulsory modules in the first term during the first year covered two subject 
areas: leadership, management and development (LMD); and evidence-based 
public health practice (EBPHP). I also attended four selected modules; three were 
done in 2008 before the OPA attachment and one in 2013. 
 
2007-8 
Taught courses 
(Full-time) 
2010-2011 
Organisational and 
Policy Analysis 
(Part-time)  
2012-2014 
Research project 
(Part-time) 
 127 
 
The compulsory modules were exclusive to DrPH students. In 2007/08 there were 
around 10 students enrolled, each from a different country in Africa, America, 
Asia, or Europe. All of us had experience in supporting or managing public health 
programmes in Government and/or NGOs. Taking advantage of this experience, 
we often discussed the similarities and differences in public health policies, 
practices and decision-making process in related to local cultures, resources and 
constrains. We shared our views on important public health issues such as health 
finance systems, maternal and child health, HIV/AIDS, TB, Accident and 
Emergency Department (AED) services, etc. 
 
The LMD module teaching sessions introduced major organisation and behaviour 
theories and their application. The most memorable part of this course was the 
three day personal development retreat. The retreat enabled me to reflect upon my 
personality, personal management and leadership styles. We spent more than a 
half day interpreting and sharing results of the Myers-Briggs personality test. I 
had a heated discussion with the coordinator and my classmates because I 
disagreed with the personality test result and claimed it not reflect my true 
personality. Several years later, however after holding a managerial position, I 
realized that the test result did reveal some of my core strengths and weaknesses 
in leadership and management.   
 
The EBPHP modules introduced the fundamental concept of evidence-based 
policy theory and research methods in public health practice. This course taught 
me to better locate, assess, collate, present, and use the research-based information 
to guide public health policy and practices. These are essential skills for the 
literature review in the OPA, research project and my work on policy decision at 
the DH. 
 
For the four selective modules, three were done in 2008 before the OPA 
attachment and one in 2013. In 2008, I selected modules on health impact and 
decision analysis, health-care evaluation, and financial management. These 
modules better equipped me for the OPA attachment. During the writing-up phase 
of the research project in 2013, I attended one more module on extended 
 128 
 
epidemiology, to cover particular skills that were required for data analysis and 
discussion in the research project.  
  
7.3 Organisational and Policy Analysis (OPA)  
The OPA attachment was undertaken over a 6 month period from June 2010 in a 
small-scale NGO, called Community Health Organisation for Intervention, Care 
and Empowerment (CHOICE), in Hong Kong, China. The analysis, writing and 
revision of the OPA report lasted another 12 months. My attachment was 
undertaken outside my normal place of work as a volunteer. 
 
It took me some effort to identify an organisation which would allow me attach 
myself to them, interview their staff, evaluate their work, and write about it. I was 
working in DH but an OPA attachment there was impossible because of 
restrictions on disclosing internal practices and information, let alone being able to 
analyse and critique it. Besides, the DH service had a recent internal evaluation 
and it seemed there was little I could recommend further. On the contrary, 
CHOICE as a small-organisation with fewer than 10 staff was eager to enrol an 
additional volunteer. It’s Chief Executive and Board Members were enthusiastic 
about exploring and discussing organisational issues such as enhancing funding, 
improving staff motivation and service provision. By studying the operation of a 
small organisation, a more comprehensive view of the whole organisation was 
obtainable.  
 
During OPA, I observed and analysed how CHOICE had achieved its public 
health goals by using semi-structured interviews, participant observation, 
document review, and relevant literature search. The data collected was analysed 
by applying various analysis frameworks and theories I learned during the taught 
modules. I studied the organisational structure, management and leadership, its 
relationships with the external environment, and how these factors impacted on 
the organisation. After completing the OPA attachment, I analysed the data 
collected and formulated a list of practical recommendations. I fedback these 
findings during a sharing session to CHOICE Board Members and staff, hoping 
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that this might encourage new ideas to emerge on enhancing the organisation’s 
effectiveness and sustainability.   
 
The OPA gave me an opportunity to gain a deeper understanding of how a small-
scale NGOs is managed, how it functions to fill service gaps and how it acted 
within the policy environment. I still participated in the activity CHOICE 
organised several years after the OPA attachment, and maintained a good 
relationship with some of the staff and Board Members. One of the Board 
Members later became a member of the Advisory Committee for my research 
project. 
 
7.4 Research project  
The research project was the most challenging part of all because of the originality 
and scientific rigour that was required. Formulating the research topic took years 
because the original research topic, which I submitted on admission to the school, 
was dropped due to a change of work. It was not until 2011 that I managed to 
formulate this research topic when I worked in the DH Vaccination Office (VO). 
During my stay in the office I assisted with the needs assessment and planning of 
a proposed change in vaccination policy and it was in this context that the research 
topic was developed. Subsequently, the research project has taken 24 months. 
 
I have conducted a literature review, prepared a research protocol and a plan for 
data collection since May 2012. The first research protocol was rejected by the 
review committee on November 2012 and a subsequent resubmission on July 
2013 was accepted. Following the committee’s approval, I proceeded to data 
collection and then result analysis. The first draft of research articles of the thesis 
was finished on January 2014. During this period, the supervisor and the advisory 
committee members gave ample academic support and guidance. The two M.Sc. 
modules, workshops and seminars I attended at the LSHTM also helped to 
strengthen my skills for undertaking the data analysis and discussion.  
 
Support from the academic staff, my supervisor and, most importantly, from 
student peers was crucial for maintaining my positive stamina and motivation. 
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DrPH students usually compose 10 percent of the post-graduate research student 
population at LSHTM. Being in the minority, our DrPH class maintained contact 
and notified others classmates about each other’s progress. This avoided feelings 
of isolation and being left behind. 
 
In undertaking the research project, I learned to take responsibility for managing 
my learning process. There were people around to support, but for the research 
project, I had to take the initiative to do it. This has required me to conduct an 
exploration of how to apply the scientific methodology in finding answers to 
specific questions. There were also opportunities to get a feel of the academic 
world and engage in writing research funding proposals, project management, 
scientific presentations, publications, etc. This training equipped me with the 
ability to better critically appraise and apply research findings in public health 
practices. 
 
 
7.5 Conclusion 
The DrPH course was unique in providing a diversity of public health knowledge 
and skills, with emphasis on practical applications. The cultural variety and 
scientific excellence of the school broadened my understanding of the subject and 
prepared me for a leading role in my public health career. 
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Annex 1 
 
50至 64歲香港人士接種季節性流感疫苗的因素 
Factors associated with uptake of influenza vaccine in people aged 
50 to 64 years in Hong Kong: a case-control study 
問卷 Questionnaire  
 
訪問員編號 Interviewer no.: 
訪問日期 Date of interview: 
訪問時間 (開始／完結) Time of interview (start / end): 
訪問地點 Location of interview: 
 
引言 Introduction  
我們誠意邀請你參與這項由楊貝珊醫生(倫敦衛生和熱帶醫學院)執行的研究。
這項目已獲得香港理工大學人類課題道德委員會和倫敦衛生和熱帶醫學院道德委員
會批准。在你決定之前，請仔細閱讀以下訊息，明白研究的內容和目的。如果你想，
可以與他人討論。 
 
這項學術研究項目目的是探討 50 至 64 歲香港人士接種季節性流感疫苗的因
素。這項研究結果可作有用的參考，從而協助公共衛生從業者制定合適流感疫苗注
射服務和社區健康推廣宣傳的工作。調查問卷只需要約 10分鐘的時間完成。 
 
參與是自願的，是由你來決定是否參加。這項研究應不會對你造成任何不適。
你有權隨時退出而不需要給予理由，這不會有任何後果。你所提供的個人資料是完
全匿名和保密的。參與者在問卷中所採用的識別碼只有研究員知道。你有權隨時退
出而不受任何懲處。如果您想查詢更多關於這項研究，歡迎在辦公時間聯絡楊貝珊
醫生(電話: 97717501) 或電郵tak.fai.tong@ polyu.edu.hk。  
 
若你對此研究有任何投訴，請以書面形式去信香港理工大學，與人類課題道
德屬下委員會秘書 Dr. Virginia Cheng 聯絡。（C / O香港理工大學研究事務處），
請註明這項研究的負責人及部門。 
 
感謝您參與這項研究。 
 
楊貝珊        
項目負責人 
 
 
You are invited to participate on a study conducted by Dr. YEUNG Pui Shan from the 
London School of Hygiene and Tropical Medicine (LSHTM). This academic research 
project has been approved by the Human Subjects Ethics Sub-committee (HSESC) of 
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The Hong Kong Polytechnic University and the LSHTM Ethics Committee. Before you 
decide it is important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully. Talk to others 
about the study if you wish.   
 
The aim of this study is to explore the factors associated with uptake of influenza 
vaccination in residents of Hong Kong aged 50 to 64 years. The result of this study may 
serve as useful reference public health workers on planning influenza vaccination service 
and health promotion work. The interview takes about 10 minutes to complete a 
questionnaire.  
 
Participation is voluntary. It is up to you to decide whether or not to take part. This study 
should not cause you any discomfort. You are free to withdraw at any time without giving 
a reason and this will not have any consequence. All information related to you will 
remain anonymous and confidential, and will be identifiable by codes only known to the 
researcher. You have every right to withdrawn from the study before or during the 
measurement without penalty of any kind. If you would like to get more information about 
this study, please contact Dr. Yeung Pui Shan at 9771 7501 during office or via 
tak.fai.tong@polyu.edu.hk.   
If you have any complaints about the conduct of this research study, please do not 
hesitate to contact Dr. Virginia Cheng, Secretary of the Human Subjects Ethics Sub-
Committee of The Hong Kong Polytechnic University in writing (c/o Research Office of the 
University) stating clearly the responsible person and department of this study.   
Thank you for your interest in participating in this study.     
 
YEUNG Pui Shan, May            
Principal Investigator                        
 
參與者的選擇和同意 
我們邀請 50至 64歲懂中文或英文的香港居民參與。如果你是，請繼續調查問卷。 
我同意貢獻將版權讓倫敦衛生和熱帶醫學院公共健康政策用作研究。 
 
Participant selection and consent 
We are choosing Hong Kong residents aged 50 to 64 who could understand Chinese or 
English, please continue the questionnaire only if you are. I hereby assign copyright of my 
contribution for research purposes to the Faculty of Public Health and Policy of the 
LSHTM. 
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抽選被訪者 Participant selection 
□ 請問你係唔係50至64歲的香港人士？（1962年至1949年出生）Ascertain the person is 
Hong Kong resident aged between 50 to 64 years? (born between 1962 to 1949) 
□ 解釋研究目的  Explain the research purpose 
□ 告訴參與是自願的 Tell the person participation is voluntary  
□ 取得書面或口頭同意  Obtain written or verbal consent 
 
調查不成功原因 Reasons for unsuccessful interview: 
□  拒絕 Refuse 
□ 前兩年未接種疫苗（太多對照個案）Unvaccinated in previous two years (too many 
controls) 
□  溝通困難  Language difficulty 
□  聲稱以前完成同樣的調查  Claimed completed the same survey before 
請選擇  Please tick box 
1. 我對所附資料的有關步驟已經得到充分的解釋(或理解口頭解釋)。這項研究應不會
對我造成任何不適。如果我參加，我明白需要做什麼。我是自願參與這項研究。 
I fully understand the information concerning this study (or have understood the 
verbal explanation). This study should not cause any discomfort. I understand 
what will be required of me and what will happen to me if I take part in it. My 
participation is voluntary. 
□  
2. 有關於這項研究的問題，已經回答了。 
My questions (if any) concerning this study have been answered by the 
interviewer. 
□  
3. 我理解我有權在研究過程中提出問題，并在任何時候決定退出研究而不會受到任何
不正常的待遇或被追究責。 
I understand I have the right to ask question during the research, and may 
withdraw from this study without giving a reason and without any unusual 
treatment or any consequence.  
□  
4. 我同意參與由楊貝珊醫生負責監督和執行的研究項目。  
I agree to take part in this study supervised and implemented by Dr. YEUNG Pui 
Shan. 
□  
 
 
______________________ 
被訪者姓名 Name of participant 
 
______________________ 
被訪者簽名 Signature of participant 
 
______________________ 
日期 Date 
______________________ 
訪問員姓名 Name of interviewer 
 
______________________ 
訪問員簽名 Signature of interviewer 
 
______________________ 
日期 Date
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以下問題請選擇一個答案，除非另有說明。 
Please choose only one answer for the following questions unless otherwise 
stated. 
 
人口統計學 Demographics 
 
1.  你的出生年份係？  What is your year of birth? _________ (1962 to 1949) 
 
2.  請問你性別係？What is your gender? 
(訪問員：喺未能確定被訪者嘅性別嘅情況下才問此問題。)  
(Interviewer: Only ask when you are unsure about the participant’s gender.) 
a. 男 Male 
b. 女 Female 
 
3. 請問你種族？ What is your ethnicity? 
a. 中國 Chinese 
b. 印尼 Indonesia 
c. 菲律賓 Philippines 
d. 白人 White (American or European) 
e. 印度人 Indian 
f. 其他 Other (請說明 Please specify:_____________) 
 
4. 請問你最高教育程度？ What is your highest educational attainment? 
g. 未受教育／幼稚園 No schooling / kindergarten 
h. 小學 Primary 
i. 中學 Secondary 
j. 大專或以上 Tertiary or above 
k. 拒絕回答 Refuse to answer 
 
5.  請問你現在職業？What is your current occupation? 
(訪問員：如未能分類，填上職業名稱。) 
(Interviewer: Write down the name of occupation if you cannot classify.) 
a. 僱主 / 經理及行政人員 Employer / manager and administrator 
b. 專業人員 / 輔助專業人員 Professional / Associate professional 
c. 文員 / Clerk  
d. 服務工作及商店銷售人員 Service worker and sales 
e. 技術工人 / 非技術工人Skilled or unskilled worker 
f. 學生 Student 
g. 料理家務者 Homemaker 
h. 退休人士 Retired 
i. 待業 Unemployed person 
j. 其他 Other (請說明 Please specify:_____________) 
 
6.  你嘅職業與醫護有關嗎？  Is your occupation health related? 
a. 有關 Yes 
b. 冇關 No 
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7.  你有冇領取綜合社會保障援助（綜援）？  
Are you receiving Comprehensive Social Security Assistance (CSSA)? 
a. 有 Yes 
b. 冇 No 
 
 
8.  請問你每月嘅個人總收入係？  What is your total monthly personal income? 
a. 沒有收入 No income 
b. 港幣$7,500以下 Below HK$7,500 
c. 港幣 HK$7,500 – $9,999 
d. 港幣 HK$10,000 – $14,999 
e. 港幣 HK$15,000 – $19,999 
f. 港幣 HK$20,000 – $29,999 
g. 港幣 HK$30,000以上 or above HK$30,000 
 
9.  你有冇吸煙？ Are you a smoker? 
a. 有 Yes 
b. 已戒煙 Ex-smoker 
c. 從來冇 Never 
 
10.  你有冇飲酒？ Are you a drinker? 
a. 有社交飲酒 Yes, social drinker 
b. 有酗酒  Yes, binge drinking 
c. 冇 No 
 
11.  你住哪個區？ Which district do you live? 
a. 中西區 Central & Western District 
b. 東區 Eastern District 
c. 離島區 Islands District 
d. 九龍城區 Kowloon City District 
e. 葵青區 Kwai Tsing District 
f. 觀塘區 Kwun Tong District 
g. 北區 North District 
h. 西貢區 Sai Kung District 
i. 沙田區 Sha Tin District 
j. 深水埗區 Sham Shui Po District 
k. 南區 Southern District 
l. 大埔區 Tai Po District 
m. 荃灣區 Tsuen Wan District 
n. 屯門區 Tuen Mun District 
o. 灣仔區 Wan Chai District 
p. 黃大仙區 Wong Tai Sin District 
q. 油尖旺區Yau Tsim Mong District 
r. 元朗區 Yuen Long District 
 
 
行為  Behaviour 
 
Q1.  你在過去的兩個疫苗接種季節有冇打流感針（自2011年九月）？   
  Have you got flu shot in past two vaccination seasons (since 2011 Sep)? 
a. 有，今年  Yes, this year (2012/13; 即自2012年9月 i.e., since September 
2012) 
b. 有，這兩年 Yes, for two years (2012/13 and 2011/12, 即自2011年9月 i.e., 
September 2011) 
c. 冇 No 
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Q2.  你2011/12年以前有沒有打過流感針？ Have you ever received a flu shot 
before 2011/12? 
a. 有 Yes  
b. 冇 No  
 
 
Q3.  你會唔會在未來幾個月內打流感針（2013年9月至2014年8月）？  
  Will you receive flu shot in the coming months (from Sep 2013 to Aug 
2014)? 
a. 一定會 Yes, definitely  
b. 可能會 Yes, probably yes 
c. 可能唔會 No, probably not 
d. 一定唔會  No , definitely not 
 
醫療系統  Health-Care System 
 
Q4.  你是否有政府免費或資助打流感針？ Are you eligible for free or subsidized 
vaccination under the Government Vaccination Programmes and Schemes? 
a. 有 Yes 
b. 冇 No 
 
 
Q5.  請問你知不知道有政府防疫注射計劃和資助計劃，和非政府的疫苗資助計劃 ？ 
Are you awareness of the Government Vaccination Programmes and 
Schemes; and non-governmental vaccination subsidy schemes? 
a. 有 Yes 
b. 冇 No 
 
 
Q6. 請問你願意比幾多錢去打流感針呢？ 
 If you need to pay, how much are you willing to pay for receiving a flu shot?  
a. $0 
b. $1 - $50  
c. $50 - $100 
d. $100 - $150 
e. 費用唔係問題 Cost is not an issue 
 
 
Q7.   如果打流感針是免費，你願意打嗎？   
Are you willing to receiving flu shot if it is FREE?  
a. 願意 Yes  
b. 不願意 No (請說明  Please specify _____________) 
 
 
 
Q8.  你上次在哪裡打流感針呢？Where did you got the flu shot last time? 
a. 在政府(公營)診所 In government clinics 
b. 在私人診所 In private clinic 
c. 在醫院 In hospital 
d. 其他地方 (請註明 Please specify: _____________) 
e. 沒有打流感針 No, have not receive flu shot 
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Q9. 到打流感針的地方方便嗎？ Was the access to receive the flu shot 
convenient? 
唔方便 Very inconvenient □ □ □ □ □ 好方便Very convenient 
     1   2   3   4   5  
 
 
信念和感覺  Belief and perceptions 
 
Q10.  你認為你喺未來12個月內感染流感嘅機會有幾高呢？ 
    What is your chance of contracting flu in the next 12 months?   
很低  Very low □ □ □ □ □  很高 Very high 
    1   2   3   4   5  
 
 
Q11.  你預計你流感嘅病情會點樣呢？ 
    What would you expect the severity of the disease to be if you get flu?   
a. 嚴重 (需要住院/可能會導致死亡) Severe (need hospitalization / may cause 
death)  
b. 中等 (需要睇醫生 / 休息 / 影響日常工作) Moderate (need doctor 
consultation / take rest / affect daily routines) 
c. 輕微 (輕微病徵，可繼續日常工作) Mild (mild symptoms and can continue 
daily routines 
d. 唔知道 Don’t know 
 
 
Q12.  你認為疫苗是安全和只有輕微的不良反應嗎？ 
  Do you think the vaccine is safe with only minor adverse reaction? 
a. 是 Yes 
b. 不是 No 
 
 
Q13.  你認為流感疫苗有效保護你嗎？ 
          Do you think the vaccine is useful in protect you from flu? 
有效 Very useless  □ □ □ □ □ 有效Very useful 
    1   2   3   4   5  
 
Q14.  你覺得打流感針，有其他好處嗎？ 
  Do you think having a flu shot has other benefits? 
a. 有，保護家人 Yes, protect family 
b. 有，履行社會規範 Yes, fulfill social norm 
c. 有，工作需要 Yes, requirement of work 
d. 有，其他原因 Yes, for other reasons  註明specify:______________ 
e. 冇 No 
 
 
Q15.  你唔打流感針，喺唔喺因為怕打針/怕痛？ 
  Will you not get the vaccine because of scare of needle or pain? 
a. 怕打針 / 怕痛 Yes 
b. 唔喺 No 
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Q16.  你認為你健康嗎？Do you think your health is good? 
唔健康Very unhealthy □ □ □ □ □ 好健康Very healthy 
    1   2   3   4   5  
 
需要 Need 
 
Q17.  你有冇任何慢性疾病，如高血壓，糖尿病，高血脂，心臟疾病，殘疾等？ 
Do you have any chronic illness, e.g., hypertension, diabetes, hyperlipidemia, 
heart diseases, disability etc?  
a. 有 Yes 
b. 冇 No 
 
 
Q18.  在過去 3個月，你需要睇醫生（西醫或中醫）嗎？Do you need to consult a 
doctor (Western or Traditional Chinese Practitioner) in the past 3 months? 
a. 只有睇西醫 Yes, only Western doctor 
b. 只有睇中醫 Yes, only Traditional Chinese Practitioner 
c. 有睇兩種醫生 Yes, both types 
d. 冇 No 
 
 
Q19.  與你家中共同居住，有冇未滿6 歲嘅兒童或者65歲或以上長輩？ 
    Are you living with children <6 years or elders ≥65 years? 
a. 有未滿6 歲嘅兒童  Yes, child / children <6 years  
b. 有未滿65 歲或以上長輩  Yes, elders ≥65 years  
c. 有未滿6 歲嘅兒童和未滿65 歲或以上長輩  Yes, both  
d. 冇 No 
 
知識 Knowledge 
 
Q20. 打流感針能否減少流感並發症及入院？ 
 Can flu shot reduce flu complications and related hospital admission? 
a. 能 Yes 
b. 不能 No 
 
 
Q21. 請講出有效預防流感嘅方法？你可以選擇多過一個答案。（開放式問題） 
  Can you list measures that are effective to prevent flu? You can give more 
than one answer. (open-ended question) 
a. 保持健康生活模式 Maintain healthy lifestyles 
b. 避免人多的地方 Avoid crowd places 
c. 保持室內空氣流通 Maintain good indoor ventilation 
d. 注意個人衞生，例如打噴嚏後洗手Observe personal hygiene, e.g., wash 
hand after sneezing and coughing 
e. 服用藥物，例如預防藥物，中藥 Take drugs, e.g., chemoprophylaxis, 
Chinese herbs  
f. 打流感針 Get a flu shot 
 
 
 139 
 
Q22.  你認為你屬唔屬於目標或高危組別嘅人士呢？ 
    Do you think you are the target or high-risk group for flu shot?  
a. 屬於 Yes 
b. 唔屬於 No 
 
 
建議和社會支持 Advice and social support 
 
Q23.  如果醫護人員提醒你，你會去打流感針嗎？ 
    Will you go to get a flu shot if health professionals advise you?  
a. 會 Yes 
b. 唔會 No 
 
 
Q24.  如果家人或朋友勸你，你會去打流感針嗎？ 
    Will you go to get a flu shot if your family or friends advise you?  
a. 會 Yes 
b. 唔會 No 
 
 
Q25.  如果有客戶系統提醒你打流感針，你會打針嗎？   
Will you get the flu shot if there is a client reminder system to remind you? 
a. 會 Yes 
b. 唔會 No 
 
 
Q26.  與你同居的家庭成員有冇打流感針？ 
    Have your family member in your household received flu shot?  
a. 有 Yes 
b. 冇 No 
 
 
外界環境因素 External environmental factors 
 
Q27.  請問您選擇打流感針會受外界因素影響嗎？ 
Will your choice of receiving flu shot affected by external 
factors? 
a. 頻繁媒體廣告 Frequent media advertisements 
b. 近期當地的流行病 Recent local epidemics 
c. 近期海外流行 Recent overseas epidemics 
d. 其他 Others (請註明 specify:____________) 
 
 
問卷調查結束，謝謝！ 
End of questionnaire, Thank you! 
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Annex 2 
Table showing the variables in the case-control study 
Predisposing socio-demography 
D1***** Age (years) Year of birth (continuous)  
Categories: 18-34, 35-49, 50-64 
D2 Sex Male 
Female 
D3 Ethnicity Chinese 
Indonesian 
Philippines 
Whit (Am/ Eur) 
Indian 
Other (_____________) 
D4 Highest educational attainment No schooling / kindergarten 
Primary 
Secondary 
Tertiary or above 
Refuse 
D5 Occupation Employer / manager & 
administrator 
Professional / Associate 
professional 
Clerk / administrative office work 
Service worker and sales 
Skilled or unskilled worker 
Student 
Homemaker 
Retired 
Unemployed person 
Other (_____________) 
D6 Occupation (Health-related) Health-care 
Non-health care 
D7 CSSA recipient Yes, No 
D8 Income No income 
Below HK$7,500 
HK$7,500 – $9,999 
HK$10,000 – $14,999 
HK$15,000 – $19,999 
HK$20,000 – $29,999 
HK$30,000 or above 
D11 District Either 1 of the 18 districts 
Knowledge 
4 Know GVP and Scheme Yes, No 
19 Flu reduce hospital admission Yes, No 
20 Flu protection % 
 
 
 
 
0%-19% 
20%-49% 
50%-69%  
70%-89%   
90%-100% 
                                               
 
***** Indicates question number in the questionnaire. 
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21 
Other measures in preventing flu 
Number of total right 
answers  
22 Being recommended group Yes, No 
Need 
16 Presence of chronic diseases Yes, No  
17 
Consult a doctor in the past 3 
months 
Yes, Western 
Yes, TCM 
Yes, both 
No 
18 Live with children <6 years or 
elders ≥65 years 
 
Yes, children 
Yes, elder 
Yes, both 
No 
Behaviour 
1 
Previous flu vaccination history 
  
 
 
Yes, this year (2012/13) 
Yes, last year (2011/12) 
Yes, for both years  
Yes, more than two years ago 
No 
2 
Will get flu shot next year 
 
 
Certainly 
Maybe 
Maybe not 
Certainly not 
D9 Smoker Yes, No 
D10 Drinker Yes, No 
Belief & perceptions 
9 Perceived chances of contracting 
influenza  
Scale 1 to 5 
10 
Perceived severity of influenza 
 
Mild  
Moderate  
Severe 
Don’t know  
11 Perceived vaccine safety Yes, No 
12 Perceived vaccine adverse 
events is minor 
Yes, No 
13 Perceived vaccine effect against 
flu 
Scale 1 to 5 
14 Believed flu vaccine has 
additional benefits other than flu 
protection 
 
Yes, protect family 
Yes, work requirement  
Yes, for other reasons (_______) 
No 
15 Self-assessed health Scale 1 to 5 
Health-care system 
3 Eligibility of using free or 
subsidised service 
Yes, No 
5 
Willingness of the out-of-pocket 
vaccine and administration cost 
$0 
$1 - $50  
$50 - $100 
$100 - $150 
Cost is not an issue 
6 Willing to receive flu shot if it is 
free 
 
Yes, No 
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7 
Preferred location to have flu shot  
 
Government clinics 
Private clinic 
Hospital 
Other (______)  
No 
8 Convenience of access to health-
care settings 
Scale 1 to 5 
26 Response to client reminder 
system  
Yes, No 
Advice & social support 
23 Advice from health professionals  Yes, No 
24 Advice from family and friends Yes, No 
25 Household member receive 
vaccine 
Yes, No 
External environment 
27 
Any external environmental 
factors 
 
 
Frequent media ads 
Recent local epidemics 
Recent nearby 
epidemics 
Others (specify:____________) 
 
 
Questions specific for vaccinated and non-vaccinated respondents 
V1a 
Reason for vaccination 
Health professional advice 
Unsatisfactory health  
Belong to high-risk group 
Vaccine is effective  
Work requirement 
Free/ subsidized vaccination   
Protect family member      
Other (_____________) 
V1b 
Location to have flu shot last 
time 
Yes, in private clinic 
Yes, in government clinics 
Yes, in hospital 
Yes, elsewhere  
No 
N1c 
Reason for non-vaccination 
Unnecessary   
Busy 
Flu is a mild illness 
Side effects 
Vaccine is ineffective 
Non-high risk group  
Expensive 
Do not know where to get it  
Other (_____________) 
N1b Scare about injection Yes, No 
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